Neutrophil dysfunction in Acute and Chronis Liver Failure by Taylor, Nicholas James
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 


















Neutrophil Dysfunction in Acute and 
Chronic Liver Failure 
 
By 





SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN THE 




Institute of Liver Studies 
Division of Transplantation Immunology and Mucosal Biology 
King’s College London School of Medicine 




I, Nicholas Taylor, declare that the work presented in this thesis is my own. 
 
 











The greatest challenge to any thinker is stating the problem in a way that 
will allow a solution 






Patients with liver disease are susceptible to sepsis which is associated with poor 
outcomes and high mortality.  The immunopathology includes a defective innate 
immune response to invading microbes and an exaggerated systemic inflammatory 
response.  Neutrophils, potential effectors of this differential response, undergo 
priming leading to alterations in phagocytic capacity and oxidative burst (OB).  
Ammonia-induced osmotic stress and a circulating pro-inflammatory milieu mediated 
through phosphorylation of the p38-MAPK signalling pathway have been postulated 
to be critical events in the development of neutrophil dysfunction in liver disease.   
This longitudinal case-control study characterised neutrophil morphology, phenotype 
and function ex-vivo in patients with acute liver failure (ALF) and cirrhosis.  The role 
of ammonia–induced osmotic stress in relation to the p38-MAPK pathway was 
explored. 
25 patients with ALF and 67 patients with cirrhosis were compared with healthy (HC) 
and sepsis controls (SC).  Utilising flow cytometry, neutrophil phenotype was 
determined by surface CD16 and CD11b expression, phagocytosis quantified with 
FITC-labelled E.coli, OB pre/post-exposure to E.coli by 123-rhodamine fluorescence, 
chemotaxis by the number of cells migrating towards a fMLP concentration gradient 
and cell volume determined by forward scatter characteristics with confirmatory 
transmission electron microscopy.  Plasma cytokine concentrations were determined 
using ELISA.  Finally, neutrophil function assays were repeated after pre-incubation 
with p38-MAPK modulators and intracellular levels of total and phosphorylated p38-
MAPK were determined.    
My data demonstrate that circulating neutrophils in ALF have impaired bactericidal 
function similar to that seen in severe sepsis.  Neutrophil function indices are 
important biomarkers in ALF and may be implicated in the development of organ 
dysfunction and increased susceptibility to sepsis. Likewise, neutrophils in patients 
with cirrhosis are dysfunctional and predict the development of infection, organ 
dysfunction and survival at 90-days and 1-year. Neutrophil swelling correlates with 
peak arterial concentration and can be abrogated ex-vivo following incubation with 
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Acetaminophen acute liver failure (AALF) 
Acute alcoholic hepatitis (AAH) 
Acute kidney injury (AKI) 
Acute liver failure (ALF) 
Acute lung injury (ALI) 
Acute-on-chronic liver failure (AoCLF) 
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Adult respiratory distress syndrome (ARDS) 
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Alcoholic hepatitis (AH) 
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Anti-diuretic hormone (ADH) 
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Aspartate aminotransferase (AST) 
Autoimmune hepatitis (AIH) 
Bacterial permeability-increasing protein (BPI) 
B-cell lymphoma extra-large (Bcl-X) 
Becton Dickinson (BD) 
Bone marrow (BM) 
Bovine serum albumin (BSA) 
Bronchoalveolar lavage (BAL) 
CC-chemokine ligand (CCL) 
CC-chemokine receptor (CCR) 
California (CA) 
Central nervous system (CNS) 
Child-Pugh class A (CPA) 
Child-Pugh class B (CPB) 
Child-Pugh class C (CPC) 
Child-Pugh score (CPS) 
Circulatory assist device (CASD) 
Cirrhosis associated immune dysfunction syndrome (CAIDS). 
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E. Coli stimulated oxidative burst (ESOB) 
Endoplasmic reticulum (ER) 
Enzyme linked immunosorbent assay (ELISA) 
Escherichia. Coli (E.coli) 
Ethylenediaminetetraacetic acid (EDTA) 
Extracellular signalling related kinase (ERK) 
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Forward scatter (FSC) 
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Intensive care unit (ICU) 
Interferon (IFN) (interferon-gamma [IFNγ]) 
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Interleukin-1 receptor (IL-1R) 
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Intracellular-adhesion molecule-1 (ICAM-1) 
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Nuclear transcription factor κB (NF-κB) 
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Partial atmosphere (Pa) 
Pathogen-associated-molecular patterns (PAMP) 
Pattern recognition receptors (PRR) 
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Primary biliary cirrhosis (PBC) 
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Protein kinase A (PKA) 
Protein kinase C (PKC) 
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p38-Mitogen activated protein kinase (p38-MAPK) 
Radioimmunoprecipitation assay (RIPA) 
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Ras-related C3 botulinum toxin substrate 2 (Rac-2) 
Reactive oxygen species (ROS) 
Receiver operated curve (ROC) 
Renal replacement therapy (RRT) 
Renin-angiotensin aldosterone system (RAAS) 
Reticulo-endothelial (RE) 
Revolutions per minute (RPM) 
Right lower (RL) 
Rough endoplasmic reticulum (RER) 
Septic controls (SC) 
 28 
Sequential Organ Failure Assessment (SOFA) 
Side scatter (SSC) 
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Soluble tumour necrosis factor receptor (sTNFR) 
Spleen tyrosine kinase (Syc) 
Spontaneous bacterial peritonitis (SBP) 
Spontaneous oxidative burst (SOB) 
Stromal-cell-derived factor (SDF-1) 
Systemic inflammatory response syndrome (SIRS) 
Subacute liver failure (SALF) 
Superoxide dismutase (SOD) 
Transmission Electron Microscopy (TEM) 
Toll-like receptors (TLR) – [TLR-2, 3,4,9] 
Transforming growth factor-β (TGF-β) 
Triggering receptor on myeloid cells (TREM-1) 
Tumour necrosis factor α (TNFα) 
Tumour necrosis factor receptor (TNFR) 
Tumour necrosis factor receptor-associated factor 6 (TRAF-6) 
T-regulatory cells (T-regs) 
United Kingdom (UK) 
United Kingdom End-Stage Liver Disease score (UKELD) 
Vascular cell adhesion protein-1 (VCAM-1) 
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Chapter 1 - Neutrophil structure, function, 

















Neutrophils are highly motile phagocytic effector cells of the innate immune system. 
They were first discovered by Elie Metchnikoff in 1884 when he inserted rose thorns 
into starfish larvae and observed wandering cells accumulate at the puncture site and 
engulf particles; a process subsequently termed phagocytosis.  (Metchnikov (1884) 
The larger cells were named macrophagocytes (macrophages) with the smaller cells 
microphagocytes; that name subsequently changing to granulocytes of which 
neutrophils are the most abundant.  Neutrophils constitute the first line of defence 
against bacterial and fungal infection, and play a critical role in the response to 
cellular damage (Witko-Sarsat et al., 2000). The speed of the neutrophil response and 
varied arsenal of anti-microbial capabilities allow them to effectively eradicate the 
majority of infections encountered. (Segal, 2005) The importance of the neutrophil 
response to infection is highlighted in patients with functional neutrophil deficiency 
syndromes such as chronic granulomatous disease, leucocyte adhesion deficiency and 
chemotherapy-induced neutropenia; these conditions can result in fulminant infection 
from bacterial and fungal pathogens, frequently from opportunistic organisms 
(Schelenz et al., 2012).  Recently there is evidence that a number of inflammatory 
conditions, such as sepsis and liver failure, are associated with a quantitative and 
qualitative antimicrobial dysfunction of neutrophils. (Brown et al., 2006, Rajkovic 
and Williams, 1986) Furthermore neutrophil antimicrobial dysfunction can 
simultaneously be associated with an over exuberant neutrophilic response leading to 
cellular damage and organ dysfunction. (Annane et al., 2005)  
 
1.2 Neutrophil function 
Functionally circulating neutrophils exist in a ‘resting state’. Neutrophils can undergo 
rapid activation and recruitment at sites of tissue inflammation due to infection, 
trauma or an autoimmune reaction.  Neutrophils migrate to sites of inflammation 
through a process called ‘chemotaxis’ being attracted by soluble factors, such as 
Interleukin-8 (IL-8) [also known as neutrophil chemotactic factor], Interferon (IFN) γ, 
complement proteins, and molecules released from damaged tissues and 
macrophages. (Williams et al., 2011) Once at the site of inflammation neutrophils 
come into close proximity to the vascular endothelium (margination) allowing then to 
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receive further chemokine signalling facilitating firm endothelial adhesion, 
subsequent activation and migration across the endothelium (diapedesis). (Guthrie et 
al., 1984, Follin et al., 1991) Upon entering the tissues neutrophils undertake three 
critical antimicrobial functions resulting in removal of invading pathogens and cell 
debris.  Firstly neutrophils are able to engulf microbes and particles in a process 
termed phagocytosis. (Lee et al., 2003) Following ingestion neutrophils proceed to 
eliminate ingested material by generating large quantities of reactive oxygen species 
(ROS) through activation of nicotinamide adenine dinucleotide phosphatase-oxidase 
(NADPH-oxidase), a process termed respiratory or oxidative burst (Dahlgren and 
Karlsson, 1999, Baldridge, 1933).  Secondly neutrophils can directly release anti-
microbial molecules such as defensins and serine proteases after fusion of granules 
with the plasma membrane.  Recently a third and slightly curious antimicrobial 
function of neutrophils has been discovered; they appear to release an extracellular 
web-like structure composed of DNA and serine proteases in response to 
lipopolysaccharide (LPS) and IL-8.  These neutrophil extra-cellular traps (NETs) 
snare and kill microbes whilst minimising damage to surrounding cells. (Brinkmann 
et al., 2004, Wartha et al., 2007) Having undergone respiratory burst neutrophils 
become apoptotic and their lysed remnants constitute pus.   
The release of ROS and serine proteases into the extracellular space from 
activated neutrophils can generate ‘collateral damage’ to surrounding cells.  This 
bystander damage can contribute significantly to tissue destruction in both acute and 
chronic disease processes, such as acute lung injury (ALI), emphysema and 
rheumatoid arthritis (Holman and Saba, 1988).  Interestingly, the absence of alpha1-
antitrypsin, the natural inhibitor to elastase, one of the serine proteases, can lead to 
excessive tissue damage resulting in emphysema and hepatic disease.  There is 
therefore a trade-off between ensuring an adequate response to eradicate invading 
microbes whilst avoiding excessive damage to bystander cells through an overly 





1.3 Neutrophil morphology 
Neutrophils or polymorphonuclear leukocytes are granulocytes of the myeloid lineage 
and are the most common form of leukocyte in humans and other primates.  On a 
blood smear neutrophils are 12-15 microns in diameter with poorly staining 
cytoplasmic granules and lysosomes (variable or “heterophil” staining) differentiating 
them from the other granulocytes, eosinophils and basophils.  Neutrophils also 
possess a characteristic variably segmented or lobar nucleus.  Immature forms have 
one (band forms) or two lobes but mature forms may have 3 to 5 lobes, connected 
together with fine threads of nuclear material.   An excessive number of immature 
forms on a blood film is termed ‘left shift’ and is indicative of infection.  During 
infection neutrophils also exhibit toxic granulation with densely stained granules 
within the cytoplasm, vacuolisation of the cytoplasm and Dhole bodies (residual 
ribosomes) [Figure 1-1].   
FIGURE 1-1 LIGHT MICROSCOPY IMAGES OF A NORMAL NEUTROPHIL (A) 
WITH 3 NUCLEAR SEGEMENTS AND AN IMMATURE OR BAND FORM (B) 
FROM A HEALTHY CONTROL.   
Courtesy of Godhev Manakkat Vijay, and Professor Barbara Bain (Manakkat Vijay et 
al., 2015)  
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1.4 Neutrophil life cycle and trafficking from bone marrow to 
peripheral blood 
Neutrophils constitute 50-70% of circulating leucocytes with the standard range for 
peripheral blood cell counts being 2.5-7.5 x 109/L.  In fact circulating neutrophils 
represent less than 2% of total body neutrophils, the majority are retained within the 
bone marrow (BM) with release into the circulating pool being tightly controlled.    
Neutrophils are produced in vast quantities upto 5-10x1010 per day (Summers et al., 
2010) and undergo development over 14-days in the BM.  Upon release into the 
circulation the average neutrophil life-span is only 5.4 days (Pillay et al., 2010).  
Thereafter in the absence of bacterial infection, ageing neutrophils shrink into 
apoptotic bodies, undergoing phagocytosis by macrophages in reticuloendothelial 
organs or the BM. (Savill et al., 1989) Under stressful conditions circulating 
neutrophil numbers can rise significantly, so called ‘stress granulopoiesis’.  
Neutrophil numbers can be increased through egress of mature neutrophils from the 
BM, reduced neutrophil apoptosis and subsequent clearance.  The retention of 
neutrophils within the BM is regulated by the CXC chemokine receptors CXCR2 and 
CXCR4 expression on the neutrophil cell surface (Christopher and Link, 2007).  
WHIM disease is a condition where autosomal dominant mutations of CXCR4 result 
in a disease characterised by warts, hypogammaglobulinaemia, infections and 
myelokathexis (retention of mature neutrophils within the BM).  This is due to a 
mutation in the CXCR4 gene generating truncated forms of the protein resulting in 
enhanced signalling. (Hernandez et al., 2003) CXCR4 activation retains neutrophils 
within the BM whereas CXCR2 facilitates egress.  Interestingly as neutrophils mature 
they have reduced surface expression of CXCR4 and the β1-Integrin, very-late 
antigen-4 (VLA4), ensuring the preferential release of these neutrophils from the BM.  
The dominant production of the CXCR4 ligand stromal-cell-derived factor (SDF-1) 
from osteoclasts results in neutrophil retention.  Granulocyte colony stimulating factor 
(G-CSF) mobilises neutrophils from the BM during sepsis by inhibiting osteoclast 
production of Stromal cell-derived factor-1 (SDF-1) and increasing the production of 
CXCR2 ligands, keratinocyte-derived chemokine (KC) and macrophage inflammatory 
protein-2 (MIP-2). (Semerad et al., 2002) In addition, granulocyte-macrophage colony 
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stimulating factor (GM-CSF) and other circulating chemokines such as IL-6 and IL-8 
appear to play critical roles in stress granulopoiesis (Zhan et al., 1998, Kopf et al., 
1994, Starckx et al., 2002).  
 
1.5 Surface receptor expression 
Circulating neutrophils are critically dependent on their surface receptors to rouse 
them from their normal ‘resting state’ with associated low metabolic activity.  Firstly 
to a ‘primed’ state of enhanced surveillance and finally to a fully ‘activated’ state 
associated with a massive increase in metabolic functioning.  Neutrophils are 
maintained in a resting state in order to prevent uncontrolled release of ROS, 
proteases, and collateral tissue damage.  Whilst in this ‘resting state’ they remain 
constantly vigilant, through the expression of an array of pattern recognition receptors 
(PRR), for the presence of molecular signatures indicating cellular damage or 
infection.  In order to activate neutrophils and the NADPH-oxidase, the principle 
enzyme involved in respiratory burst, neutrophil surface receptors need to bind 
specific ligands.  Firstly circulating neutrophils can be ‘primed’ by low ‘non-
activating’ concentrations of agonists such as GM-CSF, G-CSF, tumour necrosis 
factor α (TNFα), IL-6 and IL-8 and results in a variety of biochemical changes. 
(Condliffe et al., 1998) Priming results in a greatly enhanced neutrophil response to 
subsequent circulating stimuli or opsonised particulate matter which leads to a 
functional response ‘activation’.  Once ‘activated’ neutrophils vastly increase their 
metabolic activity, undergoing a so-called ‘respiratory burst’, thus facilitating them to 
perform defined functions including endothelial transmigration, phagocytosis, 
activation of the NADPH-oxidase, degranulation, generation of lipid mediators (e.g. 
PAF and LTB4) and cytokines. (Vignais, 2002) This two-stage activation process 
again ensures that these highly toxic cells are only fully operational at sites of 
inflammation minimising collateral tissue damage.   
Neutrophils are ‘primed’ and ‘activated’ through the binding of ligands to 
PRRs expressed on the neutrophil surface; these include Toll-like receptors (TLR), C-
type lectin receptors, N-Formyl-methionyl-leucyl-phenylanine (fMLP) receptors and 
scavenger receptors. (Gordon, 2002) PRRs recognise highly conserved molecular 
signatures which indicate infection through pathogen-associated-molecular patterns 
(PAMP), and cellular damage through disease associated molecular patterns (DAMP) 
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[for ligand-receptor interactions see Table 1-1].  For particulate matter 
immunoglobulin (Ig) fragment crystallisable (Fc)-receptors (Cluster of Differentiation 
[CD] 16, CD32, CD64) and complement receptors (CD31 and CD88) will bind to 
circulating immunoglobulin and activated complement molecules bound to pathogens.  
The complement protein C5a is an important priming molecule.  Neutrophils have a 
plethora of diverse chemoattractant receptors that overlap in a seemingly redundant 
fashion.  These include chemokine receptors (CXCR, CCR), eicosanoid receptors and 
cytokines receptors (e.g. IL-1R) allowing ‘priming’ and ‘homing’ of neutrophils to 
sites of infection and inflammation.  Stimulation of G-protein coupled chemotactic 
receptors trigger fusion of secretory vesicles with the plasma membrane and up-
regulate signal transduction pathways, resulting in augmentation of neutrophil 
adhesion and the production of reactive oxygen intermediates [Figure 1-2]. (Jaeschke, 




















Table 1-1 Neutrophil cell surface receptors and ligands 
Receptor Group Neutrophil cell surface receptors Ligand 
Pattern recognition 
receptors (PPRs) 
Toll-like receptor-2 (CD282)  
Toll-like receptor-4 (CD284) 
Toll-like receptor-5 (CD285) 
Lipoteichoic acid and others 
Lipopolysaccharide (LPS) 
Flagellin 
CD14 (in complex with TLR-4) LPS 
C-type lectins  
Mannose binding receptor 
 
Mannose binding lectin (MBL) 
Scavenger receptor CD36 
Triggering receptor expressed on 
myeloid cells (TREM-1) 
Unknown 
N-Formyl peptide receptor (FPR) fMLP 
Immunoglobulin- 
Fcγ receptor (FcγR) 
CD16 – low affinity 
CD32 – low affinity 
CD64 – high affinity 
Immunoglobulin-G Fc region 
Immunoglobulin-G Fc region 












Complement receptor CD31/CR1 
C5a 
C3b 
Eicosanoid receptors BLT1 (Leukotriene B4 receptor) 
Platelet activating factor receptor 
(PAFR) 
Leukotriene B4 
Platelet activating factor (PAF) 
Selectins CD62-L (L-selectin)  Oligosaccharide 
P-selectin glycoprotein ligand-1 (PSGL-
1) 
P-selectin 
β1-Integrins CD49d/CD29 (VLA-4) – immature 
forms and sepsis 
CD106 (VCAM-1) 
Fibronectin 
β2-Integrins CD11a/CD18 (leucocyte functional 
antigen-1) [LFA-1] 
CD54 (ICAM-1) 




FIGURE 1-2 NEUTROPHIL CELL SURFACE RECEPTORS 
Abbreviations: Fcγ - fragment crystallisable gamma; CD - cluster of differentiation; CXCR -
CXC chemokine receptor; CCR - CC chemokine receptor; MAC-1 – Macrophage 1; TLR – 
Toll-like receptor; LFA-1 – Leukocyte function antigen 1; TREM 1 – triggering receptor 
expressed on myeloid cells 1; IL-8 – interleukin-8; LT-B4 – leukotriene B4; PAF-platelet 











1.6 Toll-like receptors and down-stream second messenger systems 
TLRs are the most studied and perhaps best understood of the PRRs and highlight 
some of the critical steps involved in neutrophil activation.  TLRs are highly 
conserved in evolutionary terms and regulate the major pro-inflammatory and host 
defence functions of human neutrophils as well as other immune cells such as 
macrophages and T-cells.  They are membrane signalling receptors and key-signal 
transduction molecules in neutrophils regulating functions such as migration, 
activation and apoptosis in response to PAMPs such as LPS, lipoteichoic acid (LTA) 
and peptidoglycans (Ulevitch, 1999).  Interestingly, TLR2 but not TLR4, expression 
is increased on the surface of neutrophils by pro-inflammatory cytokines (Kurt-Jones 
et al., 2002).  TLR4 activation is complex and requires the binding of LPS in a multi-
step process.   LPS first associates with soluble LPS-binding protein (LBP), which 
facilitates complex formation with CD14.  Once LPS binds to CD14, LBP dissociates, 
and the LPS-CD14 complex physically associates with TLR4. After ligand binding, a 
complex downstream pathway is activated that can be myeloid differentiation factor-
88 (MyD88) dependent or independent.  In the MyD88-dependent pathway, 
interleukin-1 receptor-associated kinase (IRAK), and tumour necrosis factor receptor-
associated factor 6 (TRAF-6) are sequentially activated.  These adaptors mediate the 
activation of a number of intracellular kinases including p38-mitogen activated 
protein kinase (p38-MAPK), extracellular signalling-regulated kinase (ERK), c-jun N-
terminal kinase (JNK) and phosphoinositide-3 kinase (PI3K). (Takeuchi and Akira, 
2001) Ultimately nuclear transcription factor-κB (NF-κB) is activated which 
translocates to the nucleus and up-regulates the expression of a number of pro-
inflammatory cytokines.   
Activation of TLRs by PAMPs facilitates neutrophil recruitment by 
upregulation of endothelial adhesion molecule expression on endothelium directly or 
indirectly, via cytokine release from other tissues such as macrophages.   TLR 
activation leads to down regulation of IL-8R, CXCR1 and CXCR2 facilitating 
recruitment and localisation of these cells to sites of infection and inflammation 
(Mullarkey et al., 2003, Meng et al., 2004).  LPS activation of TLR4 is a potent 
activator of neutrophils, causing p38-MAPK activation, L-selectin shedding, CD11b 
expression, respiratory burst and the generation of cytokines e.g. IL-8 (Sabroe et al., 
2003).  TLR2 and TLR4 activation has been shown in a large number of studies to 
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delay Fas receptor ligation and constitutive apoptosis.  LPS priming in vivo can delay 
apoptosis in models of bacterial sepsis.  Interestingly, the increased neutrophil 
apoptosis induced by the influenza-A virus in the presence of Streptococcus 
pneumonia is thought to be the underlying mechanism whereby patients develop 
secondary pneumonia during viral infection, a frequent cause of death in infected 
patients. (Hajishengallis, 2011) LPS stimulation appears to have a modest direct effect 
in delaying neutrophil apoptosis; however indirect effects on other cells such as 
monocytes can produce a synergistic effect. (Walmsley et al., 2004) Direct effects are 
mediated through NF-κB, p38-MAPK and ERK (Sabroe et al., 2003).   
Signalling cross talk between innate immune receptors such as TLR2 and C-
type lectin receptors in the immune response against fungal pathogens allows 
amplification of weak PAMP signals.  Additionally, cross talk can lead to suppression 
of TLR-induced pro-inflammatory responses classically following glucocorticoid and 




FIGURE 1-3 EFFECTS OF TOLL-LIKE RECEPTOR LIGATION IN NEUTROPHILS.  
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1.7 p38-MAPK neutrophil activation   
MAP kinases play an important role as downstream effectors of neutrophil activation, 
mediating intracellular signal transduction and regulating cellular function in response 
to a variety of stimuli.  Studies have demonstrated that p38-MAPK is involved in an 
intracellular kinase cascade that regulates stress-activated signal transduction. 
(Zarubin and Han, 2005) Surface receptor ligation appears to be the principle 
activation step in the p38-MAPK cascade: receptors include PRRs, such as TLRs and 
fMLP, pro-inflammatory cytokine receptors such as tumour necrosis factor receptors 
and Interleukin-1 receptor (IL-1R), and selectin binding to P-selectin glycoprotein 
ligand (PSGL-1) [Figure 1-4]. (Doyle et al., 2004, Zu et al., 1998, Hidari et al., 1997) 
Signal transduction occurs through a kinase cascade resulting in the rapid activation 
of the downstream kinases MAP kinase kinase (MKK) 3 and MKK6 and subsequently 
p38-MAPK. (Kumar et al., 2003) p38-MAPK subsequently stimulates Mitogen 
activated protein kinase activated protein (MAPKAP) kinase 2 and/or MAPKAP 
kinase 3.  (Ono and Han, 2000) These kinases in turn induce the phosphorylation of 
small heat-shock proteins.  In addition p38-MAPK can phosphorylate specific 
transcription factors in vitro and in intact cells.  p38-MAPK signalling has been 
shown to involve the post-transcriptional regulation of cytokines such as TNFα and 
also cycloxygenase-2. (Dean et al., 1999) TNFα appears to specifically activate p38-
MAPK; other general activators of kinase systems include GM-CSF, fMLP, Phorbol 
myristate acetate (PMA) and inomycin.  The specific inhibitor of p38-MAPK 
SB203580 inhibits neutrophil p38-MAPK stimulation by TNFα including IL-8 
production and superoxide generation (Zu et al., 1998).  Selective inhibition of p38-
MAPK reduced neutrophil chemotaxis and superoxide production in response to 
fMLP.  Interestingly corticosteroids have been shown to inhibit p38-MAPK through 
expression of MAPK phosphatase-1, expression of which is also induced by IL-1, 
acting as a putative negative feedback loop.  (Lasa et al., 2002) TLR-mediated 
induction of scavenger receptors (SRs) occurs through MyD88, IRAK4, and p38-
MAPK.  Activation of this pathway is essential for TLR promotion of phagocytosis 






FIGURE 1-4 NEUTROPHIL PRIMING AND ACTIVATION OF P38-MITOGEN 
ACTIVATED PROTEIN KINASE (P38-MAPK) THROUGH CHEMOKINE AND 
TOLL-LIKE RECEPTOR ACTIVATION.   
 
fMLP activates G-protein coupled receptors and Ras-dependent kinase, which 
subsequently activates and phosphorylates Mitogen activated protein kinase kinase 
(MKK)-1 and -2, thus phosphorylating the mitogen activated protein kinases ERK, 
JNK and p38-MAPK.  In addition fMLP can activate p38-MAPK through the 
activation of MKK3.  PMA bypasses membrane receptors and directly activates PKC 
(protein kinase-C) by mimicking DAG (diacyl-glycerol).  PMA stimulation markedly 
increases neutrophil oxidative burst by activating NADPH-oxidase through 
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•  fMLP activates G-protein coupled receptors and Ras-dependent kinase, which subsequentally activate 
and phosphorylate MEK-1 and 2, and Erk MAPK. 
•  fMLP also activates p38 MAPK through the activation of MKK3 
•  PMA bypasses membrane receptors and directly activates PKC and mimicking DAG  
•  PMA stimulation markedly increases neutrophil oxidative burst by activating NADPH oxidase through 
redistribution of PKC and phosphorylation of p47 phox. 
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1.8 Neutrophil chemotaxis 
Neutrophils are rapidly recruited to sites of infection / inflammation through a process 
termed ‘chemotaxis’.  Initial tissue damage or infection is detected by resident 
sentinel cells, these include macrophages and mast cells, or by release of DAMPs 
from stromal cells. (Sadik et al., 2011) A huge variety of PAMP and DAMP 
molecules act on macrophages stimulating the release of pro-inflammatory mediators 
such as IL-1β, IL-6 and tumour-necrosis factor-α (TNFα) as well as chemokines. 
(Zeytun et al., 2010) Chemokines are small polypeptide cytokines released from cells 
that can induce the migration of neutrophils down a concentration gradient from a low 
to high concentration of the molecule. (Mollnes et al., 2002) Common macrophage-
derived chemokines include the CXC chemokines (CXCL1-7), IL-8 (CXCL8) and 
lipid mediators (Leukotriene B4 [LT-B4] and platelet activating factor [PAF]).  Other 
chemotactic molecules include bacterial derived proteins such as fMLP and activated 
complement proteins (e.g. C5a).  The major function of chemokines is to prime 
neutrophils via G-protein coupled receptors in a process termed ‘stimulus-response 
coupling’ leading to activation of trimeric G-proteins, followed by increased 
intracellular Ca2+ levels, lipid remodelling and protein kinase activation.  (Dale et al., 
2008)  The initial result of ‘stimulus-response coupling’ is neutrophil attachment and 
subsequent activation of the actin assembly leading to cytoskeletal rearrangement and 
polarisation of the cell with subsequent locomotion and migration down a chemokine 
concentration gradient to sites of infection or tissue injury. (Zigmond, 1977, Stossel, 
1993) Secondary stimulation by chemokines can induce neutrophil degranulation and 
respiratory burst.  Following chemokine receptor activation, downstream effector 
molecules such as the GTPases Rac1 and Rac2 (both members of the Rho family) 
(Bokoch, 1995) are involved in phagocyte migration and respiratory burst.  Full 
activation of Rac is required for NADPH oxidase activity whereas partial activation is 
sufficient for neutrophil chemotaxis. (Hoppe and Swanson, 2004) Full activation 
requires further activation of the tyrosine kinases of the Src and spleen tyrosine kinase 
(Syc) family.  In addition, Rac activation can lead to phosphorylation of ERK 1/2, 
p38-MAPK and JNK.  (Benard et al., 1999) 
Chemokines have important direct and indirect effects on neutrophil 
endothelial capture and adherence. Chemokines produced from the site of infection 
are taken-up and transported to the luminal surface of the endothelial cell, where they 
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are bound by heparan sulphate glycosaminoglycans, and are displayed here at high 
concentrations.  Chemokines can therefore come into close contact with rolling 
neutrophils and bind to specific chemokine receptors on their surface.  Chemokine 
receptor signalling stimulates neutrophils to rapidly upregulate and increases the 
avidity of β2-integrins for the endothelial ligand intercellular adhesion molecule 1 
(ICAM-1) and induces clustering of this molecule to firm up endothelial adhesion; so 
called “inside-out signalling”.  The overall effect is therefore a firming-up of integrin-
mediated binding of the neutrophil to the endothelial surface. The endothelial 
expression of ICAM-1 itself being upregulated by the pro-inflammatory cytokines 
TNFα and interleukin-1, and PAMPs released from sites of microbial infection.  The 
net result of neutrophil and endothelial upregulation is the firm adhesion of 
neutrophils to the endothelium and cytoskeletal re-arrangement leading to the 
acquisition of a characteristic asymmetric shape with an advancing pseudopodium. 
(Hirsch, 1962) 
 
1.9 Neutrophil recruitment across the vascular endothelium 
Leukocyte recruitment occurs in a targeted multi-stage process initially involving 
interaction and adherence to vascular endothelium activated by pro-inflammatory 
mediators in the region of the post-capillary venule. Following ‘activation’, 
neutrophils become highly metabolically active resulting in cytoskeletal 
rearrangement and penetration of the endothelial cell layer (diapedesis) into the extra-
cellular matrix.  Defects in leucocyte adhesion result in recurrent bacterial infection 
and can be lethal.  Two leucocyte adhesion deficiency syndromes are described in 
humans; leukocyte adhesion deficiency-type 1 (LAD1) and leukocyte adhesion 
deficiency-type 2 (LAD2).  LAD1 is a rare autosomal recessive disorder characterised 
by the absence or reduced expression of the common β subunit (CD18) of the integrin 
receptor molecules LFA-1 and Macrophage-1 (Anderson and Springer, 1987).  LAD2 
is a deficiency in the carbohydrate structure Sialyl-Lewis X that renders neutrophils 
unable to adhere to E-selectin on activated endothelial cells (Etzioni et al., 1992).  
Conversely, inhibition of neutrophil recruitment can have a positive effect on 
ischaemia-reperfusion injury (Singbartl et al., 2000), sterile inflammation (Zarbock et 
al., 2006), and autoimmune disease (Chiriac et al., 2007).  
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1.10 Tissue adherence to vascular endothelium 
Neutrophils continuously engage in weak physical interactions with the vascular 
endothelium probing for evidence of endothelial activation by brief binding events 
leading to cells rolling along the vessel wall.  The molecules involved in this process 
are the selectins, integrins and their respective ligands, which are constitutively 
expressed on neutrophils and on vascular endothelial cells.   
In flow-chambers, neutrophils are seen to roll along endothelial surfaces following 
numerous rapid on-off interactions mediated by selectins and their ligands.  This 
transient rolling slows down the neutrophil and allows brief interrogation of the 
endothelial cell surface for chemokine expression such as IL-8 and PAF.  Selectin 
adhesion is greatly enhanced following-activation of the endothelium by the pro-
inflammatory cytokines TNFα, IL-1 and IFNγ found at sites of inflammation.  
Following further signalling events integrin-endothelial interactions mediate firm 
adhesion or “arrest” of neutrophils.  Chemokine signalling induces changes in 
neutrophil receptor expression resulting in the shedding of L-selectin and up-
regulation of the β2-integrin CD11b.  The neutrophil adhesion cascade of tissue 
recruitment is therefore a multi-staged process of slow rolling, adhesion 
strengthening, intraluminal crawling, paracellular and transcellular migration, and 
migration through the basement membrane.  (Ley et al., 2007) Figure 1-5 summarises 




FIGURE 1-5 NEUTROPHIL RECRUITMENT ACROSS THE VASCULAR 
ENDOTHELIUM. (COURTESY OF DR R.D. ABELES) 
 
1.11 Selectins 
Selectins and their receptors mediate the initial low-affinity tethering of neutrophils to 
the endothelium; these interactions are easily disrupted by the sheer flow of blood 
(Kansas, 1996).  L-selectin (CD62L) is constitutively expressed on all microvilli of 
circulating neutrophils.  The molecule is a type-I transmembrane glycoprotein with an 
N-terminal calcium dependent “C-type” lectin domain and highly conserved 
cytoplasmic tail. (Zarbock and Ley, 2008) L-selectin interacts with sialylated 
oligosaccharide moieties on endothelial cell surface glycoproteins typically CD34, 
interestingly not present on liver sinusoidal endothelial cells (LSEC).  The level of 
surface expression, cytoskeletal anchoring, and the distribution of L-selectin 
determine the tethering efficiency and rolling velocity (Dwir et al., 2001, Pavalko et 
al., 1995, Kansas et al., 1993).  Cross-linking of L-selectin on neutrophils can also 
initiate β2-integrin activation (Simon et al., 2000) but L-selectin-dependent rolling 
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alone does not induce neutrophil arrest (Lawrence et al., 1995).  L-selectin expression 
on neutrophils can be rapidly down-regulated by proteolytic cleavage of L-selectin 
near the cell surface by the ‘shedase’ ADAM-17 (Smalley and Ley).  The reduced 
surface expression of L-selectin observed in neutrophils from patients with sepsis is 
thought to occur through this mechanism.  Blocking of L-selectin shedding in vivo 
increases signal input through L-selectin and results in an increase in neutrophil 
arrest, reducing rolling velocity (Hafezi-Moghadam and Ley, 1999).  It is unclear if 
this is mediated directly through increased signalling and L-selectin activation or by 
increasing endothelial adherence.   
The cytoplasmic tail of L-selectin is associated with calmodulin, α-actinin, 
both actin-binding proteins, and proteins of the ezrin-radixin-moesin (ERM) family. 
The cytoplasmic tail interacts directly with α-actinin anchoring L-selectin directly to 
the cytoskeleton, allowing L-selectin activation to facilitate neutrophil rolling and 
tethering. (Dwir et al., 2001) The ERM family proteins moesin and ezrin are involved 
in L-selectin expression on microvilli, tethering efficiency, and L-selectin shedding.  
(Ivetic et al., 2004) Activation of L-selectin through cross-linking leads to release of 
calmodulin and causes the concomitant shedding of L-selectin by conformational 
changes allowing access to cleavage sites. L-selectin cross-linking induces increased 
intracellular Ca2+ levels and Src-kinase-dependent tyrosine phosphorylation of the 
cytoplasmic tail resulting in activation of down-stream signalling pathways including 
Ras and p38-MAPK (Brenner et al., 1996, Waddell et al., 1995). 
P-selectin (CD62P) and E-selectin (CD62E) are expressed on endothelial cells 
at sites of infection and both recognise specific neutrophil carbohydrate motifs (e.g. 
Sialyl-Lewis X) mediating endothelial tethering and rolling of neutrophils.  
Constitutive endothelial expression of P-selectin is low, however following activation 
by the pro-inflammatory cytokines IL-4 and IL-13; P-selectin is rapidly translocated 
from the Weibel-Palade bodies to the luminal endothelial surface. (Woltmann et al., 
2000) P-selectin is also expressed on activated platelets but interestingly, not by 
LSEC. (Lopez et al., 1999) E-selectin is expressed exclusively by cytokine-activated 
endothelial cells and recognises glycoprotein (Sialyl-Lewis X) motifs on 
granulocytes, monocytes and T cells, and is important in neutrophil migration.   
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1.12 P-selectin glycoprotein ligand 
P-selectin glycoprotein ligand (PSGL-1) [CD162] is highly expressed on the surface 
of neutrophils and appears to be the dominant neutrophil receptor for all 3 selectins.   
PSGL-1 binds selectin molecules through oligosaccharide moieties such as the Sialyl 
Lewis X–containing O-glycan and tyrosine sulphate residues (McEver and 
Cummings, 1997).   
Binding of PSGL-1 to L-selectin leads to the formation of neutrophil 
aggregates through cell-cell interactions (Guyer et al., 1996). Physiologically selectins 
bind to their ligands with a remarkably fast on-off rate (Alon et al., 1995) under the 
presence of sheer-stress which supports adhesion, facilitating slow rolling and 
adhesion to the vascular endothelium. (Marshall et al., 2003) Antibodies targeted 
against these residues inhibit rolling velocity in vivo (Norman et al., 1995). Upon 
binding PSGL-1 initiates intracellular signalling events resulting in activation of β2-
integrins (Simon et al., 2000), tyrosine phosphorylation (Hidari et al., 1997), secretion 
of cytokines (Hidari et al., 1997), transcriptional activation (Urzainqui et al., 2002) 
and cytoskeletal rearrangements (Ba et al., 2005). The cytoskeletal tail of PSGL-1, 
like L-selectin, is associated with ERM family proteins which mediate the formation 
of protrusive plasma membrane structures (Bretscher et al., 2000).  Disruption of 
these proteins is associated with decreased rolling and adherence of neutrophils 
(Snapp et al., 2002).  ERM can also activate Syk kinase, which is involved in PSGL-
1-dependent signalling and regulates rolling.  Blockade of p38-MAPK increases 
rolling velocity and reduces the number of neutrophil-interacting cells with E-selectin 
and ICAM-1 (Simon et al., 2000).  PSGL-1 expression is down-regulated by 
endotoxin in vivo (Marsik et al., 2004)  and by G-CSF but not dexamethasone, (Jilma 
et al., 2002) which may result in leucocytosis due to decreased adhesion to P-selectin 
in the BM venules.  Dexamethasone and G-CSF both down-regulate L-selectin 
expression but only after a lag of 2 days.   
 
1.12.1 Integrins 
The β-integrins are the second class of adhesion molecules and are responsible for 
slow rolling, Velcro-like firm adhesion, post-adhesion strengthening, neutrophil 
migration, respiratory burst, phagocytosis, cell-pathogen interaction, cell-cell and cell-
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extracellular matrix interactions. (Mayadas and Cullere, 2005) Integrins are present in 
an inactive state on circulating neutrophils.   
Two subfamilies have been characterised. The molecules are heterodimers 
composed of one alpha-chain and a common beta-chain that defines the respective 
family.  β1-integrins share the common beta-chain CD29.  β1-integrins are not 
usually expressed on the surface of neutrophils, however, low levels of very-late 
antigen-4 (VLA-4), a heterodimer of CD29 and the alpha chain CD49d is expressed 
on up to 30% of neutrophils in sepsis. (Ibbotson et al., 2001) VLA-4 binds to the 
vascular cell adhesion molecule-1 (VCAM-1 or CD106), which is expressed on 
endothelium activated by pro-inflammatory cytokines.  The exact contribution of 
VLA-4 to neutrophil recruitment in sepsis is uncertain but antibody-mediated 
blocking of L-selectin and β2-integrins does not ablate neutrophil adhesion in 
neutrophils from septic patients.  (Brown et al., 2001) The β2-integrins appear to be 
the principle molecules involved in the ‘arrest’ of neutrophils on the vascular 
endothelium and subsequent migration therefore we will focus on these molecules.     
 
1.12.2 β2-Intergrin: Leucocyte function antigen-1 (CD18/CD11a) 
 The leucocyte function antigen-1 (LFA-1) comprises the common β-chain CD18 and 
the CD11a alpha chain, and is thought to be the principle B2-integrin involved in 
neutrophil adhesion and migration.  It is expressed constitutively on the neutrophil 
surface and levels are unaltered by neutrophil activation during sepsis.  The 
extracellular domain of LFA-1 contains a clever knee or “genu” which is present in a 
compact conformation with the legs of the molecule bent down towards the cell 
membrane in the resting state therefore concealing the ligand binding sites.  Inside-out 
signalling generated by selectin-ligand binding and activation by cytokines (e.g. 
TNFα) and the chemokine CXCL8 results in this genu section extending in a two-step 
process to first a low-affinity state (during rolling) and then a high-affinity state 
(during arrest), where the ligand binding site is projected away from the membrane in 
a “clasp knife” action. (Takagi et al., 2002) This leads to an enhanced affinity of LFA-
1 to its ligand on the endothelial cell, intracellular-adhesion molecule-1 (ICAM-1 or 
CD54).  ICAM-1 expression on endothelial cells is upregulated by the pro-
inflammatory cytokines TNFα and IL-1 secreted by macrophages.  (Yang et al., 2005) 
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Additionally clustering of LFA-1 occurs due to lateral mobility of the molecule at 
areas where cell-surface ligands are present, which increases cell avidity.  During 
neutrophil migration LFA-1 forms ring-like clusters at the neutrophil-endothelial 
junction. (Shaw et al., 2004) These clusters move from the leading edge to the rear of 
the neutrophil (uropod), always in contact with their major ligand ICAM-1.  Binding 
of integrins to their ligands induces outside-in signalling with concomitant activation 
of several intracellular signalling pathways.  (Zarbock and Ley, 2008) 
 
1.12.3 β2-Intergrin: Macrophage-1 (CD18/CD11b) 
The β2-integrin, comprised of CD18 and alpha chains CD11b, is termed macrophage-
1 (Mac-1) and neutrophils have constitutive low-level surface expression in the 
resting state.  However, Mac-1 is contained in secretory vesicles as well as secondary 
and tertiary granules; these fuse with the plasmalemma upon neutrophil activation.  
CD11b expression can therefore be used as a marker of degranulation and in sepsis 
Mac-1 expression is seen to be upregulated in most studies.  Mac-1 recognises the 
ligand for β2-integrin ICAM-1, expressed on endothelial cells and regulates rolling 
velocity of neutrophils in vivo. (Diamond et al., 1990) Mac-1 however binds a number 
of additional ligands, including bacterial and fungal glycoproteins, heparin, 
coagulation factor Xa, fibrinogen and complement protein C3bi. (Altieri et al., 1988, 
Beller et al., 1982) In addition Mac-1 is involved in neutrophil-platelet interactions 
and intravascular crawling of neutrophils.  Mac-1 is also critical for complement-
mediated phagocytosis.  Mac-1 cooperates functionally with other ligands including 
Fragment crystallisable-γ receptors (FcγR), TLRs and CD14. (Sabroe et al., 2003) In 
addition, activation of Mac-1 modulates neutrophil apoptosis. (Mayadas and Cullere, 
2005) Neutrophil adhesion to Mac-1 ligands, fibrinogen and ICAM-1, extends the life 
span of neutrophils.  This is mediated through activation of a Serine/Threonine 
specific protein kinase called Akt [also known as Protein kinase B], MKK activation 
and NF-κB activation. (Whitlock et al., 2000) Soluble fibrinogen can activate 
neutrophils and delay apoptosis through Mac-1 activation so adhesion is not essential 
to generate survival signals.  (Rubel et al., 2003) 
 
 51 
1.13 Neutrophil transmigration 
Upon receiving secondary chemotactic signals adherent leucocytes proceed to migrate 
through inter-endothelial spaces down a chemokine gradient. (Cinamon et al., 2004) 
Neutrophils initially crawl along blood vessel walls in a Mac-1-and ICAM-1 
dependent manner, seeking optimal sites for transmigration. (Phillipson et al., 2006) 
The route of transmigration, either paracellular or transcellular, may depend upon the 
composition of the endothelium, basement membrane, and the presence of pericytes 
which varies depending on the vascular bed encountered.  After chemokine activation 
adherent neutrophils can induce ‘docking structures’ to form on endothelial cells. 
(Carman and Springer, 2004) These structures are endothelial projections rich in 
ICAM-1 and cytoplasmic molecules such as ERM proteins and cytoskeletal 
components such as viniculin, α-actinin and talin-1.  (Barreiro et al., 2002) The 
development of these docking sites is dependent on integrin-ligand binding, which 
induces clustering in association with cytokine proteins dependent on the expression 
of phosphatidylinositol-4-5-bisphosphonate and Rho family GTPase. (Carman and 
Springer, 2004, Barreiro et al., 2002) These docking structures are seen to develop in 
projections that may initiate transendothelial cell migration.   
Transmigration is poorly understood, however, activation of p38-MAPK and 
ERK1/2 in the endothelium appears to be essential for neutrophils to transverse the 
endothelial barrier (Stein et al., 2003).  Ultimately neutrophils enter the extra-cellular 
space and accumulate in and around the infectious microbe and damaged cell. 
Specificity exists in that neutrophil migration relies on LFA-1 – ICAM-1 interactions 
in combination with the chemokine receptors CXCR1 and CXCR2 binding the 
chemokine IL-8.  This differs from monocytes which utilise VLA-4 – VCAM-1 
interactions together with the chemokine CCL2 binding to the chemokine receptor 
CCR2.  Temporally distinct expression of adhesion molecules and chemokines at 
infectious sites typically results in early neutrophil recruitment (hours to days) 
followed later by monocyte recruitment (days to weeks).  In sepsis, transmigration 
appears to be impaired and affected by a number of circulating factors, such as IL-8, 
C5a and TNFα resulting in extensive neutrophil-endothelial interactions and 
potentially enhancing vascular damage. TNFα in addition inhibits apoptosis and 
enhances production of ROS but suppresses CXCR2 expression. (Asagoe et al., 1998)   
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1.14 Neutrophil recruitment into the liver and liver sinusoidal 
endothelial cell: does it differ? 
In response to acute liver injury neutrophils marginate within the hepatic sinusoids 
and post-sinusoidal venules prior to transmigration into the tissue.  This accumulation 
is mediated by a variety of pro-inflammatory cytokines, such as IL-1 and TNFα, and 
a number of chemokines including IL-8, MIP-2, KC, cytokine-induced neutrophil 
chemoattractant-1 (CINC-1), PAF and ostopontin-1 (localised within the biliary 
epithelial cell). (Ramaiah and Jaeschke, 2007) In contrast to adhesion in post-
sinusoidal-venules neutrophil accumulation within sinusoids does not appear to be 
dependent on selectins and β2-integrins. (Jaeschke, 2000) LSEC do not express CD34 
the receptor for L-selectin and P-selectin is deficient in the liver.  Neutrophil 
accumulation within sinusoids and post-sinusoid venules does not typically cause 
liver damage per se without extravasation into the parenchyma. (Chosay et al., 1997)  
Increased production of CXC chemokines within hepatocytes can cause 
neutrophil infiltration, extravasation and consequent neutrophil-dependent 
cytotoxicity, but this is not always the case.  There appears to be a need to establish a 
chemotactic gradient, at the right time and in sufficient quantities. (Dorman et al., 
2005) Apoptotic hepatocytes can mediate neutrophil extravasation and can generate 
CXC chemokines in sufficient quantities to trigger neutrophil accumulation into the 
liver in the presence of other potent pro-inflammatory mediators (chemokine in 
isolation have little direct effect). (Jaeschke et al., 1998) Direct-cell contact through 
endothelial gaps with either apoptotic or necrotic cells may induce extravasation.  
ROS and lipid peroxidation products including lipid aldehydes are potent 
chemoattractant factors for neutrophils. (Jaeschke, 2000) Activated neutrophils can 
recruit more neutrophils by their production of LT-B4, as seen during ischaemia-
reperfusion injury. (Jaeschke, 2003) 
  
1.15 Phagocytosis 
Phagocytosis is defined as the vesicular internalisation of solids such as bacteria by 
the extension of pseudopods around the particle involving actin filaments (Bajno et 
al., 2000) and is central to the microbicidal function of neutrophils.  Pathogens and 
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foreign debris are first engulfed into a plasma membrane-derived “digestive vacuole” 
or phagosome; (Cohn and Hirsch, 1960) this subsequently acquires anti-microbial 
properties through granule fusion in a process termed ‘maturation’. (Lee et al., 2003) 
Neutrophils from sepsis patients show enhanced internalisation and destruction of 
micro-organisms. (Martins et al., 2003) 
Neutrophils can phagocytose both opsonised and non-opsonised particles.   
Phagocytosis is initiated following recognition of particles by a number of PRRs; 
these include scavenger receptors (e.g. TREM), complement (e.g. Mac-1) and 
immunoglobulin receptors (e.g. FcγR).  There are 3 types of Fc receptor produced by 
neutrophils and the pattern of surface expression depends on the state of activation.  
Resting neutrophils express the low affinity FcγRIIA (CD32) and FcγRIIIb (CD16) 
and following priming with IFN, neutrophils express the high affinity FcγRII (CD64). 
(McKenzie and Schreiber, 1998) The importance of immunoglobulin opsonisation in 
neutrophil uptake and destruction is highlighted by X-linked agammaglobulinaemia 
(Bruton’s disease) where there is defective class switching by B-cells preventing 
gamma-globulin production. This results in a neutrophil defect with the failure of 
phagocytes to clear bacterial pathogens from infected tissues and blood. (Bruton et al., 
1952) The response induced by the neutrophil depends on the ligand receptor 
response.  Complement opsonised particles are internalised by gently sinking into the 
cell, whereas FcγR ligation initiates the rapid extension of pseudopods that envelop 
around the opsonised microbe. (Greenberg and Grinstein, 2002)   
When invading microbes come into contact with neutrophils binding occurs to 
multiple ligands on the cell surface. The binding of opsonised microbes to FcγR on 
the neutrophil surface leads to clustering of the transmembrane FcγR and subsequent 
recruitment of Src-kinases to the clustered area. (Kiefer et al., 1998) These Src-
kinases activate the FcγR through phosphorylation of the tandem tyrosine residues 
within an area termed the immunoreceptor tyrosine activation motif (ITAM). 
(Greenberg and Grinstein, 2002) Phosphorylation of the ITAM generates docking 
sites for proteins bearing a SH2- domain especially the Syk kinases.  This is an 
essential step as Syk-deficient mice are unable to ingest IgG-opsonised particles. 
(Botelho et al., 2000) Downstream activation of protein and lipid kinases then occurs 
especially Phosphatidylinositide 3-kinase  (PI3K) and Phospholipase C (PLC). (Cox 
and Greenberg, 2001) These induce the polymerisation of actin and localise 
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membrane remodelling required for particle ingestion.   Cessation of PI3K is abrupt 
and in part is due to the recruitment of lipid phosphatase to the phagocytic cup. (Cox 
et al., 2001) Diacylglycerol (DAG) is also produced through the action of PLC on 
phosphatidylinositol 4,5-bisphosphate.  DAG activates protein kinase C (PKC) that 
can participate in particle uptake. (Botelho et al., 2000) Differences are seen in the 
molecules recruited, which may account for the different responses seen with 
complement and immunoglobulin mediated phagocytosis such as MEK-1, which 
appears to be selectively involved in FcγR mediated phagocytosis in neutrophils. 
(Mansfield et al., 2000)   
Once formed, phagosomes enter the endocytic pathway and undergo a rapid 
sequence of events leading to maturation. Termed the ‘kiss and run’ hypothesis, 
sequential granule fusion occurs altering both the contents and membrane 
composition of the phagosome. (Desjardins, 1995) Maturation is an energy dependent 
process resulting in vacuolar remodelling and fusion of cytoplasmic granules.  
Through this process the phagosome acquires a highly toxic environment including 
the acquisition of microbial enzymes, vacuolar (V) ATPase and the NADPH oxidase 
complex. (Kinchen and Ravichandran, 2008) The dynamics of this process are rapid 
with phagocytosis of opsonised particles and subsequent phagosome maturation 
occurring in as little as 20 seconds.  (Segal et al., 1980) 
There appears to be a hierarchy of microbial susceptibility to phagocyte-
mediated death from highly susceptible organisms such as streptococci and yeast to 
microorganisms that have adapted to survive the harsh environment of the phagosome 
such as mycobacteria that survive by suppressing calcium influx into the cell.  Others 
such as listeria evade phagocytes using the actin assembly of host cells to directly 
spread cell to cell. (Zhang et al., 2009, Flannagan et al., 2009) 
 
1.16  Neutrophil granules 
Neutrophils are characterised morphologically by their large quantity of 
poorly staining cytoplasmic granules.  The granules play an important part in the 
process of microbial killing.  Neutrophils exit the BM after going through a prolonged 
development process the purpose of which is to equip them with a complete array of 
pre-packaged antimicrobial enzymes and sufficient surface receptor expression with 
more in reserve for rapid up-regulation allowing them to operate independently of 
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protein transcription and translation in the initial phase.  The different content of 
granules is explained by the ‘targeting-by-timing’ hypothesis whereby granule 
production occurs continuously during development from the promyelocyte to the 
segmented neutrophil but due to the changing profile of granule proteins synthesised 
during different stages granule content differs.  Azurophilic granules are synthesised 
at the promyelocytic stage, specific granules at the myelocytic stage and gelatinase 
granules at the promyelocytic and band cell stage.  However, to some extent this 
should be thought of as a continuum with subsets being identified due to the presence 
of an altering array of marker proteins. (Borregaard et al., 2007) Secretory vesicles are 
endocytotic particles.  Neutrophil granules have been recognised since Metchnikov 
and Ehrlich.  Further work performed in 1952 by Chediak, a Cuban physician, 
uncovered the antimicrobial importance of these granules.  Chediak described patients 
with a rare autosomal recessive condition with several distinctive characteristics 
including recurrent pyogenic infections, partial albinism and peripheral neuropathy 
associated with giant cytoplasmic leukocyte granules.  (Chediak, 1952) Chediak-
Heigasi syndrome, as it is eponymously called, results from the defective gene 
CHS1/LYST, a gene belonging to the BEACH family of vesicle trafficking regulatory 
proteins. (Zarzour et al., 2005) The defective protein prevents the formation of the 
phagolysosome and failure of degranulation into the phagosome, cytoplasmic 
granules then become excessively enlarged in the neutrophil cytoplasm, and 
ultimately this results in impaired neutrophil bacteriolysis.  Affected children suffer 
recurrent infections and the syndrome is associated with oculocutaneous albinism. 
Different subsets of granules have now been characterised by phase contrast 
electron microscopy (Bainton, 1993), flow cytometry and functional analysis.  
Neutrophil granules develop during the promyelocytic and myelocytic phases of 
development in the BM, and their contents depend on the proteins being synthesised 
at the time and the presence of signalling peptides.  The different granules have long 
been recognised to possess microbicidal activity and contain reservoirs of digestive 
and hydrolytic enzymes as well as the components of the NADPH oxidase.  
(Faurschou and Borregaard, 2003) 
The cytoplasm contains four differing types of granules that bud from the 
Golgi network in a sequential fashion during neutrophil maturation in the BM, 
resulting in a difference in granule contents and membrane structure [see figure 1-6]. 
(Borregaard et al., 2007)  
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1.16.1 Azurophilic granules 
Azurophilic or primary granules are the first to appear during neutrophil development. 
They contain a vast array of antimicrobial factors including myeloperoxidase (MPO), 
phospholipase-A2 and three predominant neutral proteases: cathepsin G, elastase and 
proteinase-3. (Bokoch, 1995) In addition they contain antibacterial proteins including 
lysozyme (approximately one third of the cellular contents), defensins, (Ganz, 2003) 
cathelicidins (Ding et al., 1996) and bacterial/permeability-increasing protein (BPI).  
BPI is a membrane bound protein within granules that can bind and neutralise LPS, 
whilst also possessing the ability to permeabilise and neutralise E.coli. (Weiss et al., 
1978) Azurophilic granules can be identified on flow cytometry due to the 
characteristic presence of surface CD63.  (Niessen and Verhoeven, 1992) The 
granular contents are enmeshed within an extensive matrix composed of negatively 
charged sulphated proteoglycans. (Ptasznik et al., 1996) This matrix sequesters the 
mainly cationic proteins and together with the acidic environment ensures the 
enzymes are kept inactive.  Interestingly, the absence of neutrophil elastase is the 











FIGURE 1-6 NEUTROPHIL GRANULES AND SECRETORY VESICLES 
CONTENT AND SURFACE MARKERS INCLUDING RELATIONSHIP TO 
OXIDATIVE BURST AND MICROBIAL EXTERMINATION IN THE 
PHAGOSOME.  
Abbreviations: BPIP – Bacterial permeability increasing protein.    
 
1.16.2 Specific granules 
Specific or secondary granules characteristically express membrane-bound CD66b 
allowing identification by flow cytometry.  The granules contain unsaturated 
lactoferrin (able to sequester iron and copper), transcobalamin II and lysozyme 
(approximately two thirds of the cellular contents), neutrophil gelatinase-associated 
lipocalin (NGAL) and gelatinase, (Bokoch, 1995, Bundgaard et al., 1994) and a 
neutrophil specific matrix metalloproteinase (MMP) leukolysin component.  
Alexander Fleming discovered lysozyme in 1921; he demonstrated that his own nasal 
mucous could kill bacteria after ‘sneezing’ over a culture dish containing bacteria.  
Lysozyme was later shown to act by disrupting the bacterial peptidoglycan cell wall 
leading to cell lysis.    
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In addition, specific granules possess membrane bound flavocytochrome b558, 
the core component of the NADPH oxidase, which when assembled on the 
phagosome membrane acts as an electron channel. (Segal and Jones, 1979) The 
importance of specific granules is highlighted by the rare congenital absence of 
specific granules caused by the functional loss of transcription factor C/EBPε or Gfi-I. 
This condition is associated with recurrent infections with Staphylococcus aureus and 
Pseudomonas.spp.  (Lekstrom-Himes et al., 1999) 
 
1.16.3 Gelatinase granules 
Gelatinase or tertiary granules, which lack CD66b, are typified by high concentrations 
of gelatinase in the absence of lactoferrin and are likely to represent a continuum of 
specific granules.  (Bokoch, 1995) Lysozyme is present in gelatinase granules but less 
than that present in azurophilic or specific granules.   
 
1.16.4 Secretory vesicles 
Secretory vesicles characteristically contain albumin and express surface alkaline 
phosphatase and CD35. (Lee et al., 2003) These empty vacuoles are endocytotic in 
origin and serve as a reservoir of membrane components, such as CD11b. (Segal, 
2005) Secretory vesicles are the first to be mobilised during neutrophil priming, 
rapidly fusing with the plasma membrane following the binding of selectins to PSGL-
1. (McEver and Cummings, 1997) This is supported by studies showing the absence 
of secretory vesicles following neutrophil migration through a skin window chamber 
(Ptasznik et al., 1995). This mechanism is thought to underlie the upregulation of 
CD11b observed on neutrophils isolated from patients with sepsis.   
 
1.16.5 Lysosomes 
Lysosomes contain acid hydrolases and therefore perform similar duties to azurophilic 
granules but fuse with the phagosome at a later time point so are considered separate.   
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1.16.6 Granules and phagosome maturation 
Granular fusion with the phagosome and plasma membrane occurs in an elegant 
sequential fashion with increasing intracellular calcium [Ca2+]i levels within the 
neutrophil appearing to be the critical signalling event leading to granule fusion. 
(Stendahl et al., 1994) Granules possess different calcium thresholds, a characteristic 
feature that appears to be regulated by differential granular expression of a family of 
calcium responsive proteins called the synaptotagmins. (Lindmark et al., 2002) 
Secretory vesicles have the lowest threshold and azurophilic the highest. (Sengelov et 
al., 1993) The result is that secretory vesicles can fuse rapidly with the plasma 
membrane following initial neutrophil priming leading to up-regulation in expression 
of surface receptors such as CD11b.  Sequentially higher thresholds of [Ca2+]i are 
required for gelatinase, specific and finally azurophilic granules to fuse with the 
plasma membrane or phagosome (azurophilic granules principally fuse with the 
phagosome membrane).   
In order to facilitate granular fusion with the phagosome there is an associated 
calcium-dependent disassembly of the actin coat surrounding the phagosome-cup, 
revealing vesicle docking and fusion sites.  (Zeytun et al., 2010) As the phagosome 
matures further it acquires calmodulin in a calcium-dependent fashion where it can 
catalyse lipid bilayer membrane fusion. (Peters and Mayer, 1998) Finally the calcium 
binding proteins Annexin I and III appear to associate with the matured phagosome 
although their function is as yet unclear.  (Rosales and Ernst, 1997) 
Activation of Hck, a tyrosine protein kinase belonging to the Src family of 
protein kinases, appears to be important in the process of phagosome maturation.  Src 
family kinases are activated following the clustering of membrane receptors such as 
the FcγR.   Hck is localised to the azurophilic granules and upon phagocytosis of 
opsonised particles it activates and translocates towards the phagosome. The 
important role for Hck is supported by the finding that neutrophil internalisation of 
mycobacteria fails to activate Hck, leading to the failure of azurophilic granules to 
fuse with the phagosome while fusion of secretory vesicles is unaffected. (N'Diaye et 
al., 1998) Overall, comparatively little is known about the events that trigger 
membrane fusion during maturation of phagosomes in neutrophils.  
Interestingly, different stimuli can cause variability in the location of fusion 
events.  Soluble agonists, such as PMA, cause secretory vesicles and granules to fuse 
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throughout the plasma membrane; however, during phagocytosis fusion is restricted 
to the nascent and formed phagosome.  Specificity for fusion events appears to 
involve soluble N-ethylmaleimide-sensitive-fusion protein attachment protein 
receptors (SNARE), donor, and receptor SNARE molecules e.g. SNAP-23 on specific 
and tertiary granules which interact with synaxin-6 on the phagosome (terahelical 
complex). (Peters and Mayer, 1998) 
Phagosome maturation therefore involves a complex sequence of events 
initially involving rapidly increasing [Ca2+]I levels within the cell as a consequence of 
priming and activation signals. This results in the loss of the actin coat around the 
phagosome-cup followed by sequential fusion of the specific and then azurophilic 
granules with the now revealed docking sites.  Some researchers dispute the relevance 
of the sequential fusion of granules with the phagosome as granular fusion events 
occur in a rapid fashion, (Segal et al., 1980) with the suggestion that sequential 
granular fusion events have relevance at the site of the plasma membrane during 
neutrophil priming but this is far from clear.    
 
1.17 The Neutrophil NADPH oxidase 
Neutrophils can produce large numbers of ROS generated almost exclusively from 
NADPH oxidase in a process termed oxidative burst (OB). (Sbarra and Karnovsky, 
1959) Leucocyte-specific NADPH oxidase is a multi-subunit entity with membrane 
bound and soluble components that assembles into a heteromeric complex when the 
cells are stimulated. (Vignais, 2002) The importance of this step is highlighted by 
chronic granulomatous disease (CGD), a condition where OB is defective with cells 
being unable to generate superoxide.  CGD is characterised by recurrent life-
threatening bacterial and fungal infections along with granuloma formation. (Baehner 
and Nathan, 1967) Indeed, it is the study of this condition that has revealed much 
about the NADPH oxidase as a number of different defects can result in the condition; 
the most common defects occurring in the X-linked gene encoding the gp91 subunit 
of the flavocytochrome b558.  The NADPH oxidase requires assembly prior to 
activation within the phagosome with the intrinsic components of the NADPH 
oxidase being mostly absent from the nascent phagosome at rest.  The catalytic core 
of the complex, the Haem containing flavocytochrome b558, is bound to the internal 
membrane of specific granules, being delivered through fusion events during 
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phagosome maturation. The cytosolic components, termed ‘phagocyte oxidase’ 
(phox) proteins are translocated to the membrane-bound flavocytochrome b558 in 
activated phagocytes.  The NADPH oxidase is a heterodimer composed of a larger 
glycoprotein: phagocyte oxidase glycoprotein 91 (gp91phox), and a small protein: 
phagocyte oxidase protein 22 (p22phox).  The C-terminus of the gp91phox participates in 
NADPH and flavin adenine dinucleotide (FAD) binding.  The N-terminus of the 
gp91phox possesses a haem co-ordinating region, which binds two heam molecules 
either side of the plasma membrane consistent with the gp91phox function as an 
electron transporter.  p22phox provides a high affinity binding site for cytosolic 
NADPH oxidase subunits.  Associated proteins of cytosolic origin promote transition 
of flavocytochrome b558 from a resting to activated state. (Vignais, 2002) Three 
components p47phox, p67phox and a small GTP protein, either Rac-1 or Rac-2, are 
sufficient, when used in a cell free assay, to activate the flavocytochrome b558 core. 
(Abo et al., 1992) In addition, p40phox appears to be associated with p47phox and 
p67phox and may play a role in regulation of NADPH-oxidase activity. (Wientjes et al., 
1993) This process appears to involve phosphorylation of the cytosolic components 
and the involvement of phosphatidylinositol phosphates.  p47phox is heavily 
phosphorylated during neutrophil activation and appears to be an adaptor molecule 
forming a bridge between p22phox and p67phox. (Segal, 2005) Pentoxifylline attenuates 
activation of signaling molecules involved in activation of p47phox and suppress the 
subsequent assembly of the NADPH machinery through both PKA-dependent and 
PKA-independent mechanisms (Costantini et al., 2010).  p67phox binds either Rac-1 or 
Rac-2 an essential requirement for NADPH activation. (Bokoch, 1995) 
The assembled oxidase generates the superoxide anion by transfer of one 
electron from cytosolic NADPH to molecular oxygen to generate the superoxide 
anion (•O2-).  Superoxide is rapidly converted to hydrogen peroxide (H2O2) by the 
enzyme superoxide dismutase (SOD).  Superoxide and H2O2 can interact to form the 
hydroxyl radical •OH via the Harber-weiss reaction, catalysed by heavy metals such 
as iron (Fenton reaction).  The hydroxyl radical is highly toxic but there is some 
debate about its generation in vivo due to the presence of unsaturated lactoferrin in the 
granule protein, which inhibits this reaction.   Myeloperoxidase is a di-haem 
containing heterodimer abundantly present in neutrophils composing 25% of 
azurophilic granular protein.  Interestingly, the green tinge of secretions, such as pus 
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and mucous, rich in neutrophils is due to the haem molecules in MPO.  MPO converts 
H2O2 and chloride anions into hypochlorous acid, which in combination with halides 
can produce hypochlorous acid. (Weiss et al., 1982) MPO-mediated halogenation is 
important in the antimicrobial action of neutrophils but there is some debate regarding 
the exact mechanism of action, with recent work supporting an alternative hypothesis 
whereby indirect activation of granule enzymes rather than direct microbial toxicity 
occurs. (Reeves et al., 2002) However, hypochlorous acid appears to be generated 
within the phagosome but the role of MPO may in addition be to preserve the function 
of granule proteins by preventing accumulation of H2O2. (Nauseef, 2007) The 
NADPH oxidase is more pronounced in neutrophils compared to macrophages.  
Indeed, much research has focused on the role of NADPH oxidase in microbial killing 
linked to the defects seen in CGD, whereas other anti-microbial mechanisms such as 
serine proteases and defensins have to some extent been neglected.  More recently 
Segal and others have questioned the precise role of NADPH oxidase in vivo as many 
assays reported in the literature have been performed in a cell free environment and 
many of the free radical species may not form in vivo. (Segal, 2005) The exact 
location of the NADPH assembly may also be important as soluble agonists such as 
PMA can lead to assembly at the plasma membrane in vitro; however, assembly in 
vivo is thought to occur exclusively at the phagosome membrane.  The presence of a 
number of heavy metal scavengers, such as lactoferrin, within the phagosome may 
prevent the formation of the hydroxyl radicle and subsequent hypochlorous acid.  
Indeed, MPO deficiency appears to lead to little clinical consequence (cf. CGD).  It 
has therefore been postulated that the critical role of the NADPH oxidase is to 
dissolve the granule matrix and activate the enzymatic granular content, although this 
is a contentious area.   
Granules are kept acidic (approximately pH 5 by the presence of a proton 
pump) in order to maintain the acidic glycoprotein matrix and keep the proteases in a 
quiescent state.  The activity of NADPH oxidase alters the appearance of the 
phagocytic vacuole soon after the phagocytosis of bacteria, with loss of the ground 
glass appearance seen on electron microscopy.  The change in appearance of the 
phagosome fails to occur in patients with CGD, suggesting that the oxidase changes 
granule contents.  The NADPH oxidase transfers electrons into the phagosome 
depolarising the membrane but in order for continued function this charge must be 
compensated.  Phagosomes briefly increase their pH shortly after granular fusion due 
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to the consumption of H+ ions in the dismutation of superoxide to H2O2.  (Cech and 
Lehrer, 1984) K+ enters the cell as an inward rectifying current through a large 
conductance Ca2+-activated K+-channel.  This neutralises the electrogenic 
displacement of electrons by the oxidase leading to a hypertonic milieu.  The brief 
rise in vacuolar pH and hypertonic K+ facilitate dissolution of the matrix glycoprotein, 
releasing and activating the cationic proteases into solution (Reeves et al., 2002).  In 
order for these hypertonic conditions to develop, water penetration of the phagosome 
must be prevented and this is achieved by encasing the phagosome in a meshwork of 
cytoskeletal proteins, including paxillin and vinculin.  (Granfeldt and Dahlgren, 2001)  
 
1.18 Microbial killing in the phagosome 
The critical steps in neutrophil killing appear to be phagocytosis followed by 
‘oxidative burst’ and production of ROS through the actions of the NADPH oxidase 
with subsequent generation of hydrogen peroxide and ‘hypochlorous acid’ within the 
phagosome through the actions of SOD and MPO.  Hypochlorous acid has been 
shown to cause membrane changes through chlorination of membrane proteins, 
ultimately leading to cell lysis. (Vissers et al., 1994) Defensins are a second 
neutrophil membrane disruption technique; these highly conserved peptides are 
widespread across animals and plants alike, and result in disruption of microbial 
membranes through binding and formation of a pore-like membrane defect [c.f. the 
membrane attack complex of complement].  (Ganz, 2003) Gene knockout mice show 
the importance of neutrophil granular enzymes in microbial defence.  Neutrophil 
elastase (NE)-deficient mice are susceptible to gram-negative and candida infections.  
Cathepsin-G deficiency on its own produces a less severe defect with susceptibility to 
Aspergillus fumigatus and Candida.spp; however, deficiency of both enzymes causes 
a profound inability to kill phagocytosed bacteria similar to CGD despite preserved 
functioning of the NADPH oxidase and protein iodination.  (Reeves et al., 2002)  
 
1.19 Neutrophil cytokine production 
Neutrophils are not classically credited with producing significant amounts of 
cytokines at sites of inflammation; this principally being thought of as the preserve of 
macrophages.  Terminal differentiation of neutrophils was believed to preclude them 
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from undertaking further protein synthesis.  However, recently it has been shown that 
neutrophils in peripheral tissues undergo active protein transcription and translation 
releasing chemokines, cytokines and lipid mediators. (Altstaedt et al., 1996, 
Cassatella, 1995) Although neutrophils produce much smaller quantities of 
inflammatory mediators than macrophages their sheer number mean they can 
contribute significantly to the recruitment of further neutrophils and other 
inflammatory cells, particularly monocytes and macrophages.   
Following TLR activation primed neutrophils rapidly generate IL-8 in 
response to TNFα.  (Zu et al., 1998)  They also produce the anti-inflammatory IL-1R 
antagonist (Stanley et al., 1996) and the anti-inflammatory cytokine IL-10. (Zhang et 
al., 2009) There is contentious data regarding the ability of neutrophils to secrete IL-
1β, IL-6 and TNFα (Kasama et al., 2005) with macrophage contamination cited as the 
explanation for this phenomenon.  More recently however, intracellular cytokine 
staining techniques have demonstrated neutrophil production of IL-17A in an IL-23-
dependent manner in response to Aspergillus fumigatus (Werner et al., 2011).  
Neutrophils also produce macrophage colony-stimulating factor attracting 
macrophages, suggesting they mediate transmission from acute inflammation into 
either resolution or chronic infection.  (Soehnlein et al., 2009) This may lead to 
resolution of inflammation with progression to a macrophage predominant cellular 
infiltrate.  It is increasingly recognised that neutrophil cytokine production appears to 
play a role in the development of chronic inflammatory conditions such as chronic 
obstructive pulmonary disease, arthritis and inflammatory bowel disease. (Quint and 
Wedzicha, 2007, Tanaka et al., 2006, Chin and Parkos, 2006) For example, in 
immune complex-mediated arthritis neutrophils located within the joint release 
chemokines and cytokines including LT-B4, MIP-1α, MIP-2 and IL-1β, which have 
direct and indirect activity encouraging further neutrophil recruitment.  Secreted 
proteases can degrade or activate secreted chemokines and cytokines in the extra-
cellular space thereby neutrophils can recruit further neutrophils.   
 
1.20 Apoptosis and resolution of inflammation 
Apoptosis or programmed cell death has a significant role in the control of the 
immune response.  Apoptosis limits the potentially destructive effects of neutrophil 
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cytotoxicity and may prevent the survival of organisms that have adapted to the harsh 
environment within the neutrophil phagosome (e.g. mycobacteria).  Neutrophils are 
cleared from tissues by apoptosis and are subsequently phagocytosed by resident 
macrophages, a process known as efferocytosis that promotes the resolution of the 
inflammatory process.  Neutrophils are terminally differentiated cells and have a 
circulating life span of 5.4 days, undergoing constitutive apoptosis in the spleen and 
BM.   
Apoptosis is an active process that can be accelerated or delayed by competing 
anti and pro-apoptotic signals.  GM-CSF, G-CSF, IL-1, TNF, IL-6, LT-B4, C5a and 
LPS, all prolong the life span of circulating neutrophils.  (El Kebir and Filep, 2013) 
Apoptosis is regulated at the transcription level.  High doses of TNF or cellular stress 
can accelerate the spontaneous rate of apoptosis.  Caspase 3 and 8 are probably 
involved in constitutive neutrophil apoptosis.  Transcription regulation of apoptosis-
related proteins by IFN consensus sequence-binding protein promotes cell death by 
up-regulating expression of a pro-apoptotic caspase 3 precursor, and down-regulates 
the anti-apoptotic protein Bcl-X.  Other signalling pathways that promote in vitro 
survival in neutrophils include mitogen-activated protein-extracellular signal-
regulated kinase Serine/Threonine kinase (MAPK-ERK) activation and NF-κB 
mediated transcription of survival proteins.  Neutrophil adhesion to Mac-1 ligands, 
fibrinogen and ICAM-1, extend the life span of neutrophils.  The delay in apoptosis in 
response to ICAM-1 adhesion is attributed to Akt activated through the PI-3K 
pathway.  Soluble factors such as fibrinogen can promote neutrophil activation 
(increase [Ca2+] i and Mac-1 expression) in a Mac-1 dependent manner and also 
delays apoptosis through the activation of NF-κB and MAPK-ERK.  Therefore 
neutrophils do not need to be adherent to the endothelium for survival signals to be 
generated.  Antibody cross-linking of Mac-1 in the presence of anti-Fas antibody or 
TNF alters this balance as activation of Akt is decreased.  This leads to NADPH 
oxidase activation and release of ROS that leads to activation of SHIP (Src homology 
2-containing inositol phosphatase), an inositol phosphatase that hydrolyses products 
of PI-3K through the Src kinase Lyn.  Extracellular ROS may diffuse back into cells 
to signal death which may be relevant in vivo under conditions of high neutrophil 
accumulation.  Mac-1 is also required for apoptosis induced by other cell surface 
receptors perhaps due to functional co-operation of Mac-1 with other receptors.  For 
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example, TNF promotes neutrophil apoptosis in response to engagement of receptors 
for fMLP, immune complexes and Zymosan.  The role of Mac-1 in apoptosis might 
be limited to promoting ROS generation, which in turn activates caspase 8 through 
receptor independent mechanisms.   
Phagocytosis of complement-opsonised E-coli accelerates apoptosis and is 
termed phagocytosis-induced cell death (PICD).  A certain threshold of ROS 
generation is required and a sustained intracellular oxidative burst appears to be 
relevant. ROS leakage from the phagosome into the cytoplasm could provide a 
mechanism for its effects on Mac-1 –dependent caspase cleavage and PICD.  Mac-1 
dependent phagocytosis also engages survival pathways, such as the activation of 
MAPK-ERK.  However, ROS-triggered caspase 3 and 8 activation overcomes these 
survival signals, promoting rapid apoptosis of the phagocytosing neutrophil.  A more 
robust activation of MAPK-ERK also occurs during Mac-1 dependent phagocytosis in 
the presence of GM-CSF. This results in a decrease of caspase activation and the 
associated apoptosis, despite an enhanced oxidative burst under these conditions.   
Thus MAPK-ERK activation generates competing survival pathways that can avert 
PICD.  In summary, Mac-1-mediated phagocytosis in neutrophils integrates pro- and 
anti-apoptotic signals that eventually favour cell death.  These signals are driven by 
intracellular ROS production, caspase 3 and 8 and MAPK-ERK activation.  
Additional exogenous stimuli such as TNF and GM-CSF, present at inflammatory 
sites, exploit these intracellular signals generated by phagocytosis to shift the life-
death balance during phagocytosis to either enhanced survival or apoptosis.   
β2-integrin engagement during neutrophil transmigration extends the survival 
and thus pool of functional neutrophils in tissues, whereas β2-integrin-dependent 
phagocytosis of microbes accelerates apoptosis and might be a potent mechanism to 
eliminate neutrophils that have reached the end of their useful life span.  (Mayadas 
and Cullere, 2005) 
Removal of neutrophils by apoptosis is a homeostatic mechanism that prevents 
damage to healthy tissues that would otherwise occur after necrotic cell lysis.  This 
process is central to the prevention and resolution of inflammation.  Neutrophil 
apoptosis is inhibited in patients with systemic inflammation, systemic infections, 
severe sepsis and those at risk of multiple organ dysfunction syndrome (MODS).   
This reduced apoptosis is thought to be due to the activity of circulating factors that 
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include LPS, lipoteichoic acid and pro-inflammatory cytokines although binding to 
activated endothelium extends the life-span of neutrophils in contrast to unstimulated 
endothelium which exacerbates cell death. Soluble fibrinogen can activate neutrophils 
and delay apoptosis through Mac-1 activation so adhesion is not essential to generate 
survival signals.  The extended life span will contribute to neutrophil mediated tissue 
damage through release of ROS and proteolytic enzymes.  ERK kinase but not p38-
MAPK regulates LPS-induced reduction in apoptosis. (Harter et al., 2002)   
In adult respiratory distress syndrome (ARDS), IL-2 concentration in the BAL 
(Bronchoalveolar lavage) correlates with the low level of apoptosis seen.  This takes 
place through a dysregulation of a complex network of intracellular signalling and of 
organelle function that include an increase in tyrosine phosphorylation and a sustained 
mitochondrial transmembrane potential. (Melley et al., 2005)     
 
1.21 Cellular regulation of neutrophils 
Neutrophils are also regulated by other cells of the immune system particularly T-
cells. CD4+CD25+CD127- FOXP3+ T-regulatory cells (T-regs) directly inhibit 
neutrophil function, promoting apoptosis and death when exposed to LPS through 
binding to surface bound TLR4. This inhibits pro-inflammatory activities, curtailing 
over exuberant innate immune response and helping to bring about resolution of the 
inflammatory response.  (Lewkowicz et al., 2006) Upon activation, these T-regs can 
either induce themselves or CD4+CD25-FOXP3- T effectors to differentiate into IL-
17A producing cells, Th17, in the presence of TGF-ß and/or IL-6. (Xu et al., 2007) In 
contrast to the role of T-regs on neutrophils, Th17 cells recruit neutrophils into 
inflamed tissue further increasing the antimicrobial response in vitro and in vivo. 
(Annunziato et al., 2008, Kolls et al., 2008) 
 
1.22 Summary 
Neutrophils are powerful antimicrobial effector cells that undergo prolonged 
development in the BM to equip them with an array of carefully packaged granules.  
They exist in a resting state in the circulation but can be rapidly primed through 
chemokine signalling via G-protein coupled receptors.  Subsequent activation of 
protein kinase signalling cascades up-regulate an array of surface receptors which 
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recognise PAMPs and DAMPs, as well as further chemokine and cytokine signals.  
Complex interaction with the vascular endothelium leads to recruitment into sites of 
inflammation within minutes, followed by phagocytosis of invading microbes and/or 
granular fusion events which culminate in activation of the NADPH oxidase and 
subsequently other antimicrobial systems.  The result in 99% of cases is eradication of 
the microbial invader and apoptosis leading to pus formation and resolution of 
infection.  However, inappropriate or over activation of neutrophils which release 
their toxic granular contents can lead to significant tissue collateral damage and organ 
failure.  Next I will review the evidence for neutrophil-induced damage and 
dysfunction in microbial sepsis, a syndrome with many features akin to acute liver 
failure (ALF) and liver cirrhosis.  Finally the review will focus on the limited 
literature that supports neutrophil dysfunction in all forms of liver failure on which 














































2.1 Neutrophil dysfunction, its relationship to sepsis and role in multi-
organ dysfunction syndrome (MODS). 
Neutrophils are the first line of the host defence against bacterial and fungal infection.  
Neutrophils have a complex and varied arsenal of antimicrobial weaponry with a high 
degree of redundancy that is unleashed in a precisely targeted fashion at sites of 
infection akin to chemical warfare.  Neutrophil activation can however, be a double-
edged sword, and in severe sepsis inappropriate and excessive release of active 
protease enzymes and ROS contribute to tissue damage in organs distant to the site of 
initial infection.  This can ultimately lead to organ dysfunction and in the most severe 
cases MODS with its attendant mortality. (Smith, 1994, Kyriakides et al., 2001) 
During microbial infection a careful balance must be struck between a sufficient 
neutrophil response to ensure microbial eradication whilst at the same time 
minimising collateral tissue damage and ensuring timely resolution of the 
inflammatory response. (Annane et al., 2005)  
 MODS is a severe complication of acute or chronic liver failure and severe 
sepsis with a high morbidity and mortality.  Indeed there exist many phenotypic 
similarities between patients with acute or chronic liver failure and those with severe 
sepsis, with both conditions being associated with endotoxemia, haemodynamic 
derangement and abnormal immune responses. (Rajkovic and Williams, 1985) 
Similar pathophysiological processes are therefore likely to underlie both conditions.  
Substantial progress has been made over recent decades in the understanding of the 
role of neutrophils in the immunopathology of severe sepsis but in liver failure this 
exists at a more rudimentary level.  Therefore it is timely to undertake a brief review 
of the current paradigm of sepsis and the multitude of roles played by neutrophils in 
that condition.      
 
2.2 Severe Sepsis: definitions and outcomes 
It is now well understood that sepsis is associated with a generalised inflammatory 
reaction in organs remote from the initial insult.  This is termed the systemic 
inflammatory response syndrome (SIRS).  In addition it is recognised that non-
infectious SIRS can occur in extreme events in patients with trauma, burns, 
necrotising pancreatitis and liver failure.  Severe sepsis is clinically defined by the 
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presence of a SIRS score along with radiological or laboratory evidence of infection 
and sepsis-induced tissue hypoperfusion, hypotension or organ dysfunction [Figure 2-
1]. 
 SIRS is commonly a feature of hospitalised patients with liver disease often 
precipitated by infections such as spontaneous bacterial peritonitis (SBP) and 
pneumonia but equally a sterile SIRS can be seen (e.g. acute liver failure and acute 
alcoholic hepatitis).  In liver disease, differentiation between sepsis and a sterile 
response clinically is often impossible and indeed the two may co-exist.  Patients with 
SIRS from an infectious or non-infectious aetiology are at risk of progression to 
MODS; this commonly includes a combination of some or all of the following; 
haemodynamic instability (septic shock); acute lung injury (ALI); acute kidney injury 
(AKI) and delirium (or septic encephalopathy).  Clinicians who deal with liver failure 
will be only too familiar with these complications in their patients.  Many patients 
with SIRS and MODS ultimately require specialised management on an intensive care 
unit (ICU). (Annane et al., 2005) Despite advances in intensive care management 
mortality from severe sepsis remains shockingly high at 30-70%. (Angus et al., 2001) 
Table 2-1 The Systemic Inflammatory Response Syndrome adapted from the 1992 
ACCP/SCCM Sepsis definitions  
(Bone et al., 1992)  
The Systemic Inflammatory Response Syndrome (SIRS) 
SIRS = Two or more of the following 
• Temperature>38°C or <36°C 
• Heart rate >90 beats per minute 
• Tachypnoea > 20 breaths per minute or PaCO2 <4.3 kPa 
• White cell count >12 x 109/L, <4 x 109/L, or >10% immature (band) forms 
Sepsis = SIRS with radiological or laboratory evidence of infection 
Severe sepsis = sepsis-induced tissue hypoperfusion, hypotension or organ 
dysfunction 
Septic Shock = sepsis with arterial hypotension despite adequate fluid resuscitation 




In severe sepsis excessive activation of neutrophils, due to high circulating levels of 
cytokines and Toll-like receptor activation by endotoxin (LPS), has been implicated in 
the pathogenesis of both ALI (Windsor et al., 1993) and AKI.  (Thijs and Thijs, 1998, 
Awad et al., 2009) Animal models of ALI show that neutrophils contribute to lung 
injury after haemorrhage and infection. (Ayala et al., 2002) Interestingly, neutrophil 
migration into tissues further alters circulating neutrophils and groups have shown 
that in murine models of endotoxemia and haemorrhagic shock that lung-derived 
neutrophils display activation of transcription factors, intracellular kinases and 
increased expression of inflammatory cytokines; these changes were not observed in 
circulating neutrophils. (Abraham et al., 2001, Shenkar and Abraham, 1999) In human 
volunteers similar findings have been observed when endotoxin is instilled at 
bronchoscopy. (Coldren et al., 2006) Gene expression is dramatically upregulated in 
neutrophils sequestered to the lungs compared to circulating neutrophils.  Of further 
interest is that neutrophils from inflammatory foci in cystic fibrosis appear to be 
insensitive to anti-inflammatory signals such as IL-10 or corticosteroids. (Petit-
Bertron et al., 2008, Corvol et al., 2003) This suggests that fundamental changes take 
place in neutrophils after migration to inflammatory foci, a concept termed 
‘compartmentalisation.’ (Cavaillon and Annane, 2006) However, this model of ALI is 
not the same as systemic neutrophil activation as seen in SIRS or severe sepsis. The 
large number of primed circulating neutrophils in sepsis marks them out as prime 
suspects in mediating much of the damaging aspect of a robust immune response.    
 
2.3 Initiation of SIRS 
The response to bacterial and fungal infection is initiated following the detection of 
‘danger signals’ by sentinel immune cells such as tissue macrophages and dendritic 
cells.  Two groups of molecules are critical in this regard, the highly conserved 
microbial molecules called pathogen-associated molecular patterns [PAMP] 
(Medzhitov, 2001) and disease-associated molecular patterns [DAMP] (Chen et al., 
2007) released as a consequence of tissue damage or apoptosis during bacterial 
invasion.   Once PAMPs and DAMPs ligate with their respective PRRs on these 
sentinel cells they release pro-inflammatory mediators (e.g. IL-1β and TNF), 
neutrophil chemokines and lipid mediators.  The resultant activation of local vascular 
endothelium leads to neutrophil recruitment as outlined in chapter 1.  The generation 
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of DAMPs in situations of sterile inflammation, such as acute and chronic liver 
disease can generate a SIRS response including cytokine generation and 
immunomodulation.  High mobility group box-1 (HMGB-1), a nuclear factor released 
by apoptotic cells, is an important DAMP acting as a late mediator of sepsis. (Wang et 
al., 1999) Levels of HMGB-1 are increased in acute liver failure (ALF) and are 
released from the necrotic liver; (Craig et al., 2011) through subsequent TLR4 
activation this can generate a similar immunophenotype to sepsis.  (Andersson and 
Tracey, 2011) 
 
2.4 Compensatory Anti-Inflammatory Response Syndrome 
The hallmark of severe sepsis and SIRS is the generation of large quantities of pro-
inflammatory cytokines, such as IL-1β, IL-6 and TNFα, from immune cells in a so-
called ‘cytokine storm’. (Cavaillon and Annane, 2006) However, of equal importance 
is the concomitant generation of a compensatory anti-inflammatory response 
syndrome (CARS), which can be considered the counterbalance to SIRS preventing 
an overzealous pro-inflammatory response. This ultimately acts as the ‘off switch’ to 
SIRS following successful resolution of pathogenic invasion.  If CARS becomes 
excessive or protracted it may become pathological preventing clearance of infection 
and resolution of organ failure or predisposing to secondary infection.    
 CARS is characterised by the production of anti-inflammatory cytokines such 
as soluble tumour necrosis factor receptor (sTNFR), IL-10, IL-1 receptor antagonist 
(IL-1Ra) and transforming growth factor-β (TGF-β).  CARS occurs alongside the 
initial cytokinaemia of SIRS, being an adaptive response to facilitate resolution of the 
inflammatory response. (Munford and Pugin, 2001) However, high levels of anti-
inflammatory mediators in the blood stream correlate strongly with down-regulation 
of the immune response and a poor outcome from sepsis. (Bone et al., 1997) It is well 
established that the plasma of patients with sepsis has the capacity to inhibit leukocyte 
functions and can therefore be considered an immunosuppressive milieu.  (Cavaillon, 
2002) Further evidence for an altered immune status in sepsis and SIRS comes from 
the high incidence of nosocomial infection in such patients, anergy to skin test antigen 
and reduced neutrophil adherence and chemotaxis (Meakins et al., 1977, Christou, 
1985) Lymphocyte abnormalities are observed in response to IL-10 with reduced 
responsiveness and reduced numbers of both circulating and tissue lymphocytes.  
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(Friedman et al., 1997) The action of these two opposing and rapidly changing 
signalling events in patients with severe sepsis gives rise to the concept of a balance 
between SIRS and CARS.  A predominance of either state referred to as ‘immune 
dissonance’ can lead to a poor outcome from sepsis. The immune system is therefore 
constantly adapting to bring about balance. Eventually there is a swing towards CARS 
bringing about resolution of infection.  The immunosuppressive effects of CARS 
persist following resolution from the initial insult and the clinical consequences of this 
are a high incidence of nosocomial infections in intensive care populations.    (Volk et 
al., 2000) 
 
2.5 Neutrophils in severe sepsis 
Neutrophils certainly possess the mechanics to cause significant cellular damage with 
production of ROS and potent serine proteases.  Soluble mediators such as PMA have 
been shown to induce granule fusion with the plasma membrane and subsequent 
extracellular release of these elements.  (Borregaard et al., 1983) This is clearly 
desirable to localise infection and when successful, leads to abscess formation with 
containment of infection.  However, the systemic neutrophil activation seen in sepsis 
means that these actions can take place distal to the site of infection resulting in tissue 
damage and organ failure.  Post mortem analysis of patients who die of MODS 
provides support for this theory with accumulation of neutrophils in renal blood 
vessels and large-scale tissue infiltration in ALI has been observed. (Gao et al., 2002) 
Two commonly recognised phenomena need to be explained for the central role of 
neutrophils in this cellular damage to holdfast; those are the apparent discordance 
between the degree of tissue damage observed and organ function, and the augmented 
SIRS response in neutropenic sepsis.  Cell hibernation may explain the apparent lack 
of concordance between tissue damage and organ function, a process whereby 
oxidative cellular stress leads to impaired mitochondrial function. (Gabay and 
Kushner, 1999) Neutrophils can produce massive quantities of ROS potentially 
contributing significantly towards the mitochondrial oxidative stress postulated to 
mediate ‘cell hibernation’.   A small number of primed neutrophils rapidly recruited to 
tissues with subsequent activation by cytokines and chemokines may be sufficient to 
cause significant tissue destruction and oxidative damage resulting in organ failure.  
Clearly neutrophils operate alongside other immune cells but their large numbers, 
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rapid recruitment and toxic potential point to them having a critical role in the organ 
failure of severe sepsis.   
 
2.6 The generation of peripheral neutrophilia 
One of the early features of infection is an increase in neutrophil numbers and the 
proportion of immature ‘band’ forms, the so called ‘left-shift’.  Neutrophilia is a 
defining characteristic of the SIRS response and the peripheral neutrophil count can 
triple within 4 hours.  Peripheral neutrophilia results from increased granulopoiesis, 
increased mobilisation of neutrophils from the BM, demargination (neutrophils 
entering the peripheral circulation from areas of intravascular ‘marginated’ cell pools 
such as the lung), and reduced removal through apoptosis.  
 GM-CSF and other circulating chemokines such as IL-6 and IL-8 appear to 
play critical roles in stress granulopoiesis. (Zhan et al., 1998, Kopf et al., 1994, 
Starckx et al., 2002)  However, the BM possesses large stores of retained neutrophils 
with egress being regulated by CXC-chemokine receptor CXCR2 and CXCR4 
expression on the cells.  CXCR4 activation retains neutrophils within the BM whereas 
CXCR2 facilitates egress.  The dominant production of the CXCR4 ligand SDF-1 
from osteoclasts results in neutrophil retention.  G-CSF and GM-CSF mobilises 
neutrophils from the BM during sepsis by inhibiting osteoclast production of SDF-1 
and increasing the production of the CXCR2 ligands keratinocyte derived chemokine 
(KC) and macrophage inflammatory protein-2 (MIP-2).   (Semerad et al., 2002) Other 
ligands involved include corticosteroids, endotoxins, complement-derived leukocyte-
mobilising factor, C5a chemoattractant, TNFα, and androgens.  Mobilisation of BM 
reserves may result in the release of immature or early myeloid forms known as band 
forms.  Toxic neutrophils are observed in the peripheral circulation of patients with 
sepsis and possess various morphological abnormalities.  Initially changes were 
assumed to be due to effects of endotoxemia, however, it is now understood that these 
changes are acquired during maturation under extreme conditions that intensely 
stimulate neutrophil production and shorten maturation time.   These changes can be 
induced by G-CSF.  Most of the changes reflect asynchrony of maturation between 
the nucleus and the cytoplasm resulting in the persistence of the protein synthetic 
machinery such as RNA, ribosomes and rough endoplasmic reticulum (RER).  This 
leads to the presence of phenomena such as Dohle bodies (whorls of RER), basophilic 
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cytoplasm (polyribosomes and RER), toxic granulation (eosinophilic primary 
granules usually absent), nuclear immaturity (lighter and less closely clumped 
chromatin) and cytoplasmic vacuolisation (frothy cytoplasm due to lysosome 
degranulation).  The presence of toxic neutrophils and cytoplasmic vacuoles can 
reflect neutrophil autolysis in response to endotoxemia but can develop as a storage 
artefact after 4 hours of removal from the body.     
 Sepsis and the acute phase response lead to the demargination of neutrophils 
adherent to the endothelium in the lungs and other organs in response to cytokines 
such as IL-6.  (Suwa et al., 2000)  Adrenaline and corticosteroids that may be used to 
treat patients with sepsis in the ICU can also cause demargination, (Brenner et al., 
1998).  
 Neutrophil apoptosis is characteristically reduced in sepsis and SIRS with 
delay induced by G-CSF, GM-CSF, LPS, LTA, and TNFα.  Neutrophil life span is 
additionally increased when bound to vascular endothelium that is activated by pro-
inflammatory mediators whereas binding to unstimulated endothelium induces 
apoptosis.  (Ginis and Faller, 1997) A reduced release of Cathepsin-D by neutrophils 
in sepsis, an activator of caspase 8, may be a further mechanism for reduced 
neutrophil apoptosis.  Apoptosis is promoted by the effects of IL-10 thus readdressing 
the balance once CARS predominates leading to recovery from inflammation. (Keel 
et al., 1997) Interestingly however, clinical trials using G-CSF and GM-CSF to 
increase the number and maturity of neutrophils have had disappointing results with 
no improvement in mortality from sepsis reported. (Root et al., 2003, Nelson et al., 
1998)  However, mortality has been shown to improve in patients with chemotherapy-
induced neutropenia.  (Maher et al., 1994) 
 Neutrophilia whilst a marker of infection and component of the SIRS score 
does not correlate with severity of organ failure.  There is recognition in the SIRS 
score that neutropenia can be a marker of severe sepsis (Figure 7), often in elderly and 
neonates, although it is unclear if this is an inadequate response or recruitment of 
neutrophils to tissues with subsequent inappropriate activation.   
 
2.7 Neutrophil surface receptor expression 
Neutrophils from patients with sepsis display a primed phenotype with respect to 
adhesion molecule expression, shedding L-selectin [CD62L] (Gustot et al., 2009) and 
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up-regulating surface expression of CD11b (MAC-1) (Arvaniti et al., 2010) and 
CD49d (VLA-4) [Table 2-2]. (Ibbotson et al., 2001)  Shedding L-selectin, which 
mediates the brief ‘on-off’ interactions between neutrophils and the endothelium 
reduces neutrophil margination, whereas increased CD11b and VLA-4 levels coupled 
with increased CD11b affinity, (Schleiffenbaum et al., 1989) favours firm adhesion to 
activated endothelium at the site of infection.  The source of this receptor upregulation 
is through granular fusion with the plasma lemma.  Neutrophils from patients with 
sepsis show enhanced adhesion to activated endothelial membranes although 
inhibition of CD11b and β2-integrins does not abolish this suggesting a role for other 
cell adhesion molecules such as VLA-4.  One critical question is how is neutrophil 
recruitment facilitated at sites distant from the initial infection?  Clearly there is a role 
for circulating PAMPs, DAMPs and inflammatory mediators.  For example, TNFα is 
a key mediator of septic encephalopathy causing alterations in blood-brain barrier 
function and upregulation of adhesion molecules that mediate neutrophil recruitment 
to tissues following an inflammatory stimulus.  (Alexander et al., 2008)  
 Levels of the high affinity gamma-globulin receptor CD64 are increased in 
neutrophils from septic patients, a receptor not normally expressed on resting 
neutrophils, correlating with levels of the chemokine IL-8, severity of sepsis and 
mortality. (Qureshi et al., 2001, Livaditi et al., 2006) Recently CD64 has been shown 
to be a robust marker for survival when used with a combination of other septic 
biomarkers.  (Gibot et al., 2012) Work from our group has questioned whether CD64 
upregulation is a phenomenon unique to sepsis, as a similar upregulation is observed 
in ALF in a sterile inflammatory setting resulting from hepatocellular necrosis. 
(Abeles et al., 2012) Interestingly, neutrophils with enhanced expression of CD64 
show augmented respiratory burst capability providing weight to the argument that 
neutrophils in sepsis are mediators of bystander tissue damage.  
 TLR2 but not TLR4 is increased on the surface of neutrophils by G-CSF and 
GM-CSF. (Kurt-Jones et al., 2002)  Agonists of either receptor initiate a respiratory 
burst, release IL-8, shed L-selectin and increase CD11b expression.  The expression 
of CD14, the LPS co-stimulatory molecule normally expressed at low levels on 
neutrophils (predominantly being a monocyte/macrophage receptor) is increased in 
neutrophils from patients with sepsis.   
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 A further PRR triggering receptor on myeloid cells (TREM-1) has shown 
increased expression on neutrophils in sepsis but appears confined to acute 
inflammatory reactions.  Recognition of bacteria by complement, TREM-1 and TLR 
are likely to be more important in the early stages of infection as IgG levels will be 
low prior to activation of B-cell and the adaptive immune system.  The redundancy in 
the system means that targeting individual cytokines is unlikely to be successful and 
indeed anti-TNFα antibody (Fisher et al., 1996) has proven unsuccessful in sepsis.   
 IL-8 is a ligand for the high affinity chemokine receptor CXCR2 and reduced 
expression of this receptor is seen on the surface of neutrophils from septic patients 
associated with a markedly suppressed response to IL-8. (Cummings et al., 1999) 
However, CXCR1 levels are unchanged and there are contradictory reports that 
neutrophil responsiveness is impaired or normal.  Mouse models where blockade of 
CXCR1 and CXCR2 signalling is achieved can prevent MODS and disseminated 
intravascular coagulation. (Kaneider et al., 2005) Further evidence for the importance 
of the action of IL-8 comes from patients with ALI where neutrophils undergo a 
large-scale migration into the lungs. Moreover, concentrations of IL-8 in 
bronchoalveolar lavage (BAL) fluid correlate with mortality. (Panasiuk et al., 2005)  
In the lumen of the pulmonary capillaries there is enforced neutrophil contact with the 
vessel wall unlike in other organs where adhesion and migration occur in the post-
capillary venules.  Binding of neutrophils to the endothelium additionally prolongs 
neutrophil life span by reduction in apoptosis.  IL-8 therefore appears to be a critical 
chemokine in neutrophil priming, adhesion and activation in sepsis.  A further 
chemokine receptor showing upregulation on neutrophils from sepsis is the fMLP 
receptor with an enhanced response to fMLP being reported as a marker of neutrophil 
priming.  (Tschaikowsky et al., 1993)  
 Activation of TLRs and chemokine receptors leads to enhanced expression of 
the intracellular transcription gene, NFκB as a consequence of neutrophil priming in 
response to ligation of PRR during neutrophil priming. Indeed, neutrophils from 
patients with sepsis demonstrate upregulation of NFκB and reduced activation of 
NFκB is associated with improved survival. (Nakamori et al., 2003) NFκB is the main 
transcription factor required for the expression of the genes coding for inflammatory 
molecules.  For a summary of the changes to neutrophil surface markers in sepsis see 
Table 2-2. 
 79 
Table 2-2 Change in neutrophil cell-surface receptor expression in sepsis 
Neutrophil phenotype and function in 
patients with sepsis 




β2 integrins CD11b 
β1 integrins VLA-4 (CD49d) 
Down regulated 






















2.8 Neutrophil functional status in sepsis 
There is a lack of clarity regarding the functional activities of neutrophils in sepsis 
and with contradictory reports in the literature.  The veritable potpourri of findings 
may be explained by the literature being peppered by the use of a variety of models, 
assays and conditions under which these studies have been performed.  Another 
critical point in the understanding of the immunopathology that occurs in sepsis is that 
the changes are highly dynamic with an evolving picture changing over time 
depending on the predominance of a SIRS or CARS response and the specific 
microbial challenge.    
 One of the key and best understood of the neutrophil abilities is their homing 
to areas of infection and this is perhaps most clear in relation to neutrophil function.  
Not surprisingly therefore, enhanced neutrophil adhesion has been recognised in 
sepsis for some time with early studies demonstrating enhanced adhesion to petri 
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dishes and nylon threads in response to LPS stimulation.  This is achieved in vivo by a 
change in the phenotype of the cell surface expression (‘priming’) through shedding 
of L-selectin and enhancing the number and affinity of Mac-1 and non-integrin 
binding sites results in enhanced binding at sites of infection. (Dahinden et al., 1983, 
Parent and Eichacker, 1999)  The ‘primed’ phenotype should inhibit recruitment to 
uninvolved tissue beds.  However, in severe sepsis there is perturbation of this 
homeostatic mechanism with systemic neutrophil ‘priming’ being associated with 
disseminated leukocyte recruitment to organ beds distant to the initial source of 
infection.  It is therefore interesting to note that L-selectin shedding and integrin 
dysfunction render leukocyte adhesion increasingly susceptible to the effects of sheer 
stress and alternative adhesion molecules.  Through this mechanism ‘primed’ 
neutrophils are inhibited from recruitment to normally perfused sites with intact 
endothelium but can be recruited to sites with compromised perfusion or endothelial 
injury. (Ploppa et al., 2010) Interestingly, some studies suggest that in severe sepsis 
recruitment to local sites of infection is actually impaired. (Ahmed et al., 1999) 
 Neutrophil migration is reportedly defective in skin blisters in patients with 
sepsis (Merli et al., 2010).  Neutrophils from patients with sepsis have a reduced 
expression of CXCR2 but no reduction in CXCR1 with a chemotactic responsiveness 
to IL-8 that may be impaired (Chishti et al., 2004) or normal. (Cummings et al., 1999) 
Migration of isolated neutrophils in response to LT-B4 is impeded in sepsis (Tavares-
Murta et al., 2002) but it is unclear if migration in response to fMLP is altered in 
sepsis as conflicting reports have been published.  (Tavares-Murta et al., 2002, 
Cummings et al., 1999) 
 The majority of authors report a reduced neutrophil phagocytic capacity in 
sepsis but this is controversial with other studies reporting both increased and reduced 
levels of phagocytosis. (Zhang et al., 1994, Simms et al., 1991)  This is a paradoxical 
finding to what one would expect as neutrophil ‘priming’ induces surface 
upregulation of opsonin receptors such as CD11b (complement receptor) and high 
affinity IgG receptor expression.  Phagocytosis by immature neutrophils in septic 
patients has been reported to be lower than mature neutrophils a finding that may be 
important when there is a high proportion of band forms present in the peripheral 
blood smear.  On the other hand, it has been postulated that older neutrophils with the 
inhibition of apoptosis may lead to neutrophil exhaustion.   
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 Equally, conflicting reports regarding the generation of ROS by neutrophils in 
sepsis are found in the literature with authors concluding that an up- or down-
regulation is observed. (Wenisch et al., 1999, Martins et al., 2003) Kaufmann et al 
provide some explanation by demonstrating that neutrophil ROS generation in sepsis 
is stimuli dependent; hydrogen peroxide generation being reduced in response to 
Zymosan, unchanged in response to PMA and enhanced in response to TNFα and 
fMLP. (Kaufmann et al., 2006) The timing after an insult where neutrophil function is 
evaluated may be important with priming and activation being only observed for 24 
hours after an insult in burns patients.  Subsets of circulating neutrophils have been 
defined with the presence of both a ‘primed’ and normal subgroup. (Bass et al., 1986)  
 
2.9 Mechanisms for neutrophil hypo-responsiveness in sepsis 
Endotoxemia activation through TLRs and their downstream effects are critically 
important events in the activation of immune cells particularly in their response to 
gram-negative sepsis.  Ex vivo cytokine production of IL-1β, IL-1R and IL-8 is 
reduced after exposure to LPS in neutrophils obtained from septic patients compared 
to healthy controls. (McCall et al., 1993, Marie et al., 1998) This has been further 
confirmed after the intravenous administration of LPS in healthy human volunteers 
whose neutrophils displayed a reduced capacity to produce chemokines upon in vitro 
stimulation. (Schultz et al., 2000) This neutrophil hyporesponsiveness has been 
compared to the ‘endotoxin-tolerance” described in monocytes where prior exposure 
to minute quantities of endotoxin in vitro renders them refractory to re-challenge with 
the same agonist. (West and Heagy, 2002) Circulating monocytes isolated from 
patients with sepsis typically display a reduced production of TNFα and unaltered or 
enhanced production of IL-10. (Cavaillon and Adib-Conquy, 2006) Similar findings 
have been shown in patients with a variety of sterile SIRS responses such as ALF and 
following LPS administration in healthy controls.  (Antoniades et al., 2006, 
Granowitz et al., 1993) The precise mechanism leading to endotoxin tolerance is 
unclear but involves reduction in surface expression of TLR4 and further down-
stream receptor-effector uncoupling.  (West and Heagy, 2002) Interestingly however, 
the induction of endotoxin tolerance in mice enhances their resistance to fungal and 
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bacterial infections. (Rayhane et al., 2000, Lehner et al., 2001) A similar phenomenon 
of neutrophil hypo-reactivity has been reported in sepsis and SIRS.  
 A more recent study by Parker et al. shows that prolonged exposure of ex vivo 
neutrophils from healthy controls to LPS results in induction of tolerance in 
intracellular signaling pathways (including p38-MAPK) and respiratory burst. 
Tolerized neutrophils retain the ability to delay apoptosis in response to GM-CSF, 
show continued generation of IL-8 and reduced surface expression of TLR4 (Parker et 
al., 2005) suggesting that the neutrophils are reprogramed but maintain a pro-
inflammatory phenotype.   
 Serum from septic patients has potent inhibitory effects on circulating 
neutrophils and monocytes and is a so-called ‘inhibitory milieu’.  (Constantian and 
Cohen, 1978, Prins et al., 1995) Inhibitory factors can be detected in plasma from 
healthy volunteers after LPS exposure and can be removed by plasma filtration and 
adsorption. (Ronco et al., 2002) Such factors include soluble CD14, LPS-binding 
protein, high-density lipoprotein (HDL), soluble myeloid differentiation protein-2 
(MD-2) as well as the anti-inflammatory cytokines IL-10 and TGF-β. (Adib-Conquy 
and Cavaillon, 2009) IL-10 release can be favored by the action of catecholamines 
that are known to contribute to the altered responsiveness of circulating leukocytes.   
β-Blockers allow a partial restoration of the responsiveness of blood leukocytes to 
LPS in terms of TNF production. (Asehnoune et al., 2006)  Indeed, β-blockers reduce 
the mortality due to spontaneous bacterial infection post stroke (Prass et al., 2003) as 
opposed to norepinephrine-treated neutrophils which decrease the resistance of mice 
to infection.  (Tsuda et al., 2008) 
 One of the most fascinating observations that support the necessity for a 
balance in the production of pro- and anti-inflammatory responses is the observation 
that neutrophils can be rendered either hyper or hypo-responsive dependant on the 
severity of the initial septic/inflammatory insult.  Severe insults such as acute 
pancreatitis lead to an increased susceptibility to spontaneous bacterial infection 
leading to increased mortality. (Suzuki et al., 2006) Moreover modest stimulation 
induces resistance to a secondary infection (pancreatitis and burns) in caecal-ligation 
and puncture animal models. (Echtenacher and Mannel, 2002) Low grade priming 
stimuli such as prior LPS exposure dramatically reduces neutrophil activation and 
adhesion is associated with an elevated circulating neutrophil count, low degree of 
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micro-vascular plugging, and survival after a normally lethal dose of LPS.  (Barroso-
Aranda et al., 1991) Some authors have contradicted these findings suggesting that 
responses to polymicrobial and monomicrobial infection may differ and the timing of 
the insult and secondary infection may be relevant.  Neutralisation of IL-10 and the 
CCL chemokine monocyte chemoattractant protein-1 (MCP-1) reduce the deleterious 
effect, suggesting they are both serum factors that mediate this effect.   (Reich et al., 
1997, Tsuda et al., 2004) 
  
2.10 Summary of neutrophil dysfunction in sepsis 
In severe sepsis neutrophils turn from hero to villain with generalised neutrophil 
priming and activation leading to recruitment at distant sites from the initial infection 
as a result of endothelial injury.  Once recruitment occurs neutrophils release toxic 
proteases and ROS with subsequent cell and mitochondrial toxicity resulting in organ 
failure.  This is reversible over time but unchecked, neutrophil damage leads to 
MODS with its associated poor prognosis.  The complex interplay between pro- and 
anti-inflammatory signals being generated requires a balanced, dynamic and 
proportionate cytokine and chemokine response in order for successful resolution 
from infection to occur.  Post infection and after prolonged exposure to pro-
inflammatory stimuli there is immune hypo-responsiveness contributing to recurrent 
infection.  An understanding of this process may allow manipulation to prevent both 
an over-exuberant response and the development of secondary infection in the 
immunosuppressive phase.  The immune dysfunction observed in sepsis and in liver 
failure share many similarities and indeed are likely to have similar mechanisms that 
underpin them.  In addition cirrhosis adds a further dimension with the development 






























3.1 The burden of bacterial infection in acute and chronic liver failure 
Both acute and chronic liver failure are associated with an increased incidence of 
bacterial and fungal infection leading to hospitalisation and the development of 
potentially life-threatening complications.  
 Sepsis can lead to worsening liver function and precipitate complications, 
including variceal bleeding, hepatic encephalopathy (HE), AKI and MODS, 
contributing to high mortality.  Cirrhosis represents a significant health burden in the 
United Kingdom (UK) with the incidence and prevalence of the condition increasing 
exponentially; it is now the fifth largest cause of death. (Blachier et al., 2013, BASL 
and BSG, 2009) The increasing burden of liver disease poses a major challenge in 
managing these patients particularly with respect to utilisation of ICU beds and 
requirement for Liver Transplantation (LT).  With poor outcomes following sepsis 
and its associated complications, and increasing waiting list mortality for LT, there is 
an urgent need for novel approaches to reducing the rate of infection in cirrhosis.   
 ALF is a rare but frequently catastrophic consequence of acute severe hepatic 
injury arising from a wide variety of insults.  It is similarly associated with a high 
incidence of early and late bacterial and fungal infection resulting in clinical 
deterioration and MODS.  ALF patients who fulfil poor prognostic criteria are at high 
risk of death without LT, and complicating infection prevents listing for LT.  
Infection is frequently seen to complicate the post-operative course following LT in 
ALF with associated mortality contributing to over 25% of deaths (Rolando et al., 
1990).  LT at present represents the only curative therapy in end-stage chronic liver 
disease (CLD); however, with a shortage of donors for those eligible for LT up to 
20% die while on the waiting list.  
 
3.2 The incidence of infection in cirrhosis 
Infection and associated endotoxemia is present on admission or complicates 32-34% 
of hospitalised patients with cirrhosis. (Fernandez et al., 2002, Borzio et al., 2001, 
Navasa et al., 1999)  Those with the most severe liver failure are the most susceptible 
to infection with correlation seen between Child-Pugh score (CPS) and rates of 
infection in cirrhosis.  (Borzio et al., 2001) CPS is a prognostic measure of liver 
disease severity with recognised grades A, B and C each referring to worsening 2-year 
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survival as you progress from A through to C. (Pugh et al., 1973) Patients with more 
advanced disease are additionally more susceptible to developing organ dysfunction 
suggesting that immune dysfunction could be related either to liver failure or portal 
hypertension.  The in-hospital mortality from infections in cirrhosis is 15-31% and in 
septic shock can be as high as 70%.  (Plessier et al., 2003) Other risk factors for 
infection in cirrhosis include variceal bleeding, low ascites protein concentration 
(<10-15mg/L), previous episodes of spontaneous bacterial peritonitis (SBP), HE and 
invasive procedures. 
Up to 35% of patients with ALF develop bacterial and fungal infection with a 
median time to bacteraemia of 10-days; independent predictors of infection include 
high SIRS score and the presence of HE.  (Karvellas et al., 2009, Rolando et al., 1991)  
 
3.3 Aetiology of infection in liver failure 
Common infections include SBP, pneumonia, procedure-related bacteraemia, 
cellulitis and spontaneous bacteraemia. (Fernandez et al., 2002) Cirrhotic patients are 
more at risk of infection from atypical organisms such as tuberculosis and invasive 
fungal infections.  39% of infections are nosocomial with a high rate of bacteraemia 
from invasive procedures such as central venous cannulation, paracentesis and urinary 
catheterisation.  Infections are culture positive in 50-70% of cases.  In community 
infection the main causative agents are gram-negative cocci (GNC), such as E.coli, in 
60%, with gram-positive cocci (GPC) found in 30-35% and a mixed culture in the 
remaining 5-10%.  In nosocomial infection the trend is reversed with 60% GPC and 
30-35% GNC, as a result of prior antibiotic exposure and invasive procedures.  Other 
common organisms include Staphylococcus aureus, Enterococcus faecalis and 
Streptococcus spp.  In SBP there is evidence that less virulent strains of E.coli are 
responsible for infection with worsening liver failure (Bert et al., 2008) and fungal 
infections are more common e.g. Candida spp.  In ALF bacteriologically proven 
infection occurs in up to 80% of patients, 70% of bacterial isolates are GPC and 
fungal infection develops in up to 32%. (Rolando et al., 1996)   
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3.4 Immune dysfunction in chronic liver failure and predisposing 
factors 
Cirrhosis represents a state of functional immune paresis and the term cirrhosis 
associated immune dysfunction syndrome (CAIDS) has been coined. (Bonnel et al., 
2011) CAIDS comprises a number of wide-ranging immune defects in innate and 
adaptive immune responses along with up-regulation of pro-inflammatory cytokine 
production.  The immune dysfunction shares many similarities to that seen in patients 
with sepsis suggesting a similar aetiopathogenesis. (Wasmuth et al., 2005)  
A number of factors predispose to infection in cirrhosis including advancing 
severity of liver disease (Yoshida et al., 1993), variceal bleeding, (Bernard et al., 
1999, Borzio et al., 2001) low ascites protein levels (Llach et al., 1992, Such et al., 
1988) and prior episodes of SBP. (Gines et al., 1990) The underlying immune defect 
is complex and multi-faceted and contributory factors include protein malnutrition, 
alcohol consumption, and BM suppression. This occurs in association with multiple 
defects principally of the innate but also subtle defects of the adaptive immune 
system. (Rajkovic and Williams, 1985, Bolognesi et al., 1994, Shawcross et al., 
2008b)  In addition, drug therapies such as corticosteroids, immunosuppressant and 
antiviral therapies further exacerbate the situation in autoimmune and viral 
aetiologies.     
 
3.5 Disease paradigm of innate immune dysfunction, sepsis, and organ 
failure in cirrhosis 
Portal hypertension is the principle direct complication of cirrhosis being defined as 
elevation of the hepatic venous pressure gradient (HVPG) above 5mmHg, with 
clinically significant portal hypertension seen at a HVPG ≥ 10mmHg. (Groszmann et 
al., 2005) An important consequence of portal hypertension is intestinal bacterial 
overgrowth, enhanced bacterial translocation from the gut, and porto-systemic 
shunting. (Morencos et al., 1995, Chang et al., 1998)  
Bacterial translocation is the migration of bacteria or bacterial products from 
the intestinal lumen to mesenteric lymph nodes.  (Wiest and Garcia-Tsao, 2005) In 
cirrhosis slowed intestinal transit with consequent small bowel bacterial overgrowth 
and reduced mucosal barrier function is found; this is exacerbated with worsening 
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portal hypertension. (Chesta et al., 1993) Bacterial translocation leads to an increase 
in the delivery of bacterial derived molecules into the portal vein.  Normally these 
would be removed and neutralised by the reticulo-endothelial (RE) system of Kupffer 
cells and LSEC present in the liver sinusoids.  However, porto-systemic shunting, 
whereby blood from the portal circulation bypasses the liver, reduced RE function, 
and direct draining of the RE into the systemic circulation culminates in increased 
levels of circulating endotoxin and other PAMP molecules. (Riordan et al., 2003, 
Llovet et al., 1998, Chan et al., 1997) This systemic ‘spill-over’ of bacterial products 
leads to circulating monocyte dysfunction and neutrophil priming with subsequent 
generation of ROS, pro-inflammatory cytokines, and nitric oxide (NO) resulting from 
endotoxemia and leading to endothelial dysfunction. This further exacerbates the 
breakdown in intestinal barrier function. (Wiest and Garcia-Tsao, 2005) In addition to 
portal hypertension, liver cirrhosis can have direct effects on innate immune function, 
through reduced production of opsonic proteins and neutrophil dysfunction resulting 
from reduced clearance of ammonia and sodium imbalance. (Runyon et al., 1985) The 
resulting systemic immune dysfunction facilitates bacterial access to the blood stream 
and peritoneal cavity ultimately predisposing to infections such as SBP and disrupting 
the immune response to infection. (Runyon et al., 1994) 
Along with immune dysfunction, cirrhosis results in progressive 
haemodynamic alterations following systemic and splanchnic vasodilatation due to 
endothelial dysfunction and as a consequence of increased circulating vasoactive 
substances, leading to effective arterial hypovolemia. (Blendis and Wong, 2001) In 
order to counterbalance vasodilatation there is upregulation in the production of a 
number of vasoconstrictors including activation of the renin-angiotensin aldosterone 
system (RAAS) and release of anti-diuretic hormone (ADH) complimenting increased 
output from the sympathetic nervous system.   
In advanced cirrhosis, portal hypertension and ineffective sodium handling 
lead to increased peritoneal fluid production (ascites) beyond the ability for lymphatic 
resorption with subsequent accumulation.  Ascitic fluid accumulation secondary to 
portal hypertension results in a low protein transudate with consequent low levels of 
opsonins such as immunoglobulin and complement proteins. This reduced opsonic 
capacity combined with bacterial translocation and neutrophil dysfunction can lead to 
the development of SBP, one of the most common infections in decompensated 
cirrhosis.    
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Infections such as SBP are associated with an exaggerated pro-inflammatory 
response or ‘cytokine storm’ leading to further perturbation of endothelial function 
and deterioration of the precarious haemodynamic status that exists in advanced 
cirrhosis.  Hypovolaemia is further amplified by the presence of cirrhotic 
cardiomyopathy (defined as a systolic incompetence under stress, diastolic 
dysfunction and electrophysiological abnormalities) and relative adrenal 
insufficiency.  Infection can consequentially exaggerate the effects of pre-existing 
hypovolaemia leading to hypotension, with AKI being the commonest extra-hepatic 
organ dysfunction.  In severe sepsis, hypovolaemia results in inadequate tissue 
perfusion in a situation termed shock which if left uncorrected, leads to MODS 
requiring support in ICU. The disease paradigm of immune dysfunction in cirrhosis is 
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3.6 Acute-on-chronic liver failure 
A further consequence of sepsis is deteriorating hepatic function resulting in a poorly 
characterised syndrome referred to as acute-on-chronic liver failure’ (AoCLF). 
AoCLF is associated with poor short-term prognosis.  (Jalan et al., 2012a) AoCLF is 
defined as the development of deteriorating hepatic function and extra-hepatic organ 
failure in patients with cirrhosis as a consequence of an acute event such as SBP and 
variceal bleeding. (Sen et al., 2002) Diagnostic criteria have recently been refined 
with grades of severity defined based on a cohort of 1343 patients from 29 European 
liver units.  (Moreau et al., 2013) AoCLF can in itself lead to further events through 
worsening portal hypertension and synthetic liver dysfunction (including 
coagulopathy) leading to complications such as variceal bleeding and HE. AoCLF 
may be directly related to the pro-inflammatory response with TNFα inducing a pro-
apoptotic signal within the hepatocytes due to down regulation in translation of NF-
κB-dependent anti-apoptotic messenger ribonucleic acids (mRNA) into proteins as a 
result of endoplasmic reticulum (ER) stress.  Moreover, livers from LPS-challenged 
rats with cirrhosis exhibit an endothelin-1-mediated neutrophil infiltrate and 
hepatocyte necrosis.  (Urbanowicz et al., 2004) At present the underlying 
mechanism(s) leading to AoCLF are poorly understood but neutrophils may play a 
key role as discussed below. 
Evidence for a role of neutrophils in organ damage is seen in acute alcoholic 
hepatitis (AAH), a condition where neutrophil recruitment to the liver leads to severe 
necroinflammation (Bautista, 2002, Jaeschke, 2002) This condition is associated with 
elevated levels of IL-6, IL-8, IL-10, TNFα and sTNFαR1 (Stadlbauer et al., 2006), 
which corresponds with severe neutrophil dysfunction and a high incidence of HE and 
renal failure (Sen et al., 2004).  It seems likely that priming of circulating neutrophils 
and the cytokinaemia contribute to the organ failure observed in this condition.   
 
3.6.1 Circulatory failure 
Cirrhosis is characterised by a hyperdynamic circulation, with high cardiac output, 
low mean arterial pressure and reduced systemic vascular resistance.  This situation is 
further exacerbated by infection due to associated endothelial dysfunction 
demonstrated by hypo-reactivity to α-adrenoceptor agonists. (Ruiz-del-Arbol et al., 
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2003) Other important factors are likely to include cardiac dysfunction, either due to 
cirrhotic cardiomyopathy or sepsis-induced left-ventricular dysfunction, (Parker et al., 
1984) and relative adrenal insufficiency.  (Tsai et al., 2006) 
 
3.6.2 Acute kidney injury (AKI) 
AKI occurs in 30-33% of patients with cirrhosis who have SBP and in 27% of those 
with sepsis unrelated to SBP. (Follo et al., 1994) The development of AKI is 
associated with high levels of pro-inflammatory cytokines (TNFα and IL-6), NO 
metabolite levels and arterial under-filling. (Navasa et al., 1998) The cause of AKI in 
severe sepsis is multifactorial and can include pre-renal failure due to circulatory 
dysfunction, type-1 hepatorenal syndrome (HRS) [unresponsive to filling] and acute 
tubular necrosis.   
 
3.6.3 Respiratory failure 
Neutrophils are important in the aetiology of ALI in severe sepsis without cirrhosis.  
Indeed, there is a high incidence of acute respiratory distress syndrome (ARDS) in 
patients with cirrhosis. (Doyle et al., 1995) In rodent models of cirrhosis there are 
increased numbers of neutrophils marginating to the pulmonary circulation, 
susceptibility to LPS-induced lung oedema, and death.  (Chang and Ohara, 1994) 
Patients with cirrhosis requiring mechanical ventilation have mortality rates above 
50% in studies and indeed the requirement for mechanical ventilation on day-1 in 
patients with cirrhosis along with the MELD score is predictive of early mortality 
with an OR 5.7.  (Bahirwani et al., 2013, Shawcross and Wendon, 2009)  
 
3.6.4 Neurological failure and hepatic encephalopathy 
Neutrophils, along with ammonia and the SIRS response, have been directly 
implicated in the pathogenesis of HE. (Shawcross et al., 2010) Enhanced endothelial 
cell interaction in the cerebral circulation may lead to recruitment of activated 
neutrophils resulting in endothelial disruption and oxidative stress. In sepsis acute 
neurological deterioration is common and termed septic encephalopathy.  (Sprung et 
al., 1990) Acute neurological deterioration is seen in 21-33% of patients with cirrhosis 
 93 
and 60-68% in those with septic shock. (Sort et al., 1999) There appears to be a 
synergism between SIRS and hyperammonemia in the development of 
neuropsychiatric impairment in cirrhosis.  Provoked hyperammonemia induces 
neurological impairment in patients with cirrhosis and SIRS, which is associated with 
high levels of TNFα, IL-1β, IL-6 and NO metabolites; this effect was not seen after 
the resolution of SIRS.  (Shawcross et al., 2004) Activation of astrocytes and 
microglia through ligation of TLR2 and TLR3 has been shown to result in secretion of 
IL-6, CXC-10 and IFN-β and differential changes in TLR expression dependent on 
cell type. (Jack et al., 2005, Lu et al., 2005) Activation of astrocytes and microglia in 
the central nervous system (CNS) can act as a prelude to CNS inflammation, 
endothelial activation and margination of activated neutrophils. Release of ROS, NO 
and defensins (proteases) with subsequent endothelial and cellular damage may 
contribute to HE (Ramaiah and Jaeschke, 2007, González-Amaro and Sánchez-
Madrid, 1999).   Researchers have observed that levels of the cytokines IL-6 and IL-
18 were found to be significantly higher in patients with minimal-HE.  (Montoliu et 
al., 2009) 
 Whilst direct evidence for this neutrophil recruitment to the cerebral 
endothelium is currently lacking, a neutrophil predominant infiltrate is seen in septic 
encephalopathy, which has been shown to correlate with TNFα levels. (Alexander et 
al., 2008)  
 
3.7 Innate immune dysfunction in chronic liver failure 
3.7.1 Opsonisation 
Opsonisation function and subsequent receptor-mediated endocytosis is impaired due 
to low levels of immunoglobulins and serum complement proteins in cirrhosis. 
(Runyon et al., 1985, Ono et al., 2004) Furthermore, low ascitic complement levels 
correlate with decreased bactericidal activity and increased risk of SBP (Such et al., 
1988, Runyon et al., 1985). Other proteins involved in innate immunity synthesised 
by the liver include C-reactive protein (CRP), protein-C and mannose binding lectin 
(MBL).  The exact indication of deficiencies in these proteins in acute or chronic liver 
failure is unclear at present.   
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3.7.2 Neutrophils in cirrhosis 
Neutrophil express a primed phenotype in patients with cirrhosis and AoCLF 
including ‘shedding’ of L-selectin (CD62L), upregulation of surface CD11b, CD64 
and CD49d (VLA-4 not present on resting neutrophils), and down regulation of 
CD16. (Fiuza et al., 2002, Rosenbloom et al., 1995, Hayashi et al., 2003)  In 
neutrophils from patients with sepsis this primed phenotype is associated with 
enhanced expression of the intracellular transcription gene, NF-kB. (Nakamori et al., 
2003)  A similar phenotype is seen in patients with sepsis without liver disease. 
(Brown et al., 2006) However, prolonged neutrophil LPS exposure may result in 
down-regulation of cytokine/chemokine receptors and intracellular signalling 
pathways promoting receptor–effector pathway uncoupling and endotoxin tolerance. 
(Parker et al., 2005) Indeed chronic endotoxemia directly induces decreased 
expression of the TNF receptor by neutrophils in alcohol-related liver disease. (von 
Baehr et al., 2000) 
 Abnormalities in neutrophil function in cirrhosis have been observed since the 
1970’s with documented abnormalities including an increased neutrophil adherence 
both to nylon fibres and endothelial cells (Altin et al., 1983, Feliu et al., 1977, Fiuza et 
al., 2002), reduced chemotactic response, decreased aggregation and locomotion 
(Yousif-Kadaru et al., 1984, Feliu et al., 1977, Rajkovic et al., 1984) and decreased 
capacity for phagocytic and OB. (Feliu et al., 1977, Fiuza et al., 2002, Rajkovic and 
Williams, 1986)  Neutrophil dysfunction is further exaccerbated by the presence of 
superimposed inflammation such as in acute alcoholic hepatits and during infection. 
(Rosenbloom et al., 1995, Mookerjee et al., 2007b) and correlates with advancing 
liver disease. (Tritto et al., 2011) 
 Furthermore patients with cirrhosis develop neutropaenia as a consequence of 
hypersplenism, which is further exacerbated by accelerated apoptosis, shortening the 
neutrophil life-span (Kusaba et al., 1998) Enhanced neutrophil apoptosis is mediated 
through the Fas/Fas ligand pathway. (Kusaba et al., 1998, Liles et al., 1996)  Alcohol 
excess can cause direct myelotoxicity further reducing circulating neutrophil numbers 




3.7.3 Monocytes / peripheral blood mononuclear cells (PBMCs) 
 Neutrophils act in concert with PBMCs in mediating the innate immune 
response to infection.  Abnormal monocyte function is found in cirrhotic patients with 
spreading across endothelial surfaces, chemotaxis, phagocytosis and microbial-killing 
mechanisms all being reduced. (Hassner et al., 1979) Monocytes from patients with 
AoCLF have reduced antigen presentation capabilities due to reduced surface 
expression of human leukocyte antigen-DR (HLA-DR) with similar findings being 
seen in sepsis and ALF.  (Wasmuth et al., 2005, Antoniades et al., 2006) Furthermore, 
FcγR expression and function is reduced on mononuclear cells in alcohol-related liver 
disease inhibiting clearance of opsonised bacteria. (Gomez et al., 1994) The LPS-
induced monocyte production of TNFα is higher in Child-Pugh C than in Child-Pugh 
B cirrhosis, suggesting that the severity of liver disease has an impact on the innate 
immune response.  (Galbois et al., 2009) Hyper-responsiveness of ex vivo monocytes 
has been reported in primary biliary cirrhosis (PBC). (Mao et al., 2005) The absence 
of induction of the inhibitor IL-1 receptor-associated kinase M in LPS-stimulated 
cirrhotic monocytes may in part explain TNFα hyperproduction.  (Tazi et al., 2006) 
Furthermore, the normal generation of the anti-inflammatory cytokine IL-10 by 
monocytes in response to LPS appears to be defective in cirrhosis. (Le Moine et al., 
1995) 
 
3.8 Impaired adaptive immunity in cirrhosis 
Lymphocyte function is impaired in cirrhosis with defects in both B- and T-cells.  B-
cell hyper-reactivity, particularly in alcohol-related cirrhosis, results in enhanced 
production of secretory IgA from unmethylated cytosine-guanine dinucleotide (CpG) 
activated B-cells, acting through the TLR9 pathway. (Massonnet et al., 2009) There is 
expansion of activated CD4+ T-cells (Albillos et al., 2004) including Th17 cells 
which have a pro-inflammatory phenotype. (Pelletier et al., 2010) Enhanced 
suppressor T-cell function is observed despite unchanged suppressor T-cell numbers 
in alcohol and viral liver disease. (Alexander et al., 1983)  
 Recently mitogen activated CD4+ T-cell metabolic reactivity has been 
reported in hepatitis C cirrhosis and cirrhosis of other causes. (Yee et al., 2013) 
Abnormalities in natural killer (NK) cell function are seen in alcohol-related liver 
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disease. (Laso et al., 1997) The involvement of cellular immune responses not only 
predisposes to infection either directly in a similar fashion to immunoglobulin 
abnormalities but also generates a chronic immune perturbation of the innate and 
adaptive immune response resulting in abnormal responses following infection.    
 
3.9 Summary of immune dysfunction in cirrhosis 
The immunopathology in cirrhosis encompasses the entire immune system with 
involvement of humoral, cell-mediated and cellular immune functions.  The 
hierarchical importance of these defects is currently unclear and many patients with 
cirrhosis continue to survive infection, suggesting that an adequate response can be 
generated to infection in many cases.  Indeed, it is the over-exuberant and often 
inappropriate pro-inflammatory response to infection that often leads to organ 
dysfunction with poor outcomes.  This is clearly exacerbated if the immune system is 
encountering difficulty in eradicating the infecting microbe.  Neutrophils are cells 
central to the defence against microbial infection and the documented abnormalities 
are likely to be prime candidates to explain the apparent paradox of the co-existence 
of concomitant immunosuppression and immune hyper-responsiveness in liver 
cirrhosis.   
 
3.10 Defects in the innate immune system in acute liver failure (ALF) 
ALF is less studied than cirrhosis but shares many features of both chronic liver 
disease and severe sepsis including high plasma levels of pro- and anti-inflammatory 
cytokines and immune paresis.  Monocytes demonstrate a state of functional 
deactivation characterised by a reduced expression of HLA-DR and a degree of 
endotoxin tolerance with enhanced IL-10 production. (Antoniades et al., 2006)  
Complement levels are markedly reduced (the liver being the principle site of 
complement synthesis) resulting in reduced opsonic capacity and decreased 
chemoattraction. (Wyke et al., 1980) A reduction in the production of ROS and 
phagocytic capacity of neutrophils from patients with ALF has been reported both in 
vivo and in vitro. (Clapperton et al., 1997, Rolando et al., 2000a)  Fibronectin, another 
hepatically-derived opsonin involved in Kupffer cell clearance, is markedly reduced 
in ALF (Imawari et al., 1985) and indeed Kupffer cell activity is depressed as 
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demonstrated by the reduced uptake and clearance of indium-labelled micro-
aggregated albumin in ALF. (Canalese et al., 1982) Low levels of HDL, which binds 
and neutralises the bioavailability of LPS and LTA, are low in ALF due to impaired 
hepatic synthetic function.  (Zambon et al., 1995, Etogo-Asse et al., 2012) Low levels 
of HDL are also associated with a poor outcome in ALF and AoCLF. (Etogo-Asse et 
al., 2012)  
 
3.11 Mechanisms for neutrophil dysfunction in liver failure 
 Recent studies in alcohol-related liver disease suggest that defects in 
neutrophil function are affected through serum factors such as endotoxin levels. 
(Mookerjee et al., 2007b) Subsequent ex vivo removal of LPS by passing cirrhotic 
serum through a polymixin B column decreased the spontaneous OB (SOB) and 
improved phagocytic function of healthy neutrophils. Shawcross et al. propose an 
alternative mechanism with hyperammonemia and hyponatraemia functioning 
synergistically to cause neutrophil swelling, akin to cerebral astrocytes, and impaired 
phagocytosis. (Shawcross et al., 2008b) 
Levels of tuftsin, a neutrophil modulator of phagocytosis, are reduced in 
patients with cirrhosis, with an associated increased incidence of bacterial infection. 
(Trevisani et al., 2002) Neutrophils from patients with cirrhosis also display a 
markedly reduced activity of phospholipase C (PLC).  (Laffi et al., 1993, Garfia et al., 
2004) PLC is stimulated following ligation of G-protein coupled receptor activation 
(e.g. via chemokine/fMLP receptors) on the neutrophil cell membrane.  PLC and 
phosphinositide3-kinase hydrolyse and phosphorylate phosphatidylinositol 4,5-
bisphosphate, generating inositol 1,3,4-triphosphate (IP3) and DAG.  An important 
down-stream response of DAG in neutrophils is activation of PKC, which 
phosphorylates p47phox, leading to activation of NADPH oxidase, thus explaining the 
reduced production of superoxide following neutrophil stimulation observed by some 
groups. (Garfia et al., 2004)  
 Neutrophils undergo down-regulation and apoptosis following signals from 
LPS-activated regulatory T-cells mediated through TLR activation (Lewkowicz et al., 
2006) implying a role for the adaptive immune system in conditions of chronic 
endotoxemia in limiting overzealous neutrophil activation by decreasing neutrophil 
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survival.  Over-activation of these cells in liver cirrhosis may contribute to the 
immune paresis observed and merits further investigation. 
 
3.11.1 Ammonia and p38-MAPK pathways in the pathogenesis of neutrophil 
dysfunction 
Serum ammonia levels are raised in ALF and liver cirrhosis due to a reduced urea 
synthesis capacity and porto-caval shunting.  It has recently been shown by 
Shawcross et al. that ammonia at concentrations commonly seen in acute and chronic 
liver failure cause neutrophil swelling resulting in a reduced phagocytic capacity and 
high SOB (Shawcross et al., 2008b).  These results were replicated in patients with 
cirrhosis with induced hyperammonaemia suggesting a direct toxic effect of ammonia 
on neutrophils, an effect exacerbated by the presence of hyponatraemia. The p38-
MAPK intracellular signalling pathway appears to be important in mediating this 
ammonia-induced dysfunction (Figure 7).  Phosphorylation of p38-MAPK, a key 
osmoregulator and regulator of inflammatory gene expression, including TNFα, IL-1 
and IL-12 can lead to activation of neutrophil apoptotic pathways. (Zu et al., 1998, 
vom Dahl et al., 2001)  The susceptibility of neutrophils to ammonia is used to the 
advantage of some microorganisms and has been shown to be a virulence factor in 
helicobacter pylori infection and human periodontal infection. (Mayo et al., 1997, 
Niederman et al., 1990)    
 Ammonia has also been shown to depress neutrophil chemotaxis by 
decreasing the affinity of chemokine receptors for fMLP, a key bacterial chemotaxin 
and activator of neutrophils. (Coppi and Niederman, 1989)  Additionally, it has been 
recognised for many years that ammonia can impair neutrophil energy metabolism, 
which is reliant on the conversion of glutamine to glutamate.  The phosphate- 
dependent glutaminase enzyme that catalyses this reaction is inhibited by low levels 
of ammonia. (Sbarra and Karnovsky, 1959) Taken together these findings suggest a 
critical role for ammonia in the impairment of neutrophils in liver failure, which leads 




3.11.2 Role of CARS in neutrophil dysfunction in liver failure 
CARS is the counter-regulatory homeostatic mechanism which accompanies the SIRS 
response and results in increased circulating levels of anti-inflammatory cytokines and 
mediators aimed at preventing overwhelming inflammation and ultimately resolving 
infection.   It is defined by persistently elevated circulating levels of IL-4, IL-10 and 
TGF-β, and by impairment in cellular immune function.  This is demonstrable in the 
phenotypic and functional changes that occur in monocytes, resulting in their 
deactivation, an event central to the development and evolution of CARS.  Here a 
decrease in pro-inflammatory cytokine secretion is accompanied by loss of antigen 
presenting capability, while production of IL-10 is increased.  The point of transition 
from a homeostatic response to pathological state of CARS characterised by excessive 
immunosuppression and increased predisposition to infection, has not been clearly 
defined.   
 IL-10 release can be favoured by the action of catecholamines that are known 
to contribute to the altered responsiveness of circulating leukocytes.  In a murine 
model of haemorrhagic shock β-adrenoceptor blockade allowed for a partial 
restoration of responsiveness of blood leukocytes to LPS in terms of TNF 
production.(Asehnoune et al., 2006) 
 
3.12 Neutrophils, SIRS, sepsis and organ-failure 
SIRS is the systemic consequence of an exaggerated inflammatory response distant to 
the infectious or inflammatory insult. Patients with liver failure frequently display a 
SIRS phenotype.  SIRS can progress through a series of clearly defined syndromes to 
septic shock with subsequent progression to MODS and death.  SIRS is characterised 
by the generation of both pro-inflammatory cytokines (IL-1β, IL-6 and TNFα) and 
anti-inflammatory cytokines (IL-10 and TGFβ); an excess of either component of the 
response is associated with organ failure and mortality.  
Innate immune dysfunction present in liver failure, particularly in the presence of pre-
primed immune cells, leads to an exaggerated ‘cytokine storm’ when PAMPs such as 
LPS and LTA are encountered.  This is elegantly demonstrated by the re-challenging 
of PBMCs and neutrophils from patients with cirrhosis, with LPS, generating high 
levels of pro-inflammatory cytokines particularly TNFα and IL-6. (Byl et al., 1993, 
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Wang et al., 2000) Overwhelming activation of primed circulating neutrophils in 
sepsis can lead to ALI, AKI and septic encephalopathy. (Brown et al., 2006, Awad et 
al., 2009) Systemic activation of neutrophils is seen to extend neutrophil survival and 
impedes margination across the vasculature. (Brown et al., 2006) Endothelial damage 
in organs distant to the initial insult lead to neutrophil recruitment, (Nuytinck et al., 
1988) with subsequent generation and release of ROS, and granule contents (e.g. the 
serine proteases elastase and MMP) at these sites. (Smith, 1994) In addition NO 
generation from tissue macrophage and PBMCs additionally contributes to the 
oxidative stress and vasodilatation of sepsis particularly in the splanchnic bed in 
cirrhosis.  Indeed, NO metabolite concentrations correlate with LPS levels in 
cirrhosis. (Guarner et al., 1993, Lee et al., 2010)   
This process of neutrophil over-activation in response to infection can develop 
rapidly and if left unchecked, can rapidly lead to endothelial dysfunction, hypotension 
and MODS.  Interestingly, this situation can be exacerbated acutely following 
antibiotic therapy by increasing LPS levels and pro-inflammatory cytokine release. 
(Prins et al., 1995) 
 As discuss above the development of deteriorating hepatic function and extra-
hepatic organ-failure in patients with cirrhosis as a consequence of an acute event 
such as SBP and variceal bleeding is termed AoCLF. (Sen et al., 2002)  Clinically up 
to a third of patients who are admitted due to acute deterioration in cirrhosis develop 
extra-hepatic organ failure with an associated in-hospital mortality between 53-59%. 
(Jalan et al., 2012b, Shawcross et al., 2012) There is some debate as to whether 
AoCLF represents a distinct syndrome or just the natural consequence of infection in 
cirrhosis.  One of the important features of the concept of AoCLF is the potential for 
hepatic re-compensation and reversal of organ failure following successful 
management of the precipitating event, and it is this feature that sets it apart from the 
gradual decline observed in end-stage liver disease.   
 SIRS and liver failure are co-dependent phenomena with the severity of the 
underlying liver disease determining the outcome from SIRS. The presence of SIRS 
can precipitate variceal bleeding, HE and be detrimental to survival
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3.13 Hepatic recruitment of neutrophils in acute liver injury 
The liver is highly metabolically active and is dependent on a ready supply of oxygen 
delivery through the blood.  It is also the first port of contact for ingested toxin and 
through the cytochrome P450 system can generate toxic adducts from drugs which can 
directly lead to hepatotoxicity (e.g. acetaminophen) or secondary immune-mediated 
toxicity for example drug-induced liver injury (DILI).  In chronic liver failure, 
neutrophils not only contribute to the increased propensity to infection seen but have been 
directly implicated in the liver injury observed particularly in AAH. 
 Neutrophils can be rapidly recruited to the liver following systemic or local 
exposure to cytokines such as TNFα, IL-1β, IL-6, chemokines and ROS from Kupffer 
cells. (Ramaiah and Jaeschke, 2007) These pro-inflammatory mediators prime and 
activate neutrophils leading to recruitment in the hepatic sinusoids and post-sinusoidal 
venules.  Upon receiving appropriate secondary chemotactic signals neutrophils migrate 
into the hepatic parenchyma, facilitated through β2-integrin mediated adhesion along 
chemokine gradients, particularly CXC-chemokines such as IL-8, macrophage-
inflammatory protein-2 (MIP-2), KC, CINC-1 and osteopontin produced from biliary 
epithelial cells. (Koh et al., 2007) However, neutrophil recruitment to the liver sinusoid 
does not require β2-integrin adhesion molecules.  Neutrophil accumulation within the 
sinusoid or post-capillary venule does not typically cause liver injury and the liver is 
generally immunotolerant.  (Chosay et al., 1997) Hepatic parenchymal apoptosis and 
necrosis can develop directly or indirectly, through the generation of chemokines or 
through direct cell-cell contact through sieve plates triggering neutrophilic extravasation.  
(Ramaiah and Jaeschke, 2007) Complement activation, the generation of ROS and lipid 
peroxidation products from necrotic cells can enhance neutrophil recruitment. (Jaeschke, 
2000) Once recruited neutrophils generate further chemokines such as LT-B4 and IL-8. 
(Jaeschke, 2003) For neutrophils to cause cytotoxicity they need to receive further 
chemokine signals and indeed, CXC chemokine release does not always lead to 
neutrophil extravasation and there are requirements for localisation, gradient, timing 
during the inflammatory response and the balance compared to other chemoattractants. 
(Dorman et al., 2005) Neutrophils respond to apoptotic and necrotic cells, and apoptotic 
signals can trigger neutrophilic infiltration; blocking apoptosis by pan-caspase inhibitors 
prevented neutrophil extravasation into the parenchyma. (Jaeschke et al., 1998)  
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3.13.1 Neutrophil mediated parenchymal liver damage 
Once neutrophils have infiltrated the liver parenchyma they directly bind to ICAM-1 on 
hepatocytes via β2-integrins; subsequently they can degranulate releasing potent serine 
proteases and ROS such as H2O2 and hypochlorous acid.  (Jaeschke, 2006) ROS can 
diffuse into hepatocytes leading to increased intracellular oxidant stress and 
mitochondrial dysfunction.  Depleted levels of reduced glutathione within the cells due to 
the concomitant ingestion of alcohol or other drugs can aggravate hepatic injury. 
(Jaeschke et al., 1999) Oxidants appear to be the dominant mediators of damage due to 
the importance of glutathione and that inhibition of NADPH oxidase protects against 
neutrophil mediated cytotoxicity. (Gujral et al., 2004, Ho et al., 1996) Neutrophil-derived 
proteases are involved in transmigration and cell-toxicity but can also promote the 
inflammatory response by the processing of pro-inflammatory cytokines, chemokines and 
growth factors.   
 Neutrophils often exacerbate the liver damage caused by toxins causing injury in 
the liver but especially in prolonged neutrophilic hepatitis such as AAH but in 
acetaminophen-induced liver injury this is less prominent and neutrophils may be passive 
and limit extension of the area of injury.  Factors such as calpains and deoxyribonuclease 
(DNase)-1 are subsequently released from necrotic cells can promote ongoing tissue 
injury. (Limaye et al., 2003, Napirei et al., 2006) Necrotic cells release HMGB-1, which 
further promotes neutrophilic hepatitis and tissue damage through activation of TLR4 on 
macrophages and cytokine production. (Scaffidi et al., 2002) This phenomenon has been 
documented in ischaemia-reperfusion, endotoxemia, and AAH and there is some 
evidence for it in acetaminophen-induced liver toxicity. (Ramaiah and Jaeschke, 2007)   
IL-17 and IL-23 are critical mediators of neutrophil recruitment and migration 
through the induction of granulopoiesis and production of G-CSF, IL-6, TNFα and 
neutrophil chemokines. (Ley et al., 2006, Stark et al., 2005) IL-17 levels are increased in 
alcohol-related liver disease with increased production from PBMCs, with their CD4+ T-
cells displaying an IL-17 phenotype.  IL-17 secreting cells including neutrophils and T-
cells contribute to liver inflammatory infiltrates as well as foci of alcoholic hepatitis.  
(Lemmers et al., 2009) Enhanced IL-17 production is likely to contribute to neutrophil 
recruitment and liver inflammation.  Furthermore, abnormal T-cell function contributes to 
the hepatic inflammation with Lin et al. recently showing that Th1 predominant alcohol 
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dehydrogenase-specific T-cell responses correlate with disease severity in alcohol-related 
cirrhosis, especially in active alcohol drinkers.  (Lin et al., 2013) 
Neutrophil dysfunction with high SOB and reduced phagocytic capacity has been 
reported in patients with alcohol-related cirrhosis and AAH.  (Mookerjee et al., 2007b) 
Alcoholic hepatitis is defined histologically by an intense neutrophilic infiltrate within the 
liver and these cells are purported to play a key role in the associated hepatocellular 
damage. (Bautista, 2002) Both of these conditions are associated with a high incidence of 
bacterial infection, with sepsis and endotoxemia.  
 Acute overdose with acetaminophen is the leading cause of hyper-acute liver 
failure in the UK and USA.  (Bernal et al., 2013, Lee, 2004) Acetaminophen causes liver 
injury in overdose following the generation of the reactive metabolite N-acetyl-para-
benzoquinone imine (NAPQI) through the cytochrome2E1, an alternative detoxification 
route to the usual conjugation and biliary excretion that metabolises up to 90% of the 
drug.  NAPQI is further detoxified by glutathione (GSH). (Nelson and Bruschi, 2003) 
Accumulation of NAPQI leads to reactions with a sulfhydryl group, leading to 
acetaminophen protein adducts.  Acetaminophen protein adduct accumulation, 
particularly in mitochondria, leads to mitochondrial oxidative stress and cell necrosis.  
(Jollow et al., 1973) 
 Acetaminophen-induced liver damage leads to an intense neutrophil hepatic 
parenchymal infiltrate.  However, the precise role of these neutrophils appears to be in a 
supportive role to mop up damaged cells and cell debris. (Ramaiah and Jaeschke, 2007) 
Neutrophil recruitment mirrors the development of liver injury but inhibition of 
neutrophils through adhesion molecules or inhibitors of NADPH oxidase does not protect 
against hepatotoxicity. (Lawson et al., 2000) Some investigators suggest that neutrophils 
may exacerbate the liver injury in some conditions.  The role of systemic neutrophil 
activation in the accompanying MODS typically seen in acetaminophen-induced liver 
failure has been poorly studied.   
 
3.14 Neutrophils as therapeutic targets in liver failure 
Neutrophils present attractive targets for modulatory therapies in liver failure both to 
prevent initial infections but to also ameliorate the pro-inflammatory response that leads 
to organ failure.  The recruitment of activated neutrophils during an inappropriately 
vigorous response to an inflammatory stimulus into the liver and other extra-hepatic 
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organ circulations such as the brain and kidney, can lead to the clinical syndromes of 
AAH, HE and HRS. However, a paradox exists in developing pharmacotherapeutic 
agents that enhance the antibacterial properties of neutrophils as these can further 
exacerbate the exaggerated pro-inflammatory response and vice versa.  Potential 
strategies include reducing bacterial translocation from the gut, reducing neutrophil 
priming and activation  (e.g. cytokines and ammonia), inhibition of neutrophil adhesion to 
activated endothelium in susceptible organs, enhancing neutrophil phagocytosis and 
burst, and promoting neutrophil apoptosis.  The ultimate modulatory therapies may prove 
to be extra-corporeal liver support devices, plasmapheresis and LT.   
 
3.14.1 Therapies affecting bacterial translocation 
Modulation of the intestinal microbiota has been the mainstay of treatment for HE for 
many years but recently more novel agents have become available to reduce bacterial 
translocation of LPS and other bacterial activators of TLRs in addition to ammonia, 
which is principally generated from colonic bacteria. (Mencin et al., 2009) Many of these 
drugs have been used as therapies in cirrhosis with little understanding of the mechanism 
of action.  Laxatives, such as the non-absorbable disaccharide lactulose and lactilol have 
been used as first-line agents in the treatment of HE for many years. (Als-Nielsen et al., 
2004) Lactulose is thought to act by decreasing colonic pH, potentially reducing bacterial 
translocation and absorption of ammonia as well as preventing bacterial overgrowth of 
the small bowel.  Reduced bacterial endotoxemia and decreased neutrophil priming and 
activation may well have direct effects on p38-MAPK phosphorylation in addition to 
ammonia reduction.   Effects of non-absorbable disaccharides are modest and indeed 
strong supportive randomised-control trial (RCT) data is lacking. (Als-Nielsen et al., 
2004)  
 Superior agents at reducing bacterial translocation are non-absorbable antibiotics.  
Selective gut decontamination has previously been used as a strategy for the treatment of 
HE using agents such as neomycin, colistin sulphate and amphotericin.  These have been 
largely abandoned due to risks of developing of resistant bacteria and due to unpleasant 
toxicities such as ototoxicity and nephrotoxicity.  This strategy is also employed for the 
secondary prophylaxis against infection following an episode of SBP or in recurrent HE.  
Antibiotic prophylaxis with non-absorbable antibiotics such as norfloxacin, co-
trimoxazole and more recently rifaximin-α has been shown to reduce bacterial 
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translocation and the incidence of SBP. (Gines et al., 1990, Singh et al., 1995, Hanouneh 
et al., 2012, Kalambokis et al., 2012) Concern has however been raised regarding the use 
of fluoroquinolones as this may lead to the development of resistant organisms and 
Clostridium Difficile infection.  Rifaximin-α has been found to be particularly effective at 
reducing episodes of HE and acute hospital admissions with a low risk of bacterial 
resistance. (Bass et al., 2010) Interestingly norfloxacin has been shown to abrogate 
neutrophil superoxide generation and neutrophil apoptosis 24-hours following a single 
dose. (Zapater et al., 2009) In this study serum and ascitic levels of pro-inflammatory 
cytokines and NO were seen to reduce with the lowest levels correlating with peak serum 
norfloxacin levels. Trimethoprim-sulphamethoxazole did not modulate cytokine 
production suggesting a norfloxacin specific modulation of neutrophil function and 
inflammatory cytokine production possibly achieved through selective gut-
decontamination. (Zapater et al., 2009) Furthermore selective gut-contamination, 
achieved through pre-treatment with the non-absorbable antibiotic norfloxacin, prevents 
AKI in a rodent model of cirrhosis following an LPS challenge (inflammatory insult) and 
is associated with increased renal expression of TLR4. (Shah et al., 2012) 
Probiotics have been shown to reduce bacterial translocation and are associated with a 
range of improvements in liver function, prevention of infection and prevention of HE. 
(Liu et al., 2004a) Stadlbauer et al. recently showed that probiotics could restore 
neutrophil phagocytic capacity in alcohol-related cirrhosis. (Stadlbauer et al., 2008) They 
postulated that the improvements in neutrophil dysfunction seen may be due to reduced 
levels of IL-10 and lower TLR4 expression, as levels were significantly elevated in ex 
vivo neutrophils from patients compared to healthy controls prior to probiotic therapy.  
After probiotic therapy reduced expression of these molecules was seen to occur.  Further 
trials have not seen a benefit in these agents in reducing complications of cirrhosis such 
as infection and HE. (Holte et al., 2012, McGee et al., 2011, Shukla et al., 2011) The 
combination of these agents with antibiotics is therefore now being explored.   
 
3.14.2 Reduced neutrophil adhesion   
A novel way of reducing neutrophil adhesion has been shown to have promise in a model 
of ALI where a canine hookworm derived beta-2 integrin inhibitor was transfected using 
liposomal transfer into a murine model of ALI.  This resulted in reduced neutrophil 
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transmigration into the alveolar spaces and prevented lung vascular injury.  (Zhou et al., 
1998)  
 
3.14.3 Reduced neutrophil priming 
 Therapies that target the underlying pro-inflammatory cytokine milieu and reduce 
neutrophil activation indirectly currently offer more prospects at present.  On the simplest 
level, the infusion of albumin in patients with cirrhosis has been shown to reduce the 
incidence of HRS in SBP and improve survival.  (Sort et al., 1999) This appears to be 
above and beyond its role as a plasma expander and a comparison with an alternative 
colloid, Dextran-70 has demonstrated reduced levels of plasma renin and improved 
endothelial dysfunction in the albumin treated group compared to the colloid. (Planas et 
al., 1990) Albumin possesses an exposed thiol group that act as an antioxidant allowing it 
to scavenge transition metal ions and free radicals.  The use of albumin in SBP in 
combination with antibiotics significantly reduces levels of TNFα, IL-6 and NO in ascites 
and serum. (Chen et al., 2009)  
 Interestingly, extracorporeal liver support systems and albumin dialysis have been 
shown to enhance cytokine clearance (Di Campli et al., 2005, Stadlbauer et al., 2006) but 
do not appear to alter serum levels possibly due to a high rate of production.  As yet 
albumin-dialysis has not been shown to confer a survival benefit.   Haemofiltration can 
achieve a 22% reduction in median arterial ammonia concentrations over 24-hours and 
normalise hyponatraemia, both of which potentially modulate neutrophil function but its 
effects in this setting has yet to be determined. (Slack et al., 2014)  
 Plasmapheresis is the removal, treatment and return of plasma from the circulating 
blood.  The procedure is used to treat a number of inflammatory conditions such as 
Guillain-Barre syndrome and haemolytic uraemic syndrome where circulating factors are 
present. The process has the potential to remove a significant quantity of cytokines, 
PAMPs and DAMPs, which may have beneficial immunomodulatory effects.  Studies 
have shown however, that circulating concentration of cytokines seem to be unaltered 
probably due to the high levels of on-going production. (Nakae et al., 2002) However, 
high volume plasmapheresis has been shown to alleviate severe HE in patients with ALF 
with improvement in systemic haemodynamics. (Larsen et al., 1996) Plasmapheresis is 
currently being evaluated in acetaminophen-induced ALF where LT is not an option.  
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 Ongoing attempts at removal of PAMPs have shown potential benefit in sepsis 
with successful reduction in the levels of endotoxin and IL-6 using an apheresis system 
based on DEAE-cellulose. (Bengsch et al., 2005) An albumin replacement system with a 
novel endotoxin ligation (ARSeNEL) component has been developed and is undergoing 
trials by the liver failure group at UCL.  Improved survival, reduced endotoxin levels and 
improved intracranial pressure index has been observed in early studies and a clinical trial 
is being planned.  (Ryan et al., 2013) 
  Leukopheresis involves extracorporeal removal of leukocytes from the blood 
either through centrifugation or by passage of blood through an adsorptive system.  In 
each system, venous blood is removed in a continuous flow, anti-coagulated, processed to 
deplete the leukocytes and returned to the circulation.  These remove a mixture of cells 
but mainly granulocytes and lymphocytes.  These systems have been approved for use in 
inflammatory bowel disease following a RCT and a number of case series.  (Tominaga et 
al., 2013, Hanai et al., 2003)  Intriguing supportive evidence that down-regulation of 
primed neutrophils may be a therapeutic goal is suggested by studies showing 
leucodepletion improves respiratory and renal dysfunction in sepsis. (Treacher et al., 
2001) This may be of particular benefit as it targets the dysfunctional circulating 
neutrophils which are implicated in organ dysfunction while leaving neutrophils recruited 
to sites of inflammation unaffected.  This has shown success in inflammatory bowel 
disease where activated neutrophils play a key role in tissue damage but its use in liver 
disease has only been reported in a case of refractory AAH. (Ota et al., 2009) 
 Excitement surrounds the prospect of small molecules that modulate TLR4 
signalling which can potentially downregulate neutrophil activation and other cellular 
immune responses. (Mullarkey et al., 2003) Early data indicate that they can reduce LPS-
stimulated cytokine release in healthy volunteers and are awaiting phase III clinical trial 
results.  Neutrophil TLR9 expression in ALF and cirrhosis serves as a useful biomarker 
that may differentiate patients that develop high grade HE.  High baseline neutrophil 
TLR9 expression is associated with a pro-inflammatory milieu and may explain the 
propensity to develop infection and hasten the development of HE. (Manakkat Vijay et 
al., 2012) Therefore TLR9 antagonists may be of therapeutic value in restoring bacterial 
defence mechanisms.   
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3.14.4 Immunosuppressive drugs 
Neutrophils can be suppressed by corticosteroids and these drugs perturb multiple steps in 
the immune activation of all inflammatory cells including neutrophils, with reduced 
antigen presentation, cytokine production and lymphocyte proliferation.  Peripheral 
neutrophil counts increase in response to corticosteroid administration due to reduced 
margination of cells and increased export of neutrophils from the BM. Neutrophil 
adhesion is reduced which reduces recruitment into sites of inflammation.  
Corticosteroids block a key step in the production of prostaglandins and leukotrienes, 
through inhibition of phospholipase-A2; these are important neutrophil chemotactic 
molecules.  IL-1 production is also inhibited.  More long-term effects of corticosteroids 
are seen though the decreased action of T-cells and reduced clonal proliferation of T-cells 
through the inhibition of IL-2 (T-cell growth factor) production.  Circulating neutrophils 
showed increased spontaneous burst and decreased L-selectin expression in this cohort.  
Upon stimulation, neutrophils produced large quantities of IL-8 and TNFα.  Plasma 
levels of pro-inflammatory cytokines are high in AAH but IL-10 levels are barely 
detectable in comparison to patients with alcohol-related cirrhosis. (Taieb et al., 2000) 
Treatment with corticosteroids normalised cytokine profiles and neutrophil function.   
 The use of immunosuppressant drugs particularly in the setting of AAH has been 
a rather vexed question for many years.  AAH occurs in the setting of chronic liver 
disease with up to 80% of patients showing cirrhosis on subsequent liver biopsy.  
Alcoholic hepatitis is an intense neutrophilic hepatitis that is manifested by liver 
inflammation, hepatocyte injury and fibrosis and can lead to a SIRS and decompensation 
of the chronic liver disease; in the most severe form this can be associated with a high 
mortality.  (Forrest et al., 2005) Patients with mild disease are seen to spontaneously 
recover whilst the use of potent immunosuppressive drugs is a high-risk gambit in the 
cohort of patients with severe disease who are at high risk of overwhelming sepsis. As yet 
corticosteroids have not been shown to demonstrate a clear benefit in AAH, possibly due 
to heterogeneity in the patient selection. (Mathurin et al., 2011) Stratification according to 
disease severity [Maddrey’s modified discriminant function >32 (Maddrey et al., 1978)] 
can result in improved 30-day mortality especially in those with HE but is still associated 
with 40% mortality.  (Phillips et al., 2006) The recent large multi-centre STOPAH trial 
confirmed a reduced 28-day mortality but this did not reach significance at 90-days and 
1-year.  (Thursz et al., 2015) 
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 Pentoxifylline is a methylated xanthine derivative and is a competitive non-
selective phosphodiesterase inhibitor.  Pentoxifylline increases intracellular cyclic AMP, 
activating PKA resulting in the inhibition of TNF and leukotriene production. This can 
reduce inflammation and activation of neutrophils and monocytes. In placebo-controlled 
trials of pentoxifylline in AAH, the mortality rate decreased in the active therapy arm 
(26% versus 46%). This was not due to improved liver function but the reduced incidence 
of renal dysfunction in those treated with the drug. (Akriviadis et al., 2000) Modulation of 
neutrophil function would be a potential mechanism through which this effect may be 
mediated either through direct suppression of neutrophil function or secondary to reduced 
TNFα levels; a key pro-inflammatory cytokine in alcoholic hepatitis, although the precise 
mechanism of action is unclear.  However, the STOPAH trial has recently cast doubt on 
the clinical effectiveness of pentoxifylline showing that survival in groups treated with 
28-days of monotherapy was unchanged compared to placebo groups and no additional 
benefit was seen when combined with prednisolone.  (Thursz et al., 2015) 
 TNFα is a key mediator in AAH and directly targeting this cytokine with 
inhibitory monoclonal antibodies such as the anti-TNF monoclonal antibody infliximab 
has been considered an attractive strategy.  A pilot study of 20 patients with biopsy-
proven alcoholic hepatitis who were treated with corticosteroid and either infliximab or 
placebo was published in 2002. (Spahr et al., 2002) Infliximab therapy resulted in 
improved discriminant function and IL-8 levels at 28-days.  Infliximab has also been 
shown to reduce peripheral neutrophil counts in AAH. (Tilg et al., 2003) However, a 
subsequent RCT comparing corticosteroids to infliximab was stopped early due to an 
unacceptable high mortality from sepsis in the infliximab arm. (Naveau et al., 2004) 
Entanercept the soluble TNF-receptor fusion protein does not appear to have a clinical 
effect in AAH. (Boetticher et al., 2008) The effects of potent immunosuppressant drugs 
such as steroids and anti-TNF antibodies demonstrate the difficulties with suppressing 
neutrophil function.  This appears to be beneficial in some (particularly when receiving 
more moderate doses) but others develop overwhelming infection as these agents 
exacerbate the immune dysfunction already present.   
 
3.14.5 Neutrophil apoptosis 
Targeted therapies have produced mixed results in sepsis such as G-CSF (Nelson et al., 
1998, Root et al., 2003) and antagonism of pro-inflammatory cytokines (Netea et al., 
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2003) have not shown benefit unless neutrophil patients have low percentages of 
immature cells and low concentrations of G-CSF.  (Ishikawa et al., 2000)  G-CSF has 
been shown to improve neutrophil phagocytic capacity in patients with ALF.  (Rolando et 
al., 2000b) However, G-CSF therapy has been shown to benefit patients with AoCLF 
who were treated with 12 doses of G-CSF over a month and showed improvement in liver 
failure scores with reduced septic episodes and an outcome at 2-months associated with 
increased circulating numbers of neutrophils and CD34+ cells (bone-marrow derived 
stem cell).  (Garg et al., 2012) The authors’ postulate that G-CSF may improve survival 
in AoCLF through neutrophil activation and improved hepatocyte regeneration, however, 
neutrophil phenotype or functional analysis was not performed which would have 
provided additional insight into the findings. 
 
3.14.6 Novel therapies targeting specific neutrophil functions 
Hypothermia is a therapeutic measure used in ALF to prevent cerebral oedema.   
Intraoperative hypothermia has been shown to reduce the production of ROS and 
phagocytosis by neutrophils ex vivo during conditions where the core temperature was 
reduced to 33-37,° (Wenisch et al., 1996) suggesting that stabilisation of neutrophil burst 
may be a desired therapeutic goal.  It displays many beneficial effects on brain water and 
intracranial hypertension relating to decreased brain ammonia, cerebral blood flow, 
mediators of inflammation and oxidative stress. (Jalan et al., 1999, Larsen et al., 1996) 
There has however, been some concern that hypothermia may be detrimental to immune 
function impairing defence mechanisms against microbial challenge. (Stravitz and 
Larsen, 2009) Hypothermia has been shown to decrease neutrophil functions such as 
oxidative killing and phagocytosis in vivo and in vitro. (Wenisch et al., 1996, Akriotis 
and Biggar, 1985) However, D Shawcross has shown that moderate hypothermia (33 ºC) 
prevented the ammonia-induced activation of resting neutrophil oxidative burst in vitro, 
without impairing the ability of the neutrophils to phagocytose opsonised E. coli or 
undergo stimulated oxidative burst and thus kill bacteria. (Shawcross et al. unpublished 
data) 
 Modulation of intracellular second messenger systems such p38-MAPK may be 
considered to be a therapeutic target of the future as selective modulation may allow fine 
control over neutrophil functions in different circumstances.  Shawcross et al. 
demonstrated that ammonia-induced neutrophil swelling could be abrogated to some 
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extent by treating with p38-MAPK agonist isoproterenol. (Shawcross et al., 2008b) This 
not only prevented neutrophil swelling but also normalised phagocytosis.   However, 
selective p38-MAPK antagonists such as SB203580 inhibit the ammonia-induced 
increase in spontaneous oxidative burst.  As our understanding advances, other second 
messenger targets may be explored such as modulators of ERK, JNK and PI3K.  
Furthermore, other osmoregulators such as the aquaporin molecules, may provide 



































This thesis sets out to investigate the neutrophil characteristics present in acute and 
chronic liver failure and the putative role played by neutrophils in organ dysfunction in 
this condition.  I wish to challenge the traditional view that liver failure is a condition 
associated with an “immuneparesis”, instead suggesting that neutrophils actively undergo 
defective dysregulation of their anti-microbial effector functions, thus leading to an 
increased propensity to infection and playing a critical role in the development of organ 
failure, especially in the presence of complicating microbial infection.  It is only by 
understanding the mechanisms that underlie the altered behaviour of neutrophils in this 
condition that new, effective and targeted therapies can be developed to reduce the 
unacceptably high mortality from sepsis associated with liver failure.  
 
4.1 Hypothesis. 
This study aimed to test the following hypotheses: 
1. Neutrophil swelling, impaired phagocytosis and spontaneous oxidative burst are 
present in patients with liver failure and contribute to increased susceptibility to 
infection. 
2. Arterial ammonia contributes to neutrophil dysfunction and swelling, mediated 
through changes in the p38-MAPK pathway [see Figure 4-1]. 
3. Abrogation of the neutrophil dysfunction seen in liver failure can be achieved by 







FIGURE 8-1 HYPOTHESIS MODEL - AMMONIA INDUCED NEUTROPHIL SWELLING AND COMPENSATORY ACTIVATION OF P38-MAPK SYSTEM.    
p38-MAPK becomes activated following phosphorylation by MAP kinase kinase.  SB203580 is a specific inhibitor of p38-MAPK activation 
and the β-adrenergic agonist isoproterenol increased phosphorylated p38-MAPK through activation of cAMP-dependent protein kinase but not 
cJNK. (Moule and Denton, 1998) 
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4.2 Studies to be performed and their objectives. 
 
4.2.1 Study to characterise neutrophil morphology and function in acute and 
chronic liver failure 
Neutrophil morphology (cell volume and transmission electron microscopy), chemotaxis, 
phagocytic function, spontaneous and E.coli stimulated oxidative burst (SOB and ESOB) 
were compared between patients and healthy controls in order to characterise the 
neutrophil defects in acute and chronic liver disease.  Comparison of neutrophil function 
and morphology between patients with liver failure and patients with severe sepsis 
requiring ICU admission, determined if the neutrophil phenotypes are comparable.  It is 
important to determine if neutrophil activation is occurring in a similar fashion to that 
observed in sepsis, possibly due to endotoxemia, or if unique or more profound changes 
occur in the context of liver failure, which may suggest alternative pathways of neutrophil 
priming and activation.   
 Comparison with measures of disease severity, inflammation, arterial ammonia, 
and/or hyponatraemia allowed determination of the factors that correlate with neutrophil 
function confirming the findings of previous studies. Secondly, associations with the 
severity of liver disease/injury were investigated.  In addition, associations with other 
plasma-derived factors such as pro- and anti-inflammatory cytokines, immunoglobulins, 
complement and lipids, all of which may be potentially immunomodulatory, were sought 
in order to aid in the understanding of the implications of these phenomena.   
 The role of liver disease aetiology (e.g. alcohol-related liver disease and chronic 
viral hepatitis) and the presence of neutrophil dysfunction were investigated as previous 
studies have shown increased neutrophil dysfunction especially in patients with alcoholic 
hepatitis.  The association of neutrophil dysfunction with significant patient outcomes 
such as infection, variceal bleeding, HE and death were investigated to determine if 
neutrophil dysfunction could act as a predictor of such events. 
 In ALF, correlation between neutrophil phenotype/function and change over time 
was determined and compared with severity of liver injury and measures of associated 
organ failure to determine if neutrophil dysfunction predicts poor outcome that might 
help refine selection for LT.   
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4.2.2 Study to determine the contribution of neutrophil swelling and dysfunction to 
the increased susceptibility to infection seen in patients with liver failure 
Short-term and long-term follow-up of these cohorts documenting clinical end-points 
such as incidence of inflammation, infection, organ dysfunction and survival were 
performed to answer this question. My hypothesis was that patients with more severe 
neutrophil dysfunction develop more infections (e.g. SBP) and complications of their 
liver disease including variceal bleeding, HE and AKI.  In addition I wanted to determine 
if neutrophil dysfunction is an independent risk factor for death over and above severity 
of liver failure.  This may identify patients at high risk in whom antibiotic prophylaxis 
could be considered 
 
4.2.3 Study to determine the change in neutrophil morphology and function during 
the development of HE or AoCLF in patients with liver failure 
Patients admitted with HE or who developed HE during their in-patient stay had blood 
sampling performed during the acute episode of HE and (where possible) on 
convalescence to determine if there were any differences, as both ammonia and 
inflammation have been shown to play a role in the development of this complication.   A 
second sub-group of patients who had developed complications of their cirrhosis leading 
to MODS requiring ICU support (AoCLF) were also characterised.  In this population I 
wanted to know the effect of infection and an increasing inflammatory milieu on 
neutrophil phenotype/function and outcome. 
 
4.2.4 Study to determine how ammonia-reducing therapies such as haemofiltration 
and liver transplantation impact on neutrophil function? 
To document the effects of in-vivo ammonia lowering by haemofiltration and LT on 
neutrophil swelling and function, samples were obtained before and 48 hours after the 
initiation of continuous veno-venous haemofiltration (CVVH) or post-LT.  As ammonia 
or hyponatraemia-induced neutrophil swelling is believed to be an important mediator of 
neutrophil dysfunction I hypothesised that normalisation of these factors by such 
therapies would abrogate neutrophil dysfunction.  
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4.2.5 Study to determine whether arterial ammonia concentration contributes to 
neutrophil swelling and dysfunction through changes in the p38-MAPK 
pathway 
Quantification of phosphorylated and total p38-MAPK levels were measured by Cytokine 
Bead Array (CBA) assay (Becton Dickinson, UK) and subsequently determined by 
Fluorescence activated cell sorting (FACS) using ACAP array software (Becton 
Dickinson, UK).  The hypothesis that ammonia impairs neutrophil function by inducing 
cell-swelling resulting in elevated levels of phosphorylated p38-MAPK (the activated 
form) leading to activation of homeostatic mechanisms to correct cell swelling and 
induction of transcription of inflammatory genes within neutrophils was tested by 
correlating blood ammonia concentration with neutrophil swelling and function. 
 
4.2.6 Study to investigate the effect of modulators of the p38-MAPK pathway on 
neutrophil function 
In order to investigate the effect of modulators of p38-MAPK on neutrophil function ex-
vivo, analysis was performed on isolated neutrophils at baseline, following ammonia 
exposure and following incubation with 1µM isoproterenol a p38-MAPK agonist or 
10µM 4-(4-Flurophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl) 1H-imidazole 
























































5.1 Study design 
A cross-sectional case-control cohort study was devised.  Patients with ALF and cirrhosis 
were prospectively studied. Neutrophil morphology, chemotaxis, phenotype, 
phagocytosis, SOB and ESOB were determined and compared to healthy and septic 
disease controls.  Patients were recruited between October 2008 and August 2010.    
Patients with ALF, AoCLF and severe sepsis were recruited from the ICU.  Patients with 
liver cirrhosis were either recruited following admission for LT assessment or following 
































5.2 Patient cohorts - inclusion and exclusion criteria. 








patients to be 
recruited 
Samples to be taken 
Healthy controls Non-smoker and no 
alcohol / exercise within 
24 hours 
24 3 x Li+  heparin (9 ml) & 1 
x EDTA (2 ml) 
Septic disease 
controls 
Severe sepsis 24 3 x Li+  heparin (9 ml) & 1 
x EDTA (2 ml); repeat day 
3 and on recovery 
Chronic liver 
disease 
Child’s A cirrhosis 24 3 x Li+ heparin (9 ml) & 1 
x EDTA (2 ml) 
Chronic liver 
disease 
Child’s B/C cirrhosis  24 3 x Li+  heparin (9  ml) & 1 
x EDTA (2 ml) 
repeat post-LT 
HE (grade I-II) No active sepsis 24 3 x Li+  heparin (9 ml) & 1 
x EDTA (2 ml) day1; 
repeat on recovery from 
HE (grade 0) 
AoCLF Sepsis / variceal bleed / 
HE grade (III-IV) 
24 3 x Li+  heparin (9 ml) & 1 
x EDTA (2  ml) day 1; 
repeated on day 3; post LT 
or one recovery 







3 x Li+  heparin (9 ml) & 1 
x EDTA (2 ml) day 1; 
repeated on day 3; post LT 
or on recovery  
Total  168  
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5.2.1 Control cohorts 
Healthy age- and sex-matched healthy volunteers with no history of liver disease were 
recruited to the healthy control group. Their alcohol intake was <20 g/day and they had 
not drunk alcohol or exercised excessively in the 24-hours prior to blood being drawn.   
Patients with severe sepsis, as defined by the presence of a SIRS response 
[temperature>38°C or <36°C; heart rate >90 beats per minute; tachypnoea > 20 breaths 
per minute or PaCO2<4.3 kPa; white cell count >12 X 109/L or <4 X 109/L; or the 
presence of >10% immature neutrophils], (Bone et al., 1992) with radiological or 
laboratory evidence of infection and end-organ failure were recruited from the ICU to the 
sepsis disease control group.  Blood sampling was performed within 48-hours of 
admission and on subsequent days, with a convalescent sample prior to discharge [Table 
2-1]. 
 
5.2.2 Acute Liver Failure Cohorts 
ALF is a rare but frequently catastrophic consequence of severe liver injury.  Trey and 
Davidson originally defined the entity in 1970 as the onset of hepatocellular dysfunction 
in the absence of pre-existing liver disease characterised by coagulopathy and 
encephalopathy within 8 weeks of the hepatic insult, lasting no more than 26 weeks 
duration. (Trey and Davidson, 1970) In addition patients were further sub-classified 
depending on O’Grady’s classification (O'Grady et al., 1993) which uses time from 
appearance of jaundice to the development to HE;  
(i) Hyperacute liver failure being defined as a jaundice to encephalopathy time ≤ 7 days 
which is associated with severe coagulopathy and intracranial hypertension.  It is 
generally associated with a good survival rate without emergency LT.   
(ii) Acute liver failure defined as jaundice to encephalopathy time of 8-28 days and is 
typified by presentation with acute hepatitis B infection.  Patients have moderate degrees 
of coagulopathy, jaundice and intracranial hypertension with generally less favourable 
outcomes without LT.  
(iii) Subacute liver failure has a more indolent course with jaundice to encephalopathy 
time of 4-12 weeks being commonplace, with severity of jaundice outweighing the 
coagulopathy.  Intracranial hypertension is less common complicating only 
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approximately 9% of cases, as compared to 20% in acute and hyperacute liver failure. 
(Bernal et al., 2007)  For the purposes of this study ALF was considered as the 
development of encephalopathy within 28 days of the onset of jaundice and subacute liver 
failure (SALF) being defined as the development of encephalopathy 4 – 12 weeks from 
the onset of jaundice (O'Grady et al., 1989).  Exclusion criteria were age <18 or >80, 
evidence of bacterial, fungal or viral sepsis on clinical examination and/or cultures within 
48 hours of sampling, malignancy, pregnancy and any coexisting history of 
immunodeficiency including human immunodeficiency virus (HIV) infection and 
glycogen storage disease.   
Baseline sampling was performed within 48 hours of admission to the ICU and on 
subsequent days until spontaneous recovery or LT.  In those who underwent LT further 
sampling was performed 72 hours post-LT.  Subjects were followed up for 90-days.  
 
5.2.3 Cirrhosis Cohorts 
All patients had a diagnosis of cirrhosis made on biochemical, radiological and/or 
histological findings.  Exclusion criteria were age <18, evidence of bacterial, fungal or 
viral sepsis on clinical examination and/or cultures within 48 hours of recruitment (apart 
from the AoCLF study group), malignancy, pregnancy and any coexisting history of 
immunodeficiency including HIV and glycogen storage disease.  Patients were recruited 
to the following groups: Mild to moderate stable cirrhosis (Child-Pugh A and B) (Pugh et 
al., 1973); Advanced stable cirrhosis (Child-Pugh C); Hepatic Encephalopathy (West-
Haven grade I-II managed in a hospital ward environment) (Harold and Milton, 1979);  
AoCLF,  defined as the development of deteriorating hepatic function and extra-hepatic 
organ failure in patients with cirrhosis as a consequence of an acute event such as SBP 
and variceal bleeding.  (Sen et al., 2002, Moreau et al., 2013) 
 Sampling was performed at baseline, following the development of HE or sepsis 
with matched convalescent samples, and following LT.  Subjects were followed up for 12 
months or until LT [Table 2-1].   
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5.3 Sample size and power calculation 
 Based on power calculations using previous in-vitro and ex-vivo data from pilot 
data (Figure 5-1 and 5-2), a 20% reduction in neutrophil function from 90% to 70% was 
anticipated.  Comparing a proportion of 0.9 to 0.7 using the binomial proportion 
comparison and assuming a two-sided test, alpha 0.5 and power of 80%, gives a sample 
size of 24 required in each group.   
 
 
FIGURE 5-1 REDUCTION IN NEUTROPHIL PHAGOCYTOSIS 4 HOURS POST 
INGESTION OF AMINO ACID SOLUTION OR PLACEBO IN PATIENTS WITH 
CIRRHOSIS 





FIGURE 5-2 GRAPH SHOWING PERCENTAGE UPTAKE OF OPSONISED E COLI BY 
NEUTROPHILS IN HEALTHY CONTROLS AND PATIENTS WITH LIVER 
CIRRHOSIS PRE AND POST-LIVER TRANSPLANTATION 
(Taylor et al., 2009) 
 
5.4 Consent and data collection 
The study was performed in accordance with the declaration of Helsinki and ethical 
permission was granted from the North East London Research Ethics committee (Ref No 
08/H0702/52).  Following the obtaining of fully informed consent/assent, clinical, 
biochemical and physiological data were collected.  Data included tobacco and alcohol 
use, arterial ammonia (µmol/L), serum sodium levels (mmol/L), differential leucocyte 
count (x109), complement and lipoprotein levels.  The Glasgow Coma Score (GCS) 
[Table 5-2] (Teasdale and Jennett, 1974), grade of HE according to the West-Haven 
criteria [Table 5-3] (Harold and Milton, 1979), and admission SIRS score were also 
calculated. [Table 5-4]  (Bone et al., 1992) A number of organ failure scores were also 
quantified including the CPS [Table 5-5], (Pugh et al., 1973) model of end-stage liver 
disease score (MELD) (Kamath et al., 2001), United Kingdom End-Stage Liver Disease 
score (UKELD) (Barber et al., 2011), Sequential Organ Failure Assessment (SOFA) 
Score [Table 5-6] (Vincent et al., 1996) and the Acute Physiology and Chronic Health 
Evaluation (APACHE) II score. (Knaus et al., 1985) Length of ICU stay, survival and 
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number of days requiring vasopressors (terlipressin was not handled as a vasopressor in 
this study), ventilation or renal replacement therapy were also analysed.  
 Details of potentially immunomodulator therapies such as N-acetyl cysteine, 
corticosteroids, antibiotics and Pentoxifylline therapy, haemofiltration and 
plasmapharesis were recorded.  The occurrence of infection in the 4 weeks prior to 
sampling, and in the 6 weeks following sampling, were recorded along with relevant 
patient outcomes including infections (e.g. SBP, variceal bleeding, HE) and survival (6-

























Table 5-2 Glasgow Coma Scale (GCS) 
 1 2 3 4 5 6 
Eyes Does not open 
eyes 











Confused Orientated n/a 

















Table 5-3 West Haven Criteria for Semi-quantitative grading of Mental Status 
Grade 1  
 
Trivial lack of awareness 
Euphoria or anxiety 
Shortened attention span 
Impaired performance of addition or subtraction. 
Asterixis can be detected 
Grade 2 Lethargy or apathy 
Minimal disorientation for time or place 
Subtle personality change 
Inappropriate behaviour. 
Obvious Asterixis 
Grade 3 Somnolence to semi-stupor, but responsive to verbal stimuli 
Confusion 
Gross disorientation 







Table 5-4 Systemic inflammatory response syndrome (SIRS) score 
Systemic inflammatory response syndrome (SIRS) at least 2 of the criteria listed 
below must be present to diagnose. 
Temperature: >38  oC or <36  oC 
Heart rate  >90 beats per minute; 
Respiratory rate >20 breaths per minute or PaCO2 <4.3 kPa [self-ventilating] 
White blood cell 
count (WBC)  
>12 x 109/L or <4 x 109/L or the presence of >10% immature 
neutrophils 
Sepsis is diagnosed when patients meet SIRS criteria, and has a documented or 
suspected source of infection 
Severe sepsis – sepsis associated with at least one sign of organ dysfunction, 
including; hypoperfusion, or hypotension lactic acidosis, oliguria, or alteration in 
mental state.   
Septic shock – severe sepsis with hypotension unresponsive to adequate fluid 
resuscitation. 
 
Table 5-5 Child-Turcotte-Pugh score 
Parameter 1 point 2 points 3 points 
Total bilirubin 
µmol/L 
<34 34-50 >50 
Serum albumin g/L >35 28-35 <28 
INR <1.7 1.7-2.3 >2.3 
Ascites None Mild Moderate - Severe 
Hepatic 
encephalopathy 









Table 5-6 Sequential Organ Failure Assessment (SOFA) Score 
 0 1 2 3 4 
Respiratory 
PaO2/FiO2 
>400 ≤400 ≤300 ≤200 ≤100 
Coagulation 
Platelets x 103 























15 13-14 10-12 6-9 or ICP <6 
Renal 
Creatinine 
µmol/L or urine 
output mls/day 





Abbreviations: MARS-Molecular Adsorbent Recirculating System (liver assist device), 
MAP-mean arterial pressure, Dop-Dopamine, Dobu-Dobutamine epi-epinepherine, 
norepi-norepinepharine, CASD-Circulatory assist device, GCS-Glasgow coma scale, 








5.5 Blood sampling 
The schedule for blood sampling is outlined in Table 3.  Venous blood was collected 
aseptically either from a large vein without a tourniquet or from indwelling central 
venous catheters (in those patients on ICU) into heparinised pyrogen-free tubes from 
patients/volunteers and was immediately placed on ice on a tilt-table and gently mixed for 
10 minutes to pre-cool the neutrophils to 0-4 °C.  Subsequently neutrophil function tests 
were performed within 2 hours of blood being drawn.  Plasma was obtained by 
centrifugation at 4500 rpm for 10 minutes at 4 °C, and stored at -80°C for subsequent 
cytokine determination.   
 Arterial blood was sampled aseptically in pre-heparinised syringes either from 
peripheral radial artery puncture or from indwelling radial or femoral catheters. 
 
5.6 Measurement of Blood Ammonia 
Plasma ammonia estimation was performed from freshly drawn arterial blood by 
determination using bedside testing using the Ammonia test Kit II for the PocketChem 
BA device (Arkay, Inc, Kyoto, Japan).  This measures ammonia in a 20 µL blood sample 
applied to a reagent strip.  The continuous measurement range is 7-286 µmol/L and the 
normal blood ammonia level for healthy adults for this device is less than 54 µmol/L.  
The device was maintained in accordance with the manufacturer’s specification, with 
daily internal and monthly external calibration.  The device is located within the ICU so 
all samples were processed in under 5 minutes.   
 
 
5.7 Ex-vivo studies of neutrophil cell surface expression of CD16 and 
CD11b 
Neutrophil cell surface receptor expression was determined by staining with anti-CD16-
Phycoerythrin (PE) IgG1 κ and anti-CD11b-Allophycocyanin-Cyanin 7 (APC-Cy7) IgG1 
κ (both from BD Biosciences) antibodies.  Red cell lysis was achieved by the addition of 
1mL of FACS lysis solution (BD Biosciences) to 100 µL whole blood and allowed to 
stand for 10 minutes at room temperature.  Cells were then washed with a further 3 ml of 
neutrophil wash solution (NWS) and centrifuged (5 mins, 1600 rpm, 4 °C) discarding the 
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supernatant.  Cells were then re-suspended in 100 µL of NWS and then stained with anti-
CD16-PE IgG1 κ or anti-CD11b-APC-Cy7 IgG1 κ and allowed to conjugate for 1 h in the 
dark at room temperature.  Analysis of the samples was performed on a fluorescence-
activated cell sorting Canto II analyser (FACSCantoII, Becton Dickinson, San Jose, CA).  
Neutrophils were gated on forward scatter (FSC) and side scatter (SSC) characteristics 
and cells staining positive for CD16-PE and CD11b-APC-Cy7 were determined using 
flow cytometry (see Method 5.9.5 below for neutrophil gating, acquisition and analysis).   
 
5.8. Assessment of neutrophil cell volume  
 
5.8.1. Assessment of neutrophil cell volume using neutrophil forward scatter as 
determined by flow-cytometry 
 Assessment of neutrophil cell volume was performed on neutrophils isolated from 
heparinised whole blood by density centrifugation using PolymorphoprepTM using 
endotoxin free equipment in a laminar flow cabinet. PolymorphoprepTM (Axis shield, 
Norway) is a sterile and ready-made solution used for the isolation of the 
polymorphonuclear granulocytes from the whole blood. It utilises the principle that the 
PMN cells are more buoyant in density than the mononuclear cells. It contains Sodium 
diatrizoate 13.8% (w/v) and Dextran 500: 8.0% (w/v) with Density: 1.113±0.001 g/mL, 
Osmolality: 445±15 mOsm and Endotoxin: < 1.0 EU/ml (Polymorphprep™).  
 
5.8.2 Method for neutrophil isolation using PolymorphoprepTM 
1. Heparinised venous blood was collected from healthy controls and patients with 
liver failure.  Tubes were kept on ice and placed on a bench rocker prior to 
assessment of neutrophil apoptosis and samples were analysed within 30 minutes.   
2. Five mLs of polymorphoprep™ were placed in a 15 mL falcon tube. Five mL of 
blood from the lithium heparin tube were carefully layered on top of the 
polymorphoprepTM using a pipette.  Care was taken for the blood not to mix with 
the Polymorphoprep™.  
3. The tubes were centrifuged at 2800 rpm for 35 minutes at 18 °C without using a 
brake. 
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4. Three distinct layers were present after centrifugation; two clear leucocyte bands 
were seen to form in the falcon tube (Figure 5-3) above a sediment band of 
erythrocytes.  The top leucocyte layer consisted of mononuclear cells with the 
lower leucocyte layer consisting of PMN cells, including neutrophils.  The lower 
leucocyte layer was harvested using a Pasteur pipette. These PMN were diluted by 
addition of equal volume of 0.45% saline to restore the osmolality. 
5. These cells were washed twice with NWS, in a centrifuge at 2500rpm for 5 
minutes. It was re-suspended in 60 µL of neutrophil wash solution 
6. Neutrophil volume was determined by FACS Diva software, using a method 
previously reported for hepatocyte cell volume regulation (Carini et al., 1999).  
Neutrophil median FSC, as an estimation of neutrophil volume, were expressed as 
arbitrary units after normalization of 100,000 control neutrophils.  The intra-assay 
coefficient of variance was 4.7% and the inter-assay coefficient of variance was 
5.4%.  
 
FIGURE 5-3 TUBES SHOWING WHOLE BLOOD LAYERED OVER 
POLYMORPHOPREPTM  BEFORE AND AFTER CENTRIFUGATION AT 2800RPM 
WITHOUT BREAK.    
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5.8.3 Neutrophil morphology assessment by transmission electron microscopy  
In representative samples from each cohort transmission electron microscopy (TEM) was 
performed on neutrophils isolated from heparinised whole blood by density centrifugation 
using PolymorphoprepTM using endotoxin free equipment in a laminar flow cabinet as 
described above.  Neutrophils were subsequently incubated with 20 µL phosphate 
buffered saline (PBS) or 20 µL of opsonised E.coli (2x107) for 20 minute prior to fixation 
in glutaraldehyde solution and stored at 4 °C.   Subsequently TEM was performed in 
collaboration with Dr Alice Warley (at the Centre for Ultrastructural Imaging, King’s 
College London) and an independent blinded haematologist evaluated the images, with 
expertise in morphology (Professor Barbara Bain; St Mary’s Hospital) for morphological 
changes (e.g. phagosome numbers, granule density and evidence of mitochondrial stress).  
(Robinson et al., 1999) Images were analysed using the Image J software package 
(imagej.nih.gov/ij/download/) 
 
5.9 Studies to determine neutrophil chemotaxis 
Chemotaxis of ex-vivo neutrophils was determined by the MigratestTM (Orpegen Phrama) 
using the following method: 
5.9.1 Leukocyte isolation and assay procedure 
 
1. One ml of heparinised whole blood from either controls or patients was overlayed 
on top of the neutrophil separation media (12 vials are provide in the kit).  
2. The vial was left motionless at room temperature for 40 minutes.  At this point the 
upper of the 3 phases contains the leucocyte rich plasma (LRP).  500 µL of the 
LRP was aspirated using a pipette, into a 2 µL eppendorf. 
3. The fMLP was prepared from stock solution (1:200 dilution) by adding 5 µL to 
1mL of incubator buffer 
4. The following samples were prepared for each patient or control by pipetting 
incubator buffer into two wells of a multi-well plate: 
a. Negative control sample  - 350 µL Incubator buffer 
b. Positive control   - 350 µL of the fMLP working solution  
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5. Cell culture inserts were placed into both wells of a multi-well plate.  100 µL of 
LRP were added into each cell culture insert. 
6. The multi-well plate is incubated for 30 minutes at 37 °C in a water bath. 
7. The cell culture inserts were removed from the multi-well plate.  The cell 
suspensions from both wells of the multi-well plate were added into 2 separate 5 
mL Falcon tubes (tubes 1 and 2) and placed on ice.  20 µL of the cells from the 
cell culture insert of the negative control sample were added to 350 µL of 
incubator buffer in a third Falcon tube (tube 3). 
8. 20 µL of counting reagent was added to each tube, which was vortexed and 
incubated for 10 minutes in a covered ice bath.  Samples were then ready for 
acquisition. 
 
5.9.2 Flow cytometric acquisition and analysis of neutrophil migrations: 
 
1. Data were acquired after selecting forward scatter area, side scatter area and the 
Alexafluor 488/FITC channel.   
2.  A region was set over the leukocytes and counting beads (dot plot diagram of SSC 
and APC, see Figure 5-4). 
3. After activating a gate on region 1, a second region was set around the counting beads 
(dot plot SSC/FSC, see Figure 5-4); acquisition was then started and ended once 
exactly 2000 events had been recorded in region 2.  This ensured that the amount of 
granulocytes in the control sample could be compared to the number of granulocytes 
in the positive control after stimulation with fMLP.  A third region around the 
granulocytes population was set (dot plot diagram SSC/FSC, see Figure 5-4) 
4. The following data was recorded from the population in region 3; number of cells 
(negative control and fMLP stimulated sample) and mean value of the FSC signal 
(fMLP stimulated sample only) 
5. The percentage of activated cells was calculated by the number of cell expressing 
CD62L (L-selectin).  This analysis was performed on a separate histogram (Figure 5-
4) generated from region 3 of the fMLP stimulated sample and the CD62L control 
(Tube 3).  On the CD62L control histogram a marker was set for fluorescence so that 
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less than 15% of cells were activated.  This marker was applied to the fMLP-
stimulated sample and the percentage of activated cells determined. 
6.   The inter-assay precision of the assay for 10 samples was 97.0-99.4% activated 
granulocytes with a mean coefficient of variance 0.2%.   
7. The number of activated cells and cell volume was determined by mean forward 
scatter and compared between the fMLP sample and CD62L-control sample.   The 
proportion of migrating cells was compared between the fMLP and negative control 
sample (see Table 5-7). 
 
Table 5-7 Flow cytometeric parameters recorded following analysis of the MigratestTM 
 Tube No. 1 Tube No. 2 Tube No. 3 
Parameter 1 Number of cells Number of cells - 
Parameter 2 - Mean value of FSC 
signal 
Mean value of FSC 
signal 







FIGURE 5-4 MIGRATION FLOW PLOTS AND HISTOGRAM ANALYSIS OF CD62L 





5.10 Ex-vivo studies of neutrophil function 
All ex-vivo studies were performed in pyrogen-free conditions utilising non-pyrogenic 12 
x 75 mm falcon tubes.  Neutrophil function was examined in neutrophils isolated from 
whole blood to more closely resemble physiological conditions and to prevent neutrophil 
activation during separation with all samples being performed in triplicate.   
 
1.22.1 5.10.1 Quantification of neutrophil phagocytosis by flow cytometry using 
FITC-labelled Escherichia coli 
Phagocytosis was quantified using the Phagotest (Orpegen Pharma, Heidelberg, 
Germany).  This test allows the quantitative determination of leukocyte phagocytosis in 
heparinised blood using flow cytometry.  The Phagotest uses fluorescein isothiocyanate 
(FITC)-labelled opsonised E.coli bacteria as described previously (Shawcross et al., 
2008b).  In brief, 100 µL whole blood was mixed with 20 µL of FITC-labelled E.coli 
(2x107) and incubated in a water bath at 37°C for 20 minutes.  Fluorescence of bacteria at 
the cell surface was quenched using ice-cold trypan blue solution.  Samples were washed 
twice with 3 mL of NWS and centrifuged for 5 minutes at 1500 rpm at 4 °C discarding 
the supernatant.  Red cells were lysed with the addition of 1 mL of FACS lysis solution 
(BD Biosciences, San Jose, CA) and allowed to stand for 10 minutes at room 
temperature.  Cells were then washed with a further 3 ml of NWS and centrifuged (5 
minutes, 1600 rpm, 4°C) discarding the supernatant.  To identify neutrophils, cells were 
stained with anti-CD16-PE IgG1 κ or anti-CD11b-APC-Cy7 IgG1 κ and allowed to 
conjugate for 1 h in the dark at room temperature.  Analysis of the samples was 
performed on a FACSCantoII flow-cytometer (Becton Dickinson, San Jose, CA).  
Neutrophils were gated on forward and side scatter characteristics and cells staining 
positive for CD16-PE.  Phagocytosis was expressed as the percentage of neutrophils 
undergoing phagocytosis and the mean of fluorescence intensity (MFI).  The inter-assay 
and intra-assay coefficient of variance for triplicate samples were 1.6% and 10.1%, 
respectively.   
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5.10.2 Quantification of neutrophil oxidative burst by flow cytometry using 
dihydrorhodamine 123 
Neutrophil OB was quantified using the PhagoBurstTM test (Orpegen Pharma, Heidelberg, 
Germany).  This test measures the percentage of phagocytic cells that produce ROS with 
or without E.coli as described previously (Shawcross et al., 2008a).  In brief, 100 µL of 
heparinised whole blood was incubated for 20 min with 20 µL of opsonised E.coli 
(2x107) and either 20 µL of 0.81 µM PMA or 20 µL of 0.5 µM fMLP or 20 µL of NWS, 
at 37 °C.  PMA and fMLP are stimulators of oxidative burst; fMLP through its action on 
G-protein coupled chemokine receptors and PMA through a direct intracellular effect on 
Protein kinase C. (Figure 3) PMA is a potent inducer of OB whereas fMLP is a weak 
stimulator in the absence of prior neutrophil activation. 20 µL of dihydrorhodamine-123 
solution was added with a further 20 min incubation at 37 °C.  Dihydrorhodamine-123 is 
oxidised to rhodamine-123 in the presence of reactive oxidant species and gives green 
fluorescence.  Red cells were lysed and neutrophils were washed with NWS prior to 
analysis.  To identify neutrophils, cells were stained with anti-CD16-PE IgG1 and 
analysed by FACS.  Neutrophils were gated on forward and side-scatter characteristics 
and, subsequently, the percentage of CD16-positive cells producing ROS was calculated 
along with the geometric mean fluorescence intensity (GMFI).  Samples were analysed in 
triplicate.  The inter-assay coefficient of variance was 4.7 and 2.4 for SOB and ESOB, 
respectively.  The inter-assay coefficient of variance was 5.4% and 4.2% for spontaneous 
and stimulated OB, respectively.   
 
5.10.3  Method for the preparation of blood samples for the Phagotest/PhagoBurst 
test 
1. The water bath was turned on to 37 °C 
2. Blood samples were obtained from the patient – 3 x heparinised samples (9 
mL) and 1 x Ethylenediaminetetraacetic acid [EDTA] (24 mL) and placed 
immediately on ice (approximately 20 mL of either venous or arterial blood). 
One for phagocytosis and burst tests, one for chemotaxis and one heparinised 
and EDTA sample for plasma (cytokine analysis by enzyme linked 
immunosorbent assay [ELISA]). 
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3. The plasma ammonia was immediately checked using the Ammonia test Kit II 
for the PocketChem BA device located in liver intensive care unit (see above). 
4. Falcon tubes (Becton Dickinson, San Jose, CA) were labelled as per tables 5-8 
and 5-9 below:  
i. PhagotestTM - 3 x A per patient and one set of controls tubes per 
experiment: B, C, D and E (healthy control). 
ii. PhagoBurstTM test -3 x 1 and 3 x 2 per patient and one set of 
control tubes per experiment B: 5-8 (healthy control). 
5. One litre of NWS was prepared in an autoclaved bottle.  One vial of supplied 
powder (PhagotestTM and PhagoBurstTM kits) was dissolved in 1000 mL of 
double distilled water and refrigerated at 4 °C [NWS is a buffered isotonic salt 
solution provided with the PhagobustTM and PhagotestTM kits which contains 
chloracetamide and ethylendiaminetrtraacetic acid sodium salt]. 
6. One mL of NWS was added to the substrate bottle (PhagoBurstTM test).   
7. The opsonised E.coli vials (one unlabelled [PhagoBurst] and one FITC 
labelled [Phagotest]) were removed from the fridge and allowed to equilibrate 
to room temperature. 
8. The fMLP and PMA were diluted to a working concentration by adding 5 µL 
of the stock solution into an appropriately labelled 1.5 mL eppendorf tube and 
diluted with 1 mL of NWS, vortexed and kept on ice (made fresh daily). 
9. The lysing solution, containing diethylene glycol and formaldehyde, was 
diluted to a working concentration by adding 5 mL of lysing solution to 45 mL 
of double distilled water in a 50 mL Falcon tube (BD), and kept at room 
temperature (can be stored at 4 °C). 
10. 100 µL of blood was added to pre-labelled Falcon tubes from step 4. 
11. 20 µL of NWS / E.coli / PMA / fMLP were added to the relevant tubes see 
Table 5-7 (Phagotest) and Table 5-8 (PhagoBurst test) and left in the water 
bath for 20 min. 
12. The quenching solution (tryptan blue) was placed on ice (already constituted 
within PhagotestTM box). 
13. 20 µL of substrate were added to the PhagoBurstTM test tubes 1,2,3,4 and 6 
(NOT 5 and 7) and placed back in the waterbath for a further 20 min. 
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14. Meanwhile 100 µL of chilled quenching solution were added to the 
PhagotestTM tubes A-D (The quenching solution fixes the cells preventing any 
further uptake of bacteria). 
15. The PhagotestTM tubes A-D were washed by adding 2-3 mL of chilled NWS 
and centrifuged at 1600 rpm for 5 min at 4 °C.  
16. The supernatant was aspirated off and step 15 repeated. 
17. Tubes 1-7 were then removed from the water bath.  
18. For red cell lysis 1 mL of lysing solution was added to all tubes and left for 10 
min at room temperature, They were gently mixed by aspirate up and down 
gently using the pipette. 
19. If the samples were incompletely lysed, step 18 was repeated.   
20. Two mL of NWS was added to all tubes and centrifuged at 1600 rpm for 5 
min at 4 °C before the supernatant was removed. 
21. 20 µL of anti-CD16-PE and 5 µL CD11b-APC–Cy7 were added to the 
appropriate tubes, and left in a darkened cupboard for 20 minutes at room 
temperature (See Table 5-7 and 5-8). 
22. The tubes were then re-washed with NWS and centrifuged at 1600 rpm for 5 
min at 4°C. 
23. The supernatant was then removed and re-suspend in 500 µL of NWS ready 
for FACS analysis. 
24. Trypan Blue Exclusion:  
400 µL of whole blood underwent 2 lysis steps with 1 mL lysing solution as 
per step 18 above.  It was then reconstituted to 400 µL and add 100 µL of 
trypan blue was added.  10 µL was then placed onto a haemocytometer slide 





























3 x A (patient 
sample) 
100 µL 20 µL 20 µL 5 µL 
B (Anti-CD-16 
control) 
100 µL NWS 20µL 20 µL NWS 5µL 
C (Anti-CD11b 
control) 
100 µL NWS 20µL NWS 20µL 5µL 
D (Double 
negative) 
100 µL NWS 20µL NWS 20µL NWS 5µL 
E (E.coli-FITC 
control) 
100 µL 20 µL NWS 20µL NWS 5µL 
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Table 5-9 Falcon tube contents for each patient sample in the PhagoBurstTM test	
Tube 
Number 










100 µL Opsonised 
e.coli 20 µL 
20 µL 20 µL 5 µL 
2-Resting 
burst 
100 µL NWS 20 µL 20 µL 20 µL 5 µL 
3-PMA 100 µL PMA 20 µL 20 µL 20 µL 5 µL 














100 µL NWS 20 µL 20 µL NWS 20 
µL 
NWS 5 µL 
8-Double 
negative 
100 µL NWS 20 µL NWS 20 µL NWS 20 
µL 













5.10.4 Method for flow-cytometer set-up on the FacsCanto II (BD, San Jose, CA): 
1. The cytometer was turned on and the doors opened. 
2. The fluidics cart was checked  
a. Waste (empty) 
b. Shutdown fluid (adequate) 
c. Cleaning fluid 
d. Sheath fluid  
e. Bubble catcher was checked and bled especially if a component on the cart 
had been changed. 
3. The computer was turned on and logged on to FACS DIVA software.  Under the 
cytometer menu the “fluidics start-up’ was selected and the doors closed. 
4. Under the cytometer menu select “cleaning modes” and “de-gas flow-cell” were 
selected (the flow-cell was checked visually for the presence of bubbles). 
5. The cytometer set-up and tracking (CST) performance check was ran: 
a. If running the instrument for the first time a CST baseline check was 
performed – Three drops of CST beads were placed in 500 µL FACS flow. 
b. Otherwise a daily performance check was run with one drop of CST beads 
in 350 µL FACS flow (ensuring the CST beads had been vortexed for 5 
seconds). 
6. The CST outputs were checked.  The PE channel Coefficient of variance (CV) 
gives a good idea of optical performance with a good and robust percentage CV 
being between 0.1-0.2 with an excellent machine reaching 0.3.  However the exact 
value is not so important but rather the change over time.  The optical background 
(scattered laser light by the sheath fluid) was checked and if significantly 
increased from the previous reading this suggested that the flow cell was dirty 
which was managed by a long clean.  See Table 5-10 for examples of typical 
photomultiplier tubes (PMT) voltages on an optimised machine. 
7. The CST programmed was exited and DIVA software re-entered.  
8. Use CST settings was selected. 
9. “New experiment” was then selected from browser.  
10. “Tube 1” was then highlighted. 
11. The cytometer window gate extension under “Parameters” was then checked 
[ideally 7 µs]. 
 143 
12. The fluorochromes involved in the experiment were then selected. 
13. The fully stained sample (not beads) was then checked and voltage adjustments 
for FSC and SSC were made by creating a plot of FSC versus SSC.  The FSC was 
usually likely to need to be adjusted as CST was based upon 2 µM and 3 µM 
beads.  Most cell are bigger therefore the FSC was decreased (ballpark average 
300 V for cells which are 10-15 µM).  
14. The acquisition dashboard was then entered and “Acquire data” (not save data) 
selected.  
15. Thresholds were adjusted to exclude sub-cellular debris (approximately > 20,000, 
can be done by eye) and following adjustment “acquire” was clicked again to 
check the plot was not cutting into the sample.   
16. Once adjustments to FSC and thresholds had been made they were saved as 
“application settings” which were automatically updated by CST.   
17. The threshold changes were then accepted. 
18. For a repeat experiment following a new start-up the relevant application settings 
were selected to apply. 
Table 5-10 Example PMT voltages showing typical values on an optimised FacsCanto II 
flow-cytometer 
Laser  PMT voltage Bright Bead % 
Robust CV 
Blue FSC 542 1.32 
Blue SSC 368 2.84 
Blue E 432 1.75 
Blue D 477 1.41 
Blue B 513 3.08 
Blue A 691 6.15 
Red C 498 2.55 
Red A 584 3.51 





5.10.5 Compensation on a FacsCanto II (BD, San Jose, CA) flow-cytometer: 
1. Compensation controls were prepared as either cells or capture beads singly 
labelled with each detection antibody (i.e. PE, FITC and APC-Cy7) [Note separate 
compensation was performed for PhagotestTM and PhagoBurstTM as rhodamine is 
not antibody conjugated and so will need to compensate with cells].  
2. For compensation with cells label the following 5 Falcon tubes were labelled:  
I. Unlabelled lysed blood. 
II. PE labelled lysed blood. 
III. FITC labelled lysed blood or unlabelled E.coli incubated stimulated burst 
sample for rhodamine [tube 7] (emission spectra for FITC and rhodamine 
overlap and are detected on the same PMT). 
IV. APC-Cy7 labelled lysed blood. 
V. Lysed whole blood labelled with all 3 fluorochromes.  
3. 100 µL of control sample blood was added into each tube and 1 mL FACS lysis 
solution was added and aspirated up and down gently using a pipette. This was left 
for 10 min.   It was then washed twice with NWS and centrifuged at 1600 rpm for 
5 min at 4 °C.  After each cycle the supernatant was aspirated off and the cells re-
suspended in 500 µL NWS.    
4. For Compensation with beads. The beads were vortexed for 5 s and one drop of 
beads dispensed with a working concentration of antibody:  
I. 1 x Falcon tube containing blank BD compensation beads. 
II. 1 x Falcon tube containing BD compensation beads and capture beads labelled 
with antibody (incubated for 20 min at room temp in the dark to fix).  Separate 
samples were needed for each antibody. 
III. Falcon tube containing lysed whole blood labelled with all 3 fluorochromes, 
were prepared as above in step 3. 
5. Under the “experiment” menu “create compensation controls” was selected – a 
tube list and worksheet was then generated – If using beads for negative 
(unstained controls) the FSC was changed. The unstained control sample was then 
selected and acquired. 
6. A region was then moved over the bead population and “apply to all” was selected 
adjusting for cells as required. 
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7. Once adjustments had been made the data was recorded (default acquisition set-
up). 
8. The tubes are then acquired sequentially as requested (note include unlabelled 
compensation beads were included in all samples, for the burst experiments and 
compensation was set up with cells for PE/rhodamine.    
9. Manual adjustments to compensation when using beads was avoided. 
10. Once compensation/controls had been acquired the compensation matrix was 
generated by selecting “calculate compensation controls”. 
11. The “apply only” option was then selected and a fully stained sample was 
rechecked (adjusted for FSC if compensation was performed with beads). 
12. A return to the global worksheet was then performed and the first tube selected 
keeping compensation values.  The samples were then acquired and the 
experiment template exported.  
 
5.10.6 Sample gating, acquisition and analysis on the FacsCanto II (BD, San Jose, 
CA) flow cytometer. 
1. Once the FacsCanto II flow cytometer is set-up, CST and compensation was 
complete a “new experiment” was selected.  The previously saved experiment 
template should be selected and “Create experiment” was chosen. 
2. The number of tubes and the fluorochrome present in each tube were then 
selected. 
3. Any fluorochromes not used were deleted from the list and each fluorochrome 
was labelled with the appropriate antibody.   
4. On a global worksheet, a plot: FSC-H/SSC-H dot plot with a linear scale was 
created and a sample labelled with PE and FITC, such as sample A, was acquired.  
The threshold was usually set to 20,000 to exclude subcellular debris and the 
granulocyte population was gated as shown in Figure 5.4 below. 
5. 10000 total events were recorded. 
6. A population hierarchy was produce by selecting G1 to create a second dot-plot 
CD16PE/FITC with a logarithmic scale. Using the unstained cells, single labelled 
CD16-PE and single labelled FITC (beads)/Rhodamine (cells) and control 
samples second dot plot was gated into quadrants as shown in Figure 5-5 below.  
Gating for PhagoburstTM and PhagotestTM experiments was performed separately. 
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Once the gates were set the stats view was edited to display results for each 
quadrant. 
7. Once all the samples had been recorded for both the PhagotestTM and 
PhagoBurstTM experiments, the same gates were applied across each experiment 
for consistency.   
8. The upper right quadrant shows neutrophils that have not undergone phagocytosis 
and the upper left shows neutrophils that have undergone phagocytosis of the 
opsonised E.coli.  If there are a large proportion of cells in the left and right lower 
(LL and RL quadrant) this may be due to poor lysis of the sample, incorrect gating 
or neutrophil apoptosis.  Samples with a large numbers in LL and LR quadrants 
should be examined carefully for quality and results compared to the other 
triplicate samples and other samples acquired at the same time. Gating may need 
adjustments, but if significantly different then the sample should be discarded and 
results not used for further analysis.    
9. The average of the triplicate samples should be used for the final analysis 
(example flow plots of phagocytosis, SOB and ESOB obtained from a healthy 
control are shown in Figures 5-6, 5-7 and 5-8 respectively whilst corresponding 
flow plots obtained from a patient with alcohol-related cirrhosis and superimposed 





FIGURE 5-5 GATED GRANULOCYTE AND LYMPHOCYTE POPULATION ON A FLOW 
PLOT OF FORWARD- AND SIDE-SCATTER CHARACTERISTING.  PLOTS OF CD-
16-PHYCOERYTHERIN AND E.COLI-FITC SHOWING WITHOUT PRE-
INCUBATION WITH OPSONISED E.COLI FITC SHOWING GRANULOCYTE AND 
LYMPHOCYTE POPULATIONS AND GATING STRATEGY SHOWING HIGHER 




FIGURE 5-6 GATING STRATEGY FOR PHAGOBURST EXPERIMENT USING UNSTAINED AND SINGLE-LABELLED SAMPLES OF CD16-




FIGURE 5-7 FLOW CYTOMETRY PLOTS OF A GATED GRANULOCYTE POPULATION 
WITH ANCESTRY, SHOWING NEUTROPHIL PHAGOCYTOSIS AS DETERMINED 
BY UPTAKE OF OPSONISED FITC-LABELLED E.COLI SHOWING IN A HEALTHY 
CONTROL AND A PATIENT WITH ALCOHOLIC HEPATITIS (AH) SHOWING. 














FIGURE 5-8 NEUTROPHIL BURST IN NON-E.COLI EXPOSED CELLS WITH 
OXIDATION DETECTED BY THE INTENSITY OF RHODAMINE-123 
FLUORESCENCE DETECTED ON THE FITC CHANNEL IN A HEALTHY CONTROL 
AND PATIENT WITH ACUTE ALCOHOLIC HEPATITIS AND CIRRHOSIS. 
 
 
FIGURE 5-9 BURST IN NEUTROPHILS EXPOSED TO OPSONISED E.COLI WITH 
OXIDATION DETECTED BY THE INTENSITY OF RHODAMINE-123 
FLUORESCENCE IN A HEALTHY CONTROL AND A PATIENT WITH ACUTE 







5.11 Cytokine estimation using enzyme-.linked immunosorbance assay 
(ELISA) 
Plasma levels of the pro- and anti-inflammatory cytokines (TNFα, IL-1ß, IL-6, CXC8/IL-
8, IL-10 and IL-17) were determined from samples previously stored at -80 ºC using 
sandwich enzyme-linked immunosorbent assay (R&D Systems DuoSets®, UK) and 
results correlated with neutrophil function and cell volume.   
 
5.11.1  Solutions 
A. Capture antibody 
• Human TNFα capture antibody - 720 µg/mL of mouse antihuman TNFα when 
reconstituted with 0.5 mL of phosphate buffered saline (PBS).  Diluted to a 
working concentration of 4.0 µg/mL in PBS, without carrier protein (i.e. 55.6 µL 
of reconstituted solution added to 9944.4 µL of PBS).     
• Human IL-1β capture antibody – 720 µg/mL of mouse antihuman IL-1β when 
reconstituted with 1.0 mL of PBS.  Diluted to a working concentration of 4.0 
µg/mL in PBS, without carrier protein (i.e. 55.6 µL of reconstituted solution 
added to 9944.4 µL of PBS).     
• Human IL-6 capture antibody – 240 µg/mL of mouse antihuman IL-1β when 
reconstituted with 0.5 mL of PBS.  Diluted to a working concentration of 2.0 
µg/mL in PBS, without carrier protein (i.e. 41.7 µL of reconstituted solution 
added to 9958.3 µL of PBS).     
• Human CXCL8/IL-8 capture antibody - 720 µg/mL of mouse antihuman IL-8 
when reconstituted with 1.0 mL of PBS.  Diluted to a working concentration of 
4.0 µg/mL in PBS, without carrier protein (i.e. 55.6 µL of reconstituted solution 
added to 9944.4 µL of PBS).     
• Human IL-10 capture antibody –360 µg/mL of mouse antihuman IL-10 when 
reconstituted with 0.5 mL of PBS.  Diluted to a working concentration of 2.0 
µg/mL in PBS, without carrier protein (i.e. 55.6 µL of reconstituted solution 
added to 9944.4 µL of PBS).     
• Human IL-17 capture antibody - 720 µg/mL of mouse antihuman IL-17 when 
reconstituted with 1.0 mL of PBS.  Diluted to a working concentration of 4.0 
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µg/mL in PBS, without carrier protein (i.e. 55.6 µL of reconstituted solution 
added to 9944.4 µL of PBS).     
 
B. Detection antibody 
• Human TNFα detection antibody - 45 µg/mL of biotinylated goat antihuman 
TNFα when reconstituted with 1.0 mL of reagent diluent (see below).    Diluted to 
a working concentration of 250 ng/mL in reagent diluent (i.e. 55.6 mL of 
reconstituted solution added to 9944.4 mL). 
• Human IL-1β detection antibody – 54 µg/mL of biotinylated goat antihuman IL-
1β when reconstituted with 1.0 mL of reagent diluent (see below).   Diluted to a 
working concentration of 300 ng/mL in reagent diluent (i.e. 55.6 mL of 
reconstituted solution added to 9944.4 mL). 
• Human IL-6 detection antibody – 3.0 µg/mL of biotinylated goat antihuman IL-6 
when reconstituted with 1.0 mL of reagent diluent (see below).  Diluted to a 
working concentration of 50 ng/mL in reagent diluent (i.e. 50 mL of reconstituted 
solution added to 9950 mL). 
• Human CXCL8/IL-8 detection antibody – 3.6 µg/mL of biotinylated goat 
antihuman IL-8 when reconstituted with 1.0 mL of reagent diluent (see below).  
Diluted to a working concentration of 300 ng/mL in reagent diluent (i.e. 55.6 mL 
of reconstituted solution added to 9944.4 mL). 
• Human IL-10 detection antibody - 54 µg/mL of biotinylated goat antihuman IL-10 
when reconstituted with 1.0 mL of reagent diluent (see below).  Diluted to a 
working concentration of 300 ng/mL in reagent diluent (i.e. 55.6 mL of 
reconstituted solution added to 9944.4 mL). 
• Human IL-17 detection antibody – 27 µg/mL of biotinylated goat antihuman IL-
17 when reconstituted with 1.0 mL of reagent diluent (see below).  Diluted to a 
working concentration of 150 ng/mL in reagent diluent (i.e. 55.6 mL of 
reconstituted solution added to 9944.4 mL). 
 
C. Standards 
• Human TNFα standard – 290 ng/mL of recombinant human TNFα when 
reconstituted with 0.5 mL of reagent diluent.  Diluted to a high standard of 1000 
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pg/mL (i.e. dilute 3.4 mL of reconstituted solution with 996.6 mL reagent diluent) 
An eight-point serial dilution was then performed (Figure 5-10). 
• Human IL-1β standard – 100 ng/mL of recombinant human IL-1β when 
reconstituted with 0.5 mL of deionised water.  Diluted to a high standard of 500 
pg/mL (i.e. 5 mL of the reconstituted solution added to 995 mL reagent diluent).  
An eight-point serial dilution was then performed.   
• Human IL-6 standard - 120 ng/mL of IL-6 when reconstituted with 0.5 mL of 
reagent diluent.  Diluted to a high standard of 1400 pg/mL (i.e. dilute 11.7 mL of 
reconstituted solution with 988.3 mL reagent diluent).  An eight-point serial 
dilution was then performed. 
• Human CXCL8/IL-8 standard – 140 ng/mL of IL-8 when reconstituted with 0.5 
mL of reagent diluent.  Diluted to a high standard of 750 pg/mL (i.e. dilute 21.4 
mL of reconstituted solution with 978.6 mL reagent diluent).  An eight-point 
serial dilution was then performed. 
• Human IL-10 standard - 210 ng/mL of IL-10 when reconstituted with 0.5 mL of 
reagent diluent.  Diluted to a high standard of 4200 pg/mL (i.e. dilute 20 mL of 
reconstituted solution with 980 mL reagent diluent).  An eight-point serial dilution 
was then performed.   
• Human IL-17 standard – 220 ng/mL of recombinant human IL-17 when 
reconstituted with 0.5 mL of reagent diluent.  Diluted to a high standard of 2200 
pg/mL (i.e. dilute 10mL of reconstituted solution with 990 mL reagent diluent).  
An eight-point serial dilution was then performed. 
 
 




D. Streptavidin-Horseradish peroxidase (HRP) – 1.0mL of streptavidin conjugated to 
horseradish peroxidase.  Dilute to the working concentration specified.   
 
E. Phosphate Buffered saline – 137mM NaCl, 2.7 mM KCl, 8.1 mM NaHPO4, 1.5 mM 
KH2PO4, PH 7.2-7.4, 0.2 µM filtered.  5 x PBS tablets were added to 1000 mLs denatured 
water.   
 
F. Wash buffer – 0.05% Tween® 20 in PBS, pH 7.2-7.4.  5 x PBS tablets were added to 
9950 mL of denatured water and 50 µL of Tween® 20 
 
G. Block buffer (IL-8 ELISA only) – 1% BSA, in PBS with 0.05% NaN3. 
 
H. Reagent Diluent* (100 mLs) – 1% bovine serum albumin (BSA), pH 7.2-7.4, 0.2µM 
filtered. One gram bovine serum albumin was added to 100 mL PBS from stock.  
*The IL-8 ELISA required a different reagent diluent of 0.1% BSA, 0.05% Tween 20 in 
Tris-buffered Saline (20 mM Trizam base, 150mM NaCl), pH 7.2-7.4, 0.2 µM filtered. 
 
I. Substrate solution – 25 mLs citrate phosphate buffer and 1 x 0-Phenylenediamine 
dihydrochloride (SIGMAFASTTM OPD) tablet (Sigma-Aldrich) 
 
J. Stop solution - 2 N sulphuric acid (H2SO4) 
 
5.11.2 ELISA Plate preparation 
1. The capture antibody was diluted to the working concentration in PBS without 
carrier protein.  A 96-well flat-bottomed microplate (R&D systems) was then 
immediately coated with 100 µL per well of the diluted capture antibody.  The 
plate was sealed and incubated overnight at room temperature. 
2. Each well was then aspirated and washed with Wash buffer, repeating the process 
two times for a total of 3 washes.  The wash was performed by filling each well 
with Wash buffer (440 µL) using a multi-tipped pipette or autowasher.  Complete 
removal of liquid was ensured at each step.  After the final wash, remove any 
 155 
remaining water was removed by inverting the plate and blotting against clean 
paper towels.  
3. The plates were blocked by adding 300 mL of reagent diluent to each well. * Note 
the IL-8 assay uses a specific block buffer.  The plates were then incubated at 
room temperature for 1 hour. 
 
5.11.3 ELISA assay procedure 
1. Add 100 µL of sample or standards were added to reagent diluent or an 
appropriate diluent (*see IL-8 reagent diluent), per well.  Note all samples were 
performed in duplicate.  Samples were covered with an adhesive strip and 
incubated for 2 hours at room temperature on a rotating microplate mixer 
2. The Aspiration/wash steps were repeated as in step 2 of plate preparation. 
3. 100 µL of the working concentration of the detection antibody were added to each 
well.  A new adhesive strip was placed to cover and the plate was again incubated 
for 2 hours at room temperature on a rotating microplate mixer. 
4. The Aspiration/wash steps were repeated as in step 2 of plate preparation. 
5. 100 µL of the working dilution of Streptavidin-HRP was added to each well.  The 
plate was covered and incubated for 20 min at room temperature. Care was taken 
to avoid placing the plate in direct light. 
6. The Aspiration/wash steps were repeated as in step 2 of plate preparation. 
7. 100 µL of substrate solution was added to each well and the plate was incubated 
for 20 min at room temperature.  Care was taken to avoid placing the plate in 
direct light. 
8. 50 µL of Stop solution was added to each well and the plate gently tapped to 
ensure thorough mixing [Figure 5-11 shows the typical appearance of plates after 
the addition of stop solution prior to determination of optical density]. 
9. The Optical density of each well was determined immediately, using a microplate 










FIGURE 5-11 ELISA ANALYSIS OF A - INTERLEUKIN-6 AND B - TNFα WITH 
DUPLICATE STANDARDS IN LANES 1 AND 2 FOLLOWED BY 40 DUPLICATE 
SAMPLES RUNNING IN ADJACENT WELLS.   
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5.12 Experiment to determine the effects of ammonia, and the p38 agonist 
Isoproterenol and antagonist SB203580 on neutrophil function and 
levels of phosphorylated p38-MAPK.  
5.12.1 Solutions: 
A - Phosphate buffered saline 
B – 1M NH4Cl (MW 54.4).  1M solution = 2.67g NH4Cl in 50mL double distilled water. 
C – 1mM Isoproterenol (MW=247.7).  1mM solution = 0.0124 g isoproterenol in 50mL 
double distilled water. 
D- SB203580 (MW = 377.4).  Diluted as per manufacturers instruction in dimethyl-
sulphoxide (DMSO) 10 µM = 2 µL of 1 mg vial in 2 mL blood. 
 
5.12.2  Method:  
• Two mL of whole blood from control/patient were incubated and mixed with the 
appropriate solutions according to the schedule in table 5-11 for 90 minutes 
(mixing every 30 minutes) in a water bath at 37°C as per the above schedule 
[Table 5-11]. 
• The PhagotestTM and PhagoBurstTM test were performed as per the above method 
for the preparation of blood samples for the PhagotestTM/PhagoBurstTM test except 
that 100 µL of the above prepared blood was used instead of the heparinised 
blood.  
• Concentration curves were initially constructed for ammonia, isoproterenol and 
SB203580 using the following concentrations: 
§ Ammonia 100 µM, 200 µM, 400 µM, 800 µM and 1600 µM 
§ Isoproterenol 1 nM, 2 nM, 4 nM, 8 nM and 16 nM 
§ SB203580 10 µM, 20 µM, 40 µM, 80 µM and 160 µM. 
After the construction of concentration curves the following concentrations were selected; 
ammonia 200 µM, isoproterenol 1 nM and SB203580 10 µM.  The effects of changes in 
extracellular pH and partial pressure of CO2 were assessed along with neutrophil viability 
using the following methods.    
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5.12.3 The effect of ammonia on extracellular pH 
 The pH and partial pressure of carbon dioxide (pCO2) were measured using a 
Radiometer ABL 700 Series blood gas analyzer on whole blood samples with 0 - 400 µM 
NH4Cl, to assess for changes in extracellular pH resulting from incubating whole blood, 
and thus the neutrophils, with ammonia. There were no detectable differences in either 
extracellular pH or pCO2 between controls and whole blood incubated with up to 400 µM 
NH4Cl from which the neutrophils were isolated 90 minutes later. 
 
5.12.4 Assessment of neutrophil viability was performed using the following 2 
methods: 
-Trypan Blue Exclusion Test 
There was no difference in the number of non-viable cells between neutrophils isolated 
from control whole blood and neutrophils isolated from whole blood incubated for 90 
minutes with 100 or 400 µM NH4Cl [1.57, 1.78 and 1.77% non-viable for 0, 100 and 400 
µM NH4Cl, respectively]. 
-Annexin V-FITC and Propidium Iodide 
 Two experiments were performed. The first assessed apoptosis/cell death and the 
duration of incubation with ammonia, and the second assessed the relationship between 
concentration of ammonia and apoptosis/cell death.  
Ammonia-induced apoptosis or necrosis was excluded by staining with propidium 
iodide and annexin V-FITC. Up to 5 hours of incubation in a waterbath at 37 ºC with 100 
µM NH4Cl resulted in only 1-2% of neutrophils showing evidence of early apoptosis 
(annexin V-FITC positive, propidium iodide negative) and necrosis/cell death (annexin 
V-FITC positive and propidium iodide positive) as measured with flow cytometry. After 
5 hours, the neutrophils began to die with >20% of them staining positive with both 
annexin V-FITC and propidium iodide as measured with flow cytometry. Furthermore, 
incubation with ammonia for up to 120 minutes at concentrations of NH4Cl up to 400 µM 
did not induce apoptosis or cell death and this cannot therefore account for the 





Table 5-11 Schedule for treating control and patient blood samples in order to determine 
the effects of ammonia and p38 modulators on neutrophil function and levels of total and 
phosphorylated p38-MAPK	
Sample Whole blood PBS 1M NH4Cl 1mM 
Isoprotorenol 
SB203580 
Control 0 2 mL 0 0 0 
Ammonia  200µM 1096 µL 0 
 
4 µL 0 0 
Isoproterenol 1nM 1098 µL 0 0 2 µL 0 
SB203580 10µM 1098 µL 0 0 0 2 µL 
Ammonia      200 
µM &  Isoproterenol     
1 nM 
1096 µL 0 2 µL 2 µL 0 
Ammonia 200µM & 
SB203580 
10µM 
1096 µL 0 2 µL 0 2 µL 
*Patients studied had an arterial ammonia concentration of  >100µM/L to ensure that they 
have been exposed to a supra-physiological concentration in vivo so that ammonia-






5.13 Experiment to determine total and phosphorylated p38-MAPK using 
cytometric bead array 
5.13.1  Preparation of Cells in Suspension: 
1. Cells were treated as per the schedule in Table 5-11 to induce or inhibit p38-
MAPK phosphorylation.   
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2. Cells were counted in the sample (trypan blue exclusion test) and an 
approximation of the protein concentration (should be >1 mg/ml see protein 
estimation later on) was calculated. 
3. The sample was denature the sample by adding 1 mL ice-cold FACS lysis buffer 
containing 0.1% Triton ® X-100 (detergent) to the cells.  The sample was 
incubated for 15 minutes at 4°C and pelleted insoluble material was obtained by 
centrifugation (14,000 rpm for 3 minutes).   
4. The supernatant was transferred to a clean tube and add the appropriate amount of 
5x denaturation buffer added so that the final concentration of denaturation buffer 
was 1x. 
5. The sample was denatured by immediately placing it in a boiling water bath (or 
heating block at 100°C) for 5 minutes.  The sample may very viscous and difficult 
to pipette due to the presence of deoxyribonucleic acid [DNA] in which case 40µL 
of DNase I was added or the sample passed through a 26 gauge needle several 
times, or both). 
6. The protein concentration was determined using the Bradford Reagent* 
7. At this point the sample could be stored at -70 °C for up to 6 months, then thawed 
and centrifuged at 14,000 rpm for 3 min before the sample could be used to pellet 
debris. 
8. The cell lysate sample was diluted to the desired dilutional factor (i.e. 1:2, 1:10 or 
1:20) using the appropriate volume of assay diluent.  It was vital that the sample 
must be diluted at least 1:4 to reduce percentage of sodium dodecyl sulphate 
(SDS) and the lysate should not contain more than 20µg total protein. 
9. Sample dilutions were mixed thoroughly before transferring to the appropriate 
assay tubes containing capture beads. 
 
5.13.2  Preparation of cytokine bead array cell signalling flex set standards 
1. The lyophilised sphere was transferred to a 1.5 mL microfuge tube.  
2. The standard was reconstituted adding 100 µL of assay diluent, warming the 
tube to 37°C and vortexing.   
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3. Once reconstituted, the standard was stored at 4°C and was stable for 3 
months.  If using a frozen reconstitute standard, it was re-warmed and 
vortexed thoroughly. 
4. Falcon tubes were labelled and arranged in the following order: 
a. Top standard: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 and 1:256 (2 further 
dilutions could be performed if low levels expected). 
5. 20 µL of each Cell Signalling BD CBA Flex Set Standard to be run in the 
experiment were added to the Top Standard tube.  
6. Assay Diluent (yellow buffer) was added to the Top Standard Tube to bring 
the volume up to 1mL. 
7. 500 µL of Assay Diluent were added to each of the remaining tubes. 
8. A serial dilution was performed [Figure 5-12]. 
9. Assay diluent alone served as a negative control. 
10. Standards were run in the order of the least concentrated (assay diluent) to the 
most concentrated (Top standard). 
 
5.13.3  Preparation of cytokine bead array cell signalling flex set capture beads 
The Capture beads are at a 50x concentration and must be diluted to their optimal 
concentration before adding to a given assay tube or well. 
 
• The number of flex sets to be used was determined (size of multiplex, in our case 
two). 
• The number of tests per experiment was determined.  (A few additional tests were 
prepared so as not to run out). 
• Each capture bead was vortexed thoroughly for 15 seconds. 
• The total volume to be used was determined by multiplying the number of tests by 
50 µL. 
• The volume of each capture bead (1 µL = 1 test) was determined so the required 
volume in µL was equal to the number of tests. 
• The volume of Capture Bead Diluent needed to dilute the beads was determined 
by subtracting the volume of capture bead from the total volume required. 
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• The Capture Beads and Capture Bead Diluent were pipetted into a tube labelled 
Mixed Capture Beads. 
 
5.13.4  Preparation of cytokine bead array cell signalling flex set PE Detection 
Reagents 
The PE detection reagent is at a 50x concentration and was diluted to the optimal 
concentration before adding to a given assay tube or well.  This section could be 
performed during the initial 3-hour incubation of capture beads with samples/standards. 
• Determination of the number of flex sets to be used (size of multiplex).  The 
number of tests per experiment was determined.  It was recommended that the 
user prepare a few additional tests than they anticipate using to ensure that there 
was enough material prepared for the experiment. 
• The total volume to be used was determined by multiplying the number of tests by 
50 µL.  The PE detection reagent was brought to room temperature and mixed 
well before use.  The solution was somewhat viscous so care was taken in making 
sure that the exact volume was pipetted. 
• The volume of each PE Detection Reagent (1 µL = 1 test) was determined so the 
required volume in µL was equal to the number of tests. 
• The volume of Detection Reagent Diluent needed to dilute the PE detection 
reagent was determined by subtracting the volume of PE detection reagent from 
the total volume required. 
• The detection reagents and Detection reagent diluent were pipetted into a tube 
labelled Mixed PE Detection Reagents and stored at 4 °C, protected from light 
until ready to use. 
 
5.13.5  Cytokine bead array cell signalling flex set assay procedure 
• All reagents were prepared as described in previous sections before starting the 
experiment. 
• The mixed Capture Beads were vortexed for at least 5 seconds and 50 µL of the 
mixed capture beads were added to each assay tube. 
• 50 µL of Standard or sample were added to the assay tubes. 
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• The assay tubes were gently mixed and incubated for 3 hours at room temperature 
whilst being protected from direct exposure to light. 
• 50 µL of the Mixed PE Detection Reagent was added to each assay tube.  The 
tubes were gently mixed and incubated for 1 hour at room temperature and 
protected from direct sunlight (note once Mixed PE Detection Reagent is added, 
the liquid in each well should appear green in colour). 
• One µL of Wash Buffer was added to each assay tube and centrifuged at 1600 rpm 
for 5 minutes. 
• The supernatant was carefully aspirated and discarded from each assay tube. 
• 300 µL of Wash Buffer was added to each assay tube which were briefly vortexed 
to re-suspend beads. 
• The samples were then analysed on a flow cytometer.  It was recommended that 
each tube be mixed gently before analysing on the FACS.  The appropriate FACS 
instrument instruction manual was referred to for acquiring the BD CBA Flex 
Sets.    
 
5.13.6  Bradford assay 
This method involves the binding of the Coomassie Brilliant Blue to the proteins in acidic 
medium. The binding of the dye to protein causes a shift in the absorption maxima from 
465nm to 595nm. This shift is observed and measured at 595nm using a 
spectrophotometer. (Bradford, 1976) This is a rapid and stable colorimetric assay. 
Increasing protein concentration increases the presence of bound dye, hence a 
concentration dependent colorimetric response can be obtained. 
1. The reagent was brought to room temperature and gently vortexed. 
2. The protein standards were then prepared, ranging from 0.1-1.4 mg/mL [Table 
5-11]. 
3. Five µL of the standards were added to each well on a 96-well plate in 
duplicate. The blank control was made by adding 5 µL of 
Radioimmunoprecipitation assay (RIPA) buffer. 
4. The samples whose protein concentration was being determined was then 
added in duplicate, assuming the range of the unknown to be in between 0.1-
1.4 mg/mL. 
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5. 250 µL of the Bradford reagent was then added to each well and mixed for 30 
seconds. 
6. This was then incubated at room temperature for 30 minutes [Figure 5-12 
illustrates a typical plate appearance after incubation]. 
7. The absorbance at 595nm was then read in a UV spectrophotometer. 
8. Absorbance versus protein concentration for each standard was then plotted.  
Unknown concentrations of protein in the samples were determined by 
plotting against the standard curve. 
 
 
Table 5-12 Serial dilution of protein standard for Bradford assay to determine protein 
concentration in a solution  
STANDARD SAMPLE BSA 
(mg/mL) 




0 0 1000 
0.1 100 900 
0.2 200 800 
0.4 400 600 
0.6 600 400 
0.8 800 200 












FIGURE 5-12 BRADFORD ASSAY PLATE WITH DUPLICATE PROTEIN STANDARDS IN 
LANES 1 AND 2 RUNNING FROM HIGHEST PROTEIN CONCENTRATION IN THE 
WELLS AT THE TOP LEFT-HAND CORNER.  DUPLICATE PATIENT SAMPLES 













Where appropriate, values are expressed as median and inter-quartile range.  Group 
comparisons were performed using the Chi-squared test for categorical and Mann-
Whitney U test for continuous variables.  Paired-sample comparisons were performed 
using the Wilcoxon matched-pair test for categorical variables.  Correlation between 2 
continuous variables was performed using linear regression.  P<0.05 was considered as 
statistically significant.  Non-parametric Area Under the Receiver Operator Curve 
(AUROC) curve analysis was performed for outcome measures.  Survival analysis was 
performed using the Kaplan-Meier log-rank method.  Statistical analyses were performed 
using GraphPad Prism 4.0 for Mac (GraphPad Software, Inc., San Diego, CA).  
Multivariate analysis was performed using SPSS 16.0 for Macintosh (SPSS Inc, CA, 































Chapter 6 – Circulating neutrophil dysfunction in 



















Acute liver failure (ALF) is a rare but frequently catastrophic consequence of an acute 
primary hepatic injury arising from a wide variety of insults.  It is characterised by 
coagulopathy and encephalopathy, with a variable dynamic of progression to multiple 
organ dysfunction syndrome (MODS) and death. (Trey and Davidson 1970) Liver 
transplantation (LT) remains the only curative option in advanced ALF with poor 
prognostic criteria and contributes to 10% of liver transplants in the western world. 
(Bernal et al., 2010)   
Neutrophils are rapidly recruited to the liver in response to hepatic injury in ALF, 
(Schlayer et al., 1988); once there they become activated by cytokines (e.g. IL-8 and 
TNFα) and can contribute to tissue damage by release of proteolytic enzymes and 
reactive oxygen species (ROS). (Ramaiah and Jaeschke, 2007) Systemic neutrophil 
activation with associated immuneparesis is well recognised in severe sepsis; a condition 
which shares many phenotypic features with ALF including microvascular dysfunction, 
haemodynamic instability, coagulopathy, encephalopathy and high levels of both pro-
inflammatory and anti-inflammatory cytokines. (Brown et al., 2006) In severe sepsis 
excessive activation of neutrophils, due to high circulating levels of cytokines and Toll-
like receptor activation by endotoxin (LPS), has been implicated in the pathogenesis of 
acute lung and kidney injury (Awad et al., 2009).  Neutrophils might therefore serve as 
critical effector cells of the progressive parenchymal liver damage and MODS in ALF.    
There is a high incidence of bacterial and fungal infection early in the course of ALF 
(Karvellas et al., 2009) which may preclude listing for LT.  ALF is also associated with 
an acute and often precipitous increase in plasma ammonia levels.  (Bernal et al., 2010) A 
recent study has shown that neutrophils exposed to ammonia have reduced phagocytic 
activity of opsonised E. coli and high spontaneous production of ROS suggesting a direct 
toxic effect of ammonia on neutrophils. (Shawcross et al., 2008a) Neutrophil dysfunction 
has also been previously reported in ALF with reduced complement expression, (Wyke et 
al., 1982) impaired neutrophil adhesion,(Altin et al., 1983) decreased production of ROS 
(Clapperton et al., 1997), and decreased neutrophil phagocytosis and intracellular killing 
(Rolando et al., 2000a).   
I postulate that circulating neutrophil dysfunction is present in ALF and may add 
value as a prognostic marker of severity and outcome. The aim of this prospective case-
control longitudinal study was therefore to characterise circulating neutrophil phenotype, 
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phagocytic activity (NPA) and production of ROS, in neutrophils isolated from the 
peripheral blood of patients with ALF and comparing it to healthy (HC) and septic 
controls (SC). Indices of neutrophil phenotype and function were examined in respect of 
severity and nature of liver injury, severity of organ failure, liver prognostic criteria of 
survival and eventual outcome. The relationship between plasma-derived factors and 
neutrophil function was also examined in order to aid identification of other associated 
biomarkers in ALF. 
 
6.2 Patients recruited 
Twenty-five patients with ALF or SALF were recruited non-consecutively on admission 
to the liver ICU at King’s College Hospital between October 2008 and August 2010.  
ALF was defined by the onset of hepatocellular dysfunction in the absence of pre-existing 
liver disease characterised by coagulopathy and encephalopathy and an illness of less 
than 26 weeks duration. ALF was further sub-classified according to the criteria defined 
by O’Grady et al. (O'Grady et al., 1993) depending on the time between the onset of 
jaundice and encephalopathy.  
(i) Hyperacute (jaundice to encephalopathy time <7 days) consisting 
predominantly of patients with acetaminophen-induced liver failure (AALF). 
(ii) Acute liver failure (jaundice to encephalopathy time 8-28 days) typified by 
patients presenting with fulminant viral hepatitis.  
(iii) Sub-acute Liver Failure (SALF) (jaundice to encephalopathy time 5-12 
weeks) typified by those presenting with non-acetaminophen drug-induced 
liver injury and seronegative/acute autoimmune hepatitis. 
 
6.2.1 Inclusion Criteria 
Patients with ALF/SALF were included if they were aged >18 years and <80 years.  
Healthy age and sex-matched non-smoking volunteers with no history of liver disease 
were used as HC. The HC alcohol intake was <20 g/day and volunteers had not drunk 
alcohol or exercised excessively in the 24 hours prior to blood being drawn. SC patients 
were recruited from the general ICU and had severe sepsis with MODS. Severe sepsis 
was defined by the presence of a SIRS score ≥ 2 (16), with radiological and/or laboratory 
evidence of infection and 1 or more extra-hepatic organ failure(s). Patients presenting 
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with ALF/SALF were given empirical intravenous antibiotic and antifungal cover as 
standard of care. This consisted of tazocin 4.5 grams every 8 hours (substituted for 
meropenem 1 gram every 8 hours if penicillin allergic) and fluconazole 400mg once 
daily. 
 
6.2.2 Exclusion criteria  
Patients were excluded from the ALF/SALF cohorts if on presentation they had evidence 
of bacterial, fungal or viral infection on clinical examination, radiological or laboratory 
investigation, malignancy and any coexisting history of immunodeficiency including HIV 
and glycogen storage disease.  Patients with pre-existing liver disease, a history of alcohol 
intake >20g/day or who were on immunosuppressive therapies such as steroids or 
azathioprine were also excluded. 
 
6.3 Patient baseline demographics and clinical parameters 
15 non-consecutive patients with ALF and 10 patients with SALF were recruited.  
Baseline (on admission to ICU) patient demographics, biochemical and physiological 
parameters are detailed in Tables 6-1, 6-2 and 6-3, respectively.  The ALF group were 
heterogeneous in terms of aetiology and severity of liver injury [acetaminophen n=6; 
acute viral hepatitis n=3; other n=6].   Other aetiologies in the ALF cohort included one 
each of seronegative autoimmune hepatitis, Budd-Chiari syndrome, ischaemic hepatitis 
and eosinophilic hepatitis, with 2 further patients suffering a drug-induced liver injury 
(DILI).  The predominant aetiology in SALF was seronegative / acute autoimmune 
hepatitis n=7, other aetiologies included hepatitis B virus infection in one patient and 
DILI in a further two patients.    
Within the ALF (n=15) cohort 9 (60%) fulfilled King’s College Hospital criteria 
for poor prognosis, (O'Grady et al., 1989) of whom 4  (44%) underwent successful LT, 4 
(44%) were declined LT due to co-morbidity and 1 (12%) was listed but died of cerebral 
oedema before a graft became available. One patient met poor prognostic criteria but was 
declined LT due to psychiatric co-morbidity but survived following plasmapheresis.  In 
the SALF (n=10) cohort 8 (80%) fulfilled poor prognostic criteria; of whom 6 (60%) 
underwent LT; 1 (10%) was declined due to co-morbidity; and 1 (10%) recovered and 
was de-listed. Two SALF patients died (one post-LT from MODS).   
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All patients with ALF/SALF were significantly unwell with MODS and indeed, 
MELD and SOFA scores were significantly higher in the ALF and SALF cohorts 
compared to the SC (p=0.001 and p=0.0035, respectively) [Table 6-2]. Patients with 
SALF had a tendency to be older, with higher bilirubin and lower arterial ammonia, but 
due to the small numbers in the groups, these comparisons did not reach significance.  
For underlying diagnosis in the septic controls see Table 6-1.  Co-morbidities 
included chronic obstructive pulmonary disease in the faecal peritonitis patient and 
previous stroke, hypertension, diabetes mellitus and hypercholesterolaemia in the 
pneumonia patient.    
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Table 6-1 Baseline demographic data and outcomes for patients with ALF/SALF 










Death / LT 
Number 6 15 10 10 15 
Median Age 40.5 (24-70) 33 (26-48) 52.5 (44-60) 34 (28-44) 51 (32-59) 



































5  (33) 
4 (27) 
1 (7) 











    
Transplant-free 90-day survival   7/15 (40) 3/10 (30) 10/10 (100) 0 (0) 
Poor prognostic criteria* 9/15 (60) 8/10 (80) 2/10 (20) 15 (100) 
Declined LT 4/9 (44) 1/10 (10) 2/2 (100) 3/15 (20) 
Underwent LT 4/9 (44) 6/10 (60)  10/15 (67) 
Listed for LT but died before grafted 1/9 (12) - 1/15 (7) 
Listed but survived without LT - 1/10 (10) 1/10 (10) 
Died (%) 4 (67) 4/15 (27) 2/10 (20) 6/15 (40) 
Data presented as number of cases (percentage) or median (IQR) for the variables as appropriate. 
* Fulfilled King’s College Hospital poor prognostic Criteria.   
Abbreviations: ALF- Acute Liver failure; SALF – Sub-acute Liver Failure; HAV-Hepatitis A virus; HBV-Hepatitis B virus; HEV-Hepatitis E 
virus; LT-Liver transplantation.  
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Table 6-2 Clinical and organ failure parameters of patients with ALF/SALF on day of recruitment. 
Clinical/Biochemical/Organ Failure 
Variables 
Severe sepsis n=6 ALF n=15 SALF n=10 p-value 
(Kruskal Wallis) 
Body Mass Index 24.5 (20.8-29.7) 21.8 (21.4-24.7) 25.3 (23.2-27.4) 0.74 
Antibiotics and antifungals* 6 (100%) 13 (87%) 9 (90%) 0.65 










Mean arterial pressure (mmHg) 83 (74-88) 71.5 (67-81.5) 80 (73-94) 0.05 
Number requiring invasive ventilation 3 (50%) 9 (60%) 6 (60%) 0.91 
Number requiring vasopressors 4 (66%) 6 (40%) 3 (30%) 0.36 
Number requiring hemofiltration 2 (33%) 10 (66%) 6 (60%) 0.37 
Days on hemofiltration 3 (3-5) 4.0 (3.25-7.25) 4.0 (1.5-5.0) 0.63 
Organ failure scores     
SIRS Score 3 (2-3) 2 (1-2.5) 1 (1-2) 0.22 
MELD Score 13 (9-14) 34.2 (31.7-41.4) 42.4 (28.1-48.8) 0.001 Δ 
SOFA Score 6 (4.5-6.5) 16 (14.5-17.0) 16 (15.5-17.5) 0.04 Δ 
APACHE II Score 14 (11-17) 21 (17.5-24.5) 22 (18.5-23.5) 0.17 
Data presented as number of cases (percentage) or median (IQR) for the variables as appropriate. 
Abbreviations: ALF – Acute Liver Failure; SALF - Sub-acute Liver Failure; MELD-Model of End-stage liver disease; SOFA-Sequential Organ 
Failure Score; APACHE II-Acute Physiology and Chronic Health Evaluation II. SIRS-Systemic inflammatory response syndrome score  
 
* Patients presenting with ALF/SALF were given empirical intravenous antibiotic and antifungal cover as standard of care. This was tazocin 4.5 
grams every 8 hours (substituted for meropenem 1 gram every 8 hours in those who were penicillin allergic) and fluconazole 400mg once daily. 
 
Δ = Values in both ALF and SALF cohorts were significantly increased compared with septic controls.  The Kruskal-Wallis test was utilised 








Table 6-3 Biochemical and neutrophil parameters of patients with ALF/SALF on day of recruitment 




Acute liver failure 
N=15 




Haemoglobin (g/dL) 9.0 (8.2-9.7) 9.5 (8.2-11) 9.3 (8.7-12.8) 0.44 
Neutrophil count (x 109^L) 11.7 (8.2-15.5) 7.5 (5.5-11.0) 7.9 (5.1-10.1) 0.31 
INR 1.32 (1.19-1.38) 3.21 (2.25.4.70) 3.18 (2.27-7.15) 0.002 Δ 
Aspartate Aminotransferase (IU/L) 35 (32-42) 386 (237-2577) 203 (131-1062) 0.001 Δ 
Bilirubin (µmol/L) 9 (7-10) 106 (80.0-210.5) 189 (136.8-266.0) 0.001 Δ 
Albumin (g/L) 27 (20-29) 21 (19.5-25.0) 17 (13.8-27.0) 0.39 
Sodium (mmol/L) 142 (137-146) 142 (140.5-145.5) 143 (136.5-144.8) 0.90 
Creatinine (µmol/L) 105 (69-138) 161 (89.5-214.0) 132 (89.3-120.5) 0.51 
Lactate (mmol/L) 0.9 (0.7-1.2) 2 (1.4-3.0) 2 (1.65-2.5) 0.025 Δ 
C-reactive protein (mg/L) 226 (116-349) 17.3 (5.3-31.8) 23 (8.1-29.5) 0.001 § 
Arterial ammonia (µmol/L) 22 (19-25) 75 (62-107) 61.5 (44-84) 0.001 Δ 
High Density Lipoprotein (mmol/L) 0.5 (0.35-0.65) 0.35 (0.18-0.50) 0.1 (0.10-1.13) 0.02 < 
Arterial pH 7.4 (7.38-7.43) 7.4 (7.37-7.46) 7.49 (4.43-7.52) 0.15 
Data presented as number of cases (percentage) or median (IQR) for the variables as appropriate. 
Δ = Values in both Acute liver failure (ALF) and subacute liver failure (SALF) cohorts were significantly increased compared with septic 
controls, §= C- reactive protein was significantly greater in septic controls compared with both ALF and SALF cohorts, < = High density 
lipoprotein values were significantly lower in SALF cohort compared to the ALF cohort.  The Kruskal-Wallis test was utilised with Dunn’s 










Table 6-4 Neutrophil function test and cytokine results in acute / subacute liver failure. 
 Severe sepsis 
(N=6) 
Acute liver failure 
(N=15) 




Neutrophil function     
 Phagocytic Activity (%) 
 










E. Coli stimulated 









Tumour necrosis factor-α 
(pg/ml) 
20 (17-67) 47 (30-114) 69 (15-128) 0.18 
Interleukin-1β (pg/mL) 
 
872 (69-2652) 2887 (1236-9053) 7603 (2897-18128) 0.06 
Interleukin-6 (pg/mL) 
 
96 (75-172) 140 (51-821) 73 (25-237) 0.47 
Interleukin -8 (pg/mL) 
 
65 (34-74) 154 (71-239) 98 (73-304) 0.20 
Interleukin -10 (pg/mL) 
 
78 (20-289) 247 (36-896) 299 (55-623) 0.06 
Interleukin -17 (pg/mL) 
 
78 (20-289) 227 (72-891) 358 (109-625) 0.03* 
Data presented as number of cases (percentage) or median (IQR) for the variables as appropriate. The Kruskal-Wallis test was utilised with 
Dunn’s multiple comparison test and p<0.05 was considered statistically significant. 










Table 6-5 Neutrophil function test results determined by day of admission to liver unit and post-liver transplant in patients with acute/subacute 
liver failure. 























E. Coli stimulated 











Table 6-6 Clinical and organ failure parameters of spontaneous survivors versus non-survivors/transplanted with ALF/SALF on day of sampling 
Clinical/Biochemical/Organ 
Failure Variables 
Liver Failure Spontaneous 
Survivors (N=10) 















Mean arterial pressure (mmHg) 77 (70-95) 74 (68.5-79) 0.52 
Number requiring invasive 
ventilation 
4 (40%) 11 (73%) 0.10 
Number requiring vasopressors 2 (20%) 8 (53%) 0.10 
Number requiring hemofiltration 5 (50%) 11 (73%) 0.23 
SIRS Score 1 (1-2) 2 (1-2.5) 0.60 
Organ Failure scores    
MELD Score 32 (26-42) 42 (33-49) 0.71 
SOFA Score 16 (14-16) 16 (15-17) 0.50 
APACHE II Score 22 (10-22) 21 (19-26) 0.39 
Data presented as number of cases (percentage) or median (IQR) for the variables as appropriate.  
Abbreviations: LT: liver transplantation: MELD-Model of End-stage liver disease; SOFA-Sequential Organ Failure Score; APACHE II-Acute 
Physiology and Chronic Health Evaluation II. SIRS-Systemic inflammatory response syndrome score  
† Significant differences between spontaneous survivors and death/transplanted are shown using the Mann-Whitney U test; p<0.05 was 





Table 6-7 Biochemical and neutrophil parameters of spontaneous survivors versus non-survivors/transplanted with ALF/SALF. 
Clinical/Biochemical/Organ Failure 
Variables 
Liver Failure Spontaneous 
Survivors (N=10) 




Haemoglobin (g/dL) 10.7 (8.1-11.5) 9.3 (8.9-10.9) 0.98 
Neutrophil count (x 109^L) 5.5 (4.1-6.1) 10.1 (6.8-12.1) 0.01 † 
INR 4.6 (2.9-6.6) 3.3 (.8-5.6) 0.24 
Aspartate Aminotransferase (IU/L) 317 (164-1047) 386 (192-1362) 0.57 
Bilirubin (µmol/L) 106 (82-125) 204 (134-285) 0.048 † 
Albumin (g/L) 21 (18.5-28.5) 20 (16-26) 0.50 
Lactate (mmol/L) 2.1 (1.2-2.8) 1.95 (1.7-2.5) 0.64 
Arterial ammonia (µmol/L) 69 (60-94) 144 (91-199) 0.81 
High Density Lipoprotein (mmol/L) 0.3 (0.1-0.4) 0.1 (0.1-0.3) 0.35 
Arterial pH 7.47 (7.4-7.5) 7.43 (7.38-7.47) 0.22 
Neutrophil function     
% Neutrophil Phagocytic Activity 78.2 (56.3-83.3) 53.6 (36.6-69.0) 0.047 † 
% Neutrophil Resting Burst 10.1 (3-18) 10.4 (4-25) 0.77 
% Neutrophil Stimulated Burst 85.3 (66-91) 85.8 (76-94) 0.37 
Plasma Cytokines    
TNFα pg/mL 85 (25-103) 47 (27-103) 0.64 
IL-1 pg/mL 2887 (1277-4212) 7697 (1591-22572) 0.36 
IL-6 pg/mL 81 (59-140) 87 (32-559) 0.49 
IL-8 pg/mL 129 (47-377) 115 (76-239) 0.25 
IL-10 pg/mL 188 (46-411) 479 (57-920) 0.96 
IL-17 pg/mL 74 (37-281) 418 (162-926) 0.90 
Data presented as number of cases (percentage) or median (IQR) for the variables as appropriate. 
† Significant differences between spontaneous survivors and death/transplanted are shown using the Mann-Whitney U test; p<0.05 was 
considered statistically significant. 
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6.4 Neutrophil phenotype 
Neutrophil surface receptor expression of CD16 (FcγRIII) and CD11b (Mac-1) was 
performed on days 1, 4 and 7 in 8/15 of the ALF cohort and compared to HC (n=8) and 
SC (n=5). Neutrophil expression of CD16 was significantly reduced in the ALF cohort 
compared to HC (p<0.001) on day 1. [Figure 6-1] CD16 expression was also reduced in 
the SC group compared to HC but this did not reach statistical significance. The CD16 
downregulation persisted in the ALF group on days 4 and 7 regardless of outcome but 
normalized within 72 hours post-LT. No differences were observed in neutrophil surface 
receptor expression of CD11b in patients with ALF/SALF or in SC (data not shown).  
Reduced expression of CD62L (L-selectin) was seen in a sample from a 23 year old male 
with ALF due to eosinophilic hepatitis who was admitted with jaundice, coagulopathy 
and low-grade encephalopathy.  A sample analysed on day 4 of admission, following 
resolution of HE, showed 26% of his resting neutrophils expressed an activated 
phenotype with low CD62L expression (normal ≤ 10%).   
 
 
FIGURE 6-1 NEUTROPHIL CD16 EXPRESSION ON DAY 1 OF ICU ADMISSION  
(IMMUNOGLOBULIN G: FCγRIII) IN HEALTHY CONTROLS (N=8) AND SEPTIC 
CONTROLS (N=5) COMPARED TO PATIENTS WITH ACUTE LIVER FAILURE 
[ALF] (N=8)  
Differences between healthy controls and patients were calculated using the Kruskal-
Wallis test (p=0.0006) with Dunn’s multiple comparison test. ALF patients had 

































6.5 Neutrophil phagocytic activity (NPA) 
Neutrophils isolated from the ALF, SALF and SC cohorts on day 1 all demonstrated 
reduced NPA compared to HC [median (IQR) NPA in the cohorts were as follows: HC 
77.7% (72.8-83.7), SC 70.2% (55.6-78.3), ALF 66% (48.8-81.5) and SALF 39.6% (32.5-
63.9)] [Table 6-4 and Figure 6-2 and 6-3]. The SALF group showed the greatest 
reduction in NPA (SALF versus HC p<0.01).   NPA in the SC cohort showed a non-
significant reduction in NPA compared to HC’s.  Overall, NPA remained depressed on 
follow up ICU admission days (p=0.047) in the ALF/SALF cohorts compared to HC 
[Table 6-5].  Figure 6-4 charts the typical NPA trend observed on admission and on days 
5 and day 9 in an ALF and SALF survivor compared to that observed in an ALF 
transplanted and SALF death. NPA was significantly improved 72 hours post-LT 
compared to pre-LT levels; p=0.03 [Figure 6-5].  
 
FIGURE 6-2 PERCENTAGE NEUTROPHIL PHAGOCYTIC ACTIVITY OF 11 HEALTHY 
CONTROLS (HC), 6 SEPTIC CONTROLS (SC), 15 ACUTE LIVER FAILURE (ALF), 
AND 10 SUBACUTE LIVER FAILURE (SALF) PATIENTS 
Differences between HC and patients were calculated using the Kruskal-Wallis test 
(p=0.014) with Dunn’s multiple comparison test. Neutrophil phagocytic activity was 
significantly reduced in the SALF group compared to HC (p<0.01 **). 
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FIGURE 6-3 REPRESENTATIVE FACS PLOTS OF NEUTROPHIL FUNCTION TESTS IN (A) A HEALTHY CONTROL (HC), (B) A PATIENT WITH 
ACETAMINOPHEN-INDUCED ALF (AALF) AND (C) THE AALF PATIENT 72 HOURS POST-LT.  
(i) Shows the plots obtained for phagocytic activity with opsonised E. coli labelled with FITC, (ii) Spontaneous (unstimulated) oxidative burst, (iii) Oxidative 
burst with fMLP, (iv) Oxidative burst with PMA and (v) Oxidative burst with opsonised E. coli. The x-axis of the plots represents FITC/rhodamine 
fluorescence intensity and the y-axis represents CD16 fluorescence intensity. Gates were set using the patients unlabelled (double negative) neutrophils. 
Neutrophils that have undergone phagocytosis/burst appear in the upper right quadrant of each plot and the overall percentage of neutrophils is labelled. 
These plots show that in this representative ALF patient there is reduced phagocytic activity compared to a HC (54.7 versus 92.7%) and increased 























FIGURE 6-4 THE TYPICAL NEUTROPHIL PHAGOCYTIC ACTIVITY TREND 
OBSERVED IN AN ALF AND SALF SPONTANEOUS SURVIVOR COMPARED TO 
THAT OBSERVED IN AN ALF (TRANSPLANTED) SURVIVOR AND SALF NON-
SURVIVOR ON ADMISSION, DAY 5 AND DAY 9. 
 
 
FIGURE 6-5 THE IMPACT OF LIVER TRANSPLANTATION (LT) ON THE MEDIAN 
NEUTROPHIL PHAGOCYTIC ACTIVITY (%) ON 6 ALF/SALF PATIENTS WHO 



































6.6 Neutrophil oxidative burst (OB) 
Neutrophil spontaneous production of ROS (SOB) was increased in the patients with 
ALF compared to HC who went on to require LT, which was reversed within 72 hours 
post-LT [Table 6-5]. However, SOB was statistically unchanged overall when the 
ALF/SALF cohorts were compared with the HC and SC groups (p=0.11) [Figure 6-6]. No 
difference in neutrophil SOB was seen when comparing AALF to non-AALF aetiologies 
(p=0.99) but an increase in SOB was observed on days 5-9 of ICU admission (p=0.013) 
with improvement in SOB in those surviving beyond 10 days and 72-hours post-LT 
[Figure 6-7].   
 Neutrophil E. coli stimulated oxidative burst (ESOB) was significantly reduced in 
the SC cohort (p<0.05) whilst ALF/SALF neutrophils killed E. coli as effectively as HC 
[Figures 6-8 and Table 6-4]. 
 
FIGURE 6-6 MEDIAN NEUTROPHIL SPONTANEOUS OXIDATIVE BURST OF 
HEALTHY CONTROLS (HC), SEPTIC CONTROLS (SC), PATIENTS WITH ACUTE 
LIVER FAILURE (ALF) AND SUB-ACUTE LIVER FAILURE (SALF).  
Differences between groups were calculated using the Kruskal-Wallis test (p=0.11) with 





FIGURE 6-7 DETERIORATION IN NEUTROPHIL SPONTANEOUS OXIDATIVE BURST 
(SOB) IN PATIENTS WITH ACUTE / SUBACUTE LIVER FAILURE COMPARED TO 
HEALTHY CONTROLS AND PATIENTS WITH ALF/SALF FOLLOWING LIVER 
TRANSPLANTATION 
Differences between groups were calculated using Mann-Whitney U test.  Neutrophil 
SOB was significantly increased compared to healthy controls at days 0-4 (p=0.094) and 





FIGURE 6-8 MEDIAN NEUTROPHIL STIMULATED OXIDATIVE BURST WITH 
OPSONISED E COLI OF HEALTHY CONTROL (HC, N=11) AND SEPTIC CONTROL 
(SC, N=6) COMPARED TO ACUTE LIVER FAILURE (ALF, N=15) AND SUBACUTE 
LIVER FAILURE PATIENTS (SALF, N-10) 
Differences between groups were calculated using the Kruskal-Wallis test (p=0.014) with 
Dunn’s multiple comparison test. The SC group had significantly lower stimulated 









































6.7 Neutrophil function, organ failure scores and plasma-derived 
factors in ALF and SALF 
In the ALF cohort, there was no association seen between neutrophil function and SIRS 
score, MELD and SOFA score and absolute neutrophil count. Patients with AALF 
(hyperacute) had higher plasma levels of the pro-inflammatory cytokines TNFα, IL-6 and 
IL-8 (all p<0.05) compared to non-AALF [Figure 6-9]. IL-17 was significantly elevated 
in the AALF patients who died or underwent LT compared to spontaneous survivors 
(p=0.008) [Table 6-4]. In the ALF cohort spontaneous SOB did not correlate with serum 
biochemistry, arterial ammonia or organ failure scores. 
In the SALF cohort, decreasing NPA correlated with increasing peak arterial 
ammonia concentration (p=0.001; r2=0.677) [Figure 6-10], increasing concentration of 
plasma IL-10 (p=0.019; r2=0.407) [Figure 6-11] and plasma IL-17 (p=0.0003; r2=0.708) 
[Figure 6-12].  In the SALF cohort, increased neutrophil ROS production correlated with 
higher serum high-density lipoprotein levels (p=0.001; r2=0.763) but showed no 
significant association with organ failure scores.  
 When ESOB was impaired in the ALF cohort it correlated with lower plasma 
concentrations of IL-6 (p=0.038; r2=0.190), IL-10 (p=0.047; r2=0.175) and IL-17 
(p=0.007; r2=0.301) [data not shown] and in the SALF cohort, correlated with higher 
plasma concentrations of IL-8 (p=0.007; r2=0.465) [Figure 6-13] and lower plasma 







FIGURE 6-9 COMPARISON OF INFLAMMATORY CYTOKINE LEVELS IN 
NEUTROPHILS FROM PATIENTS WITH ACETAMINOPHEN-INDUCED (AALF) 
AND NON-ACETAMINOPHEN INDUCED (NON-AALF) ACUTE LIVER FAILURE 
Difference between groups were calculated using Mann-Whitney U test, *p<0.05. 
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FIGURE 6-10 CORRELATION BETWEEN IMPAIRED NEUTROPHIL PHAGOCYTIC 
ACTIVITY (%) AND ARTERIAL AMMONIA (µMOL/L) IN THE SUBACUTE LIVER 
FAILURE COHORT (R2=0.677; P=0.001). 
 
 
FIGURE 6-11 CORRELATION BETWEEN PERCENTAGE NEUTROPHIL PHAGOCYTIC 
ACTIVITY AND PLASMA IL-10 CONCENTRATION (PG/ML) IN PATIENS WITH 
SUBACUTE LIVER FAILURE 
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FIGURE 6-12 THE CORRELATION BETWEEN IMPAIRED NEUTROPHIL PHAGOCYTIC 
ACTIVITY (%) AND PLASMA IL-17 (PG/ML) IN SUBACUTE LIVER FAILURE 
 
FIGURE 6-13 THE CORRELATION BETWEEN IMPAIRED NEUTROPHIL E.COLI 




6.8 Neutrophil Function and Patient Outcomes 
 
Patients who died and those proceeding to LT had lower NPA on day 1 than spontaneous 
survivors (p=0.047) [Table 6-7 and Figure 6-14]; however, this was not maintained after 
exclusion of patients undergoing LT (p=0.19).  No difference was observed when 
comparing admission neutrophil spontaneous OB in spontaneous survivors to patients 
who died or underwent LT (p=0.5) [Table 6-7].    
Four deaths occurred in the ALF cohort; 3 patients died of MODS (two on day 10 
of ICU admission and one on day 45) and 1 died of uncontrolled intracranial 
hypertension. In the SALF cohort, 2 patients died from MODS on days 15 and 17 of the 
ICU admission, respectively. The incidence of culture positive sepsis in the ALF/SALF 
cohorts overall was low with one patient with seronegative SALF developing an episode 
of staphylococcus epidermidis bacteraemia on day 3 (day 1 NPA 29.7% improving to 
40.3% post LT on day 6) and in another seronegative SALF a Klebsiella species urinary 






FIGURE 6-14 MEDIAN PERCENTAGE NEUTROPHIL PHAGOCYTIC ACTIVITY OF 
PATIENTS WITH ACUTE/SUBACUTE LIVER FALURE WHO SPONTANEOUSLY 
SURVIVED (9 PATIENTS) WITHOUT LIVER TRANSPLANTATION (LT) 
COMPARED TO THOSE WHO DIED OR UNDERWENT LT (10 PATIENTS) 











Neutrophil dysfunction has been implicated both in the immune paresis observed in ALF 
(Altin et al., 1983, Clapperton et al., 1997) and in direct injury to the liver (Ramaiah and 
Jaeschke, 2007) and extra-hepatic organs. (Awad et al., 2009) Neutrophil driven 
hepatocellular injury has also been shown to contribute to hepatocellular damage in 
models of ischemia-reperfusion injury, (Jaeschke, 2006) alcoholic hepatitis (Bautista, 
2002) and endotoxemia. (Dorman et al., 2005) Neutrophil recruitment is seen within the 
liver in AALF (Lawson et al., 2000) and there is evidence to suggest that hepatocyte 
injury is amplified by neutrophil infiltration in a mouse model of AALF. (Liu et al., 
2004b) Neutrophils are also likely to contribute to liver injury in ALF, resulting from 
their overwhelming capacity to produce large quantities of ROS and proteases following 
recruitment and activation within the hepatic sinusoids.  For this reason, the relationship 
between circulating neutrophil function and the progression and outcomes of acute liver 
injury was therefore explored in this study.  
The observation of a reduction in NPA and elevated SOB in ALF/SALF cohorts, 
akin to that frequently observed in sepsis, (Brown et al., 2006) may explain why patients 
with ALF exhibit phenotypic features of septic shock with microvascular dysfunction, 
hemodynamic instability, coagulopathy, encephalopathy, MODS and high levels of 
circulating pro-inflammatory cytokines. Why the severity of NPA is less so in those 
presenting with ALF compared to SALF is less clear but the development of impaired 
NPA may occur in a time dependent manner as evidenced by the most severe reduction in 
phagocytic ability seen in cases of SALF, where the liver injury takes on a more insidious 
course over several weeks. Indeed, many patients with established SALF may present 
with moderate portal hypertension with features of splenomegaly and ascites.  
Nevertheless, NPA on admission appears to be a predictor of spontaneous survival 
compared to conventional organ failure scores such as SOFA and MELD, which did not 
predict poor outcome in this study. Trying to understand the relationship between 
neutrophil phagocytic dysfunction and poor prognosis therefore seems critical. LT 
resulted in rapid improvement of neutrophil phagocytic function within 72 hours but not 
complete reversal, which could be the result of ischemia-reperfusion phenomena, ongoing 
production of pro-inflammatory cytokines/SIRS or sepsis.   
The incidence of ‘culture positive’ sepsis was low in this ALF/SALF cohort 
overall and indeed the observed deaths could not be directly attributed to infection, 
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suggesting phagocytic dysfunction is either a reflection of general immune activation or a 
specific factor related to liver failure.  Peak plasma ammonia levels demonstrated a robust 
correlation with poor phagocytic function in SALF and high circulating levels of IL-10 
and IL-17.  Ammonia was previously shown to impair NPA and induce SOB in healthy 
neutrophils exposed to supraphysiological concentrations of ammonia ex vivo and in rats 
fed an ammonia-rich diet. (Shawcross et al., 2008a) The peak arterial ammonia 
concentration did not however correlate with impaired NPA in the ALF cohort but might 
be attributed to the impact of ammonia reduction by continuous veno-venous 
hemofiltration prior to neutrophil sampling.   
Pro- and anti-inflammatory cytokine profiles might be expected to show a closer 
association with neutrophil OB than phagocytic activity although this was not generally 
the case.  Higher plasma IL-10 and IL-17 concentrations correlated with impaired NPA 
and may suggest the development of a CARS in this condition (Antoniades et al., 2008) 
with involvement of T-regulatory cells. (Lewis et al., 2012) However, the condition with 
the highest levels of pro-inflammatory cytokines, AALF demonstrated only modest 
neutrophil dysfunction.  CD4+CD25+CD127-FOXP3+ T-regulatory cells directly inhibit 
neutrophil function, promoting apoptosis and death when exposed to lipopolysaccharide 
through TLR4 expressed on their surface which inhibits pro-inflammatory activities. 
(Lewkowicz et al., 2006) This is an important role in the direct control of innate immune 
responses.  Upon activation, these T-regulatory cells can either induce themselves or 
CD4+CD25-FOXP3-T effector cells to differentiate into IL-17A producing cells (Th17) 
in the presence of TGF-beta and/or IL-6. (Xu et al., 2007) In contrast to the role of T-regs 
on neutrophils, one of the functions of Th17 is to recruit neutrophils into inflamed tissue 
further increasing the antimicrobial response in vitro and in vivo. (Annunziato et al., 
2008, Kolls et al., 2008) The balance between Th-17 and T-regulatory cells are important 
in modulating innate immune response in the liver and they have been shown to play an 
important role in acute and chronic hepatitis B virus infection as well as autoimmune 
hepatitis although little is know about their role in ALF.  (Xue-Song et al., 2012, Grant et 
al., 2014) 
The evidence for a role of increased circulating neutrophil production of ROS as a 
contributor to the development of MODS and poor outcomes in ALF in this study is less 
clear than that of NPA.  Interestingly, in the SALF cohort increased SOB correlated with 
increased serum high-density lipoprotein levels and higher SOFA and APACHE II 
scores.  High-density lipoprotein plays an important role in the transport of cholesterol to 
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the adrenal gland for steroidogenesis thus modulating the response to sepsis and critical 
illness. Low concentrations of high-density lipoprotein have recently been shown to be a 
predictor of poor outcome in ALF but were not associated with an increased risk of 
sepsis. (Etogo-Asse et al., 2012) The problem with measuring spontaneous neutrophil 
ROS production in isolated circulating cells is that this may not reflect the production 
within the hepatic parenchyma or other organs so it is difficult to draw firm conclusions.  
In addition, ALF and SALF patients are a heterogeneous patient group who are prone to 
deteriorating rapidly necessitating a number of invasive interventions such as high flow 
hemofiltration and mild hypothermia potentially influencing neutrophil function and 
which are difficult to control for constituting the main weakness of this study. 
Furthermore, the empirical use of potent broad-spectrum antibiotics and anti-fungal 
agents as standard of care in this study is also likely to have abrogated any increased 
susceptibility to developing sepsis in this cohort. 
Neutrophil stimulated OB with E. coli was significantly reduced in the SC group, 
whilst ALF/SALF neutrophils killed E. coli as effectively as HC.  This may represent the 
fact that neutrophils in patients with sepsis have been exhausted fighting the infection and 
have very little capacity left for responding to the E. coli. Alternatively, it could result 
from the development of CARS. 
In summary, circulating neutrophils in patients with ALF/SALF have impaired 
bacteriocidal function similar to that seen in patients with severe sepsis and MODS.  
Neutrophil function indices are important biomarkers of poor prognosis in ALF/SALF 
and can be implicated as important mediators in the development of cellular and organ 
dysfunction and the increased susceptibility to developing sepsis. Clearly these neutrophil 
function tests in their present format are cumbersome to perform and cannot be performed 
at the bedside but development of a rapid test of neutrophil dysfunction may offer the 
possibility for refinement of current prognostic criteria and might tailor therapy to those 
at highest risk.  These data also support the circulating neutrophil as a novel therapeutic 






















Chapter 7 –The severity of circulating neutrophil 
dysfunction in patients with cirrhosis is associated 



















Cirrhosis is associated with an increased incidence of microbial infection resulting in 
hospitalisation and complicating hospital admissions in up to 40% of cases. (Fernandez et 
al., 2002) Infection can lead to worsening liver function and precipitate complications, 
including variceal bleeding, HE, AKI and MODS, contributing to high mortality. The 
exponential increase in the incidence of cirrhosis in the United Kingdom (BASL and 
BSG, 2009) poses a major challenge in managing these patients particularly with respect 
to utilisation of ICU beds and requirement for LT. With poor outcomes following sepsis 
and its associated complications, and increasing waiting list mortality for LT, there is an 
urgent need for novel approaches to reducing the rate of infection in cirrhosis.   
Cirrhosis represents a state of functional immune paresis with defects in 
opsonisation, innate and adaptive immune responses and up-regulation of pro-
inflammatory cytokine production akin to that observed in patients with sepsis. (Wasmuth 
et al., 2005) Neutrophils are key effector cells of the innate immune response and show 
defects in phagocytic capacity and OB in cirrhosis. (Shawcross et al., 2008a, Rajkovic 
and Williams, 1986) In patients with cirrhosis bacterial translocation, porto-systemic 
shunting and reduced reticulo-endothelial function culminate in increased levels of 
circulating endotoxin and other PAMP molecules.  PAMPs interact with PRR, such as 
Toll-like receptors (TLR), expressed on the neutrophil surface leading to in the priming 
of circulating neutrophils. (Sabroe et al., 2003) Neutrophil priming also occurs in 
response to circulating chemokines and pro-inflammatory cytokines. (Condliffe et al., 
1998) In the primed state circulating neutrophils show altered surface receptor 
expression, increased basal superoxide production and reduced thresholds for undergoing 
phagocytosis and OB. (Colotta et al., 1992, Hayashi et al., 2003) Primed circulating 
neutrophils have been postulated to play a central role in the development of acute kidney 
and lung injury in sepsis, (Brown et al., 2006, Awad et al., 2009) as well as accumulating 
in other organs in patients who died of MODS. (Nuytinck et al., 1987) The generation 
and release of ROS and granule contents, such as serine proteases (e.g. elastase and 
MMP-9) by neutrophils at these sites result in tissue damage and the development of 
MODS. (Smith, 1994) 
Antibiotic prophylaxis is inadequate at reducing the incidence of infection in 
patients with cirrhosis and may be associated with the development of multi-drug 
resistant organisms. (Fernandez et al., 2002) A greater understanding of the pathogenic 
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mechanisms underpinning neutrophil dysfunction in cirrhosis might facilitate better 
identification of those at risk of developing infection and promote the development of 
neutrophil-targeted therapies.  
The aim of this longitudinal prospective study was to investigate whether 
defective neutrophil functioning in patients with cirrhosis predicts the development of 
infection and extra-hepatic organ dysfunction. To test the hypothesis we characterised 
neutrophil phenotype and functional capacity in a large cohort of cirrhotic patients in 
relation to clinical characteristics, plasma biochemical and cytokine profile and the 
development of infection and organ dysfunction at 90-days and 1-year.    
 
7.2 Patients recruited 
From October 2008 to August 2010 a total of 67 patients were recruited to the following 
cohorts: 49 patients with stable cirrhosis (CLD); 12 patients with acute-on-chronic liver 
failure  (AoCLF) as previously defined by Sen et al (Sen et al., 2002); and 13 patients 
with hepatic encephalopathy (HE) and are detailed in Table 7-1.  Three patients with 
stable cirrhosis subsequently developed either AoCLF (n=2) or HE (n=1).  Results of the 
investigations from these cohorts were compared with 11 healthy controls (HC) and 6 
septic controls (SC) recruited concomitantly during this time period.    
Baseline demographic, biochemical and physiological parameters are detailed in 
Tables 7-1 and 7-2. The aetiology of cirrhosis across the 3 groups was: alcohol-related 
liver disease (ARLD) 44.8% (30/67); chronic viral hepatitis 16.4% (11/67); autoimmune 
liver disease (including autoimmune hepatitis, primary biliary cirrhosis and primary 
sclerosing cholangitis) 22.4% (15/67); other 16.4% (11/67).   Aetiology of liver disease in 
the other group comprised cryptogenic cirrhosis (n=4), non-alcoholic steatohepatitis 
(n=3), haemochromatosis (n=2), and Budd-Chiari syndrome (n=2). In the alcohol group 
14/26 (54%) patients were consuming alcohol prior to hospital admission. In patients with 
alcohol-related cirrhosis who were abstinent from alcohol 12/26 (46%), the median 
(range) length of abstinence was 12 months (5-120 months). 
 A number of significant differences were observed in baseline biochemical 
variables between the individual cohorts. The haemoglobin level and platelet count were 
lower in the AoCLF cohort compared to stable cirrhosis (p<0.01 and p<0.05, 
respectively) whereas neutrophil count (p<0.01), CRP (p<0.05), serum creatinine 
(p<0.001), bilirubin (p<0.001), INR (p<0.001), aspartate aminotransferase (AST) 
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(p<0.01), MELD, SOFA and APACHE II (all p<0.001) were all significantly higher in 
the AoCLF cohort [Table 7-2].  
The median (range) length of follow-up, including deaths, in the stable cirrhosis 
and AoCLF cohorts was 282 days (1-1021) and 12 days (0-805), respectively. Five 
patients were lost to follow-up in the stable cirrhosis group at a median of 48 days (1-
282).  During the study follow-up 7 deaths occurred in the stable cirrhosis cohort, 2 from 
sepsis, at a median of 77 days.  16 patients with stable cirrhosis underwent LT at a 
median of 34 days and 26 patients survived to 12 months without LT [Figure 7-1].  In the 
AoCLF cohort 9 patients died, 6 from MODS secondary to bacterial and fungal infection, 
at a median of 12 days.    Three AoCLF patients underwent LT all within 45 days and one 




Table 7-1 Characteristics of patients with cirrhosis. 
 Healthy Controls 
(n=11) 
Cirrhosis † (n=49) HE (n=13) AoCLF (n=12) 
 
Median Age (range) 33 (30.5-33.5) 52 (43-61) 57 (45-61) 44 (39-62) 

























7 (14) 7 (54) 6 (50) 
Ascites 34 (69) 10 (77) 11 (92) 













Antibiotics 16 (33) 10 (77) §§ 11 (92) §§§ 
Active infection 0 (0) 3 (23) § 7 (58) §§ 
B-blockers 23 (47) 3 (23) 2 (17) 
Ventilated 0 0 6 (50) 
Vasopressors 0 0 6 (50) 
CVVH 0 0 8 (75) 
1 year LT free survival 28 (57) 6 (46) § 1 (8) §§§ 
90 day LT free survival 34 (69) 6 (45) § 1 (8) §§§ 
Transplanted within 1-year 14 (29) 2 (15) 3 (25) 
Data presented as number of cases (%) or median (IQR) for the variables as appropriate. p-values calculated using Chi-squared for 2 groups and 
Kruskal-Wallis for 3 or more groups with Dunn’s multiple comparison test; p value <0.05 considered significant, § p ≤ 0.05 versus cirrhosis, §§ 
p ≤ 0.01 versus cirrhosis, §§§ p ≤ 0.001 versus cirrhosis.   
Abbreviations: AoCLF: acute-on -chronic liver failure; CVVH: continuous veno-venous haemofiltration; HE: hepatic encephalopathy; IQR: 













Haemoglobin (g/L) 105 (95-127) 84 (80-93) § 84 (55-103) §§ <0.001 
Neutrophil count (x 109/L) 3.2 (2.0-4.4) 4.0 (2.9-8.8) 9.7 (7.6-15.6) §§ <0.001 
Platelets (x 109/L) 103 (81-155) 111 (68-128) 77 (58-104) 0.193 
C-reactive protein (mg/L) 9 (5-25) 22 (13-44) 52 (29-93) §§ 0.003 
Sodium (mmol/L) 137 (134-139) 135 (133-135) 137 (134-142) 0.269 
Creatinine (µmol/L) 80 (70-88) 93 (84-122) 180 (150-210) §§ <0.001 
Bilirubin (µmol/L) 38 (24-84) 134 (73-350) 432 (293-553) §§ <0.001 
Albumin (g/L) 32 (28-38) 28 (24-35) 27 (26-34) 0.066 
INR 1.42 (1.24-1.71) 1.9 (1.5-2.3) § 2.4 (1.9-2.9) §§ <0.001 
Aspartate Aminotransferase (IU/L) 58 (45-102) 77 (50-94) 116 (81-186) § 0.020 
Arterial ammonia (µmol/L) 75.5 (52-122) 71 (58-92) 69 (55-103) 0.786 
Child-Pugh score (IQR) 
Child-Pugh class A (%) 
Child-Pugh class B (%) 














MELD 14 (11-20) 24 (19-33) § 34 (30-38) §§ <0.001 
UKELD 54 (51-58) 60 (57-64) § 63 (60-68) §§ <0.001 
APACHE II 9 (7-11) 10 (6-11)** 21.5 (19-25) §§ <0.001 
SOFA 3 (2-5) 5 (4-7)** 15 (11-17) §§ <0.001 
Data presented as number of cases (percentage) or median (IQR) for the variables as appropriate. p-values calculated using Kruskal-Wallis with 
Dunn’s multiple comparison test; § p ≤ 0.05 versus cirrhosis, §§ p ≤ 0.01 versus cirrhosis, ** p ≤ 0.01 versus AoCLF. 
Abbreviations: AoCLF: acute-on-chronic liver failure; HE: hepatic encephalopathy; IQR: interquartile range; MELD-Model of End-stage liver 
disease; SOFA-Sequential Organ Failure Score; APACHE II-Acute Physiology and Chronic Health Evaluation II. UKELD: United Kingdom 







FIGURE 7-1 FLOW DIAGRAM TO ILLUSTRATE THE OUTCOMES OF THE 62 PATIENTS WITH CIRRHOSIS RECRUITED TO THE STUDY.  
Abbreviations: AoCLF: acute-on-chronic liver failure; LT: liver transplantation; MODS: multiple organ dysfunction syndrome
62	Patients	with	chronic	liver	disease	recruited	 
49	Patients	with	stable	cirrhosis	 No	active	infection,	HE	or	organ	dysfunction/failure. 
7	deaths Median	77days	(range	46-196)									2	deaths	sepsis	and	MODS 1	died	on	LT-waiting	list 
16	underwent	successful	LT Median	34	days	 (range	5-315) 
26	transplant-free	survival	at	12	months 8	episodes	of	infection	occurred	within	90-days 3	developed	AoCLF	 (1	survived) 
13	Patients	with	AoCLF 
9	deaths Median	12	days	(range	1-81) 6	died	MODS	due	to	bacterial/fungal	infection	 2	died	on	LT-waiting	list 
3	underwent	successful	LT Days	0,1,	and	45	days 
1	survived	a	10-day	ITU	admission	with	diverticular	perforation 
32	underwent	LT	assessment 20	listed	for	LT 12	declined 8	underwent	LT	assessment 5	listed	for	LT 3	declined 
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7.3 Study to characterise neutrophil phenotype, function and morphology 
in chronic liver disease 
 
7.3.1 Neutrophil phenotype 
Baseline neutrophil surface receptor expression of CD16 (FcγRIII) was unchanged in 
patients with cirrhosis compared to HC (p=0.544) [Figure 7-2]. Neutrophil surface 
receptor expression of CD11b (Mac-1) in patients with cirrhosis increased compared to 
HC (p=0.023) [Figure 7-2].  Reduced neutrophil CD62L expression was found in 2 out of 
3 patients with cirrhosis in the chemotaxis study [Table 7-5] indicating an activated 
phenotype. 
 
FIGURE 7-2 NEUTROPHIL SURFACE CD16 (IMMUNOGLOBULIN G: FCγRIII) AND 
CD11B EXPRESSION MEASURED BY MEAN FLUORESCENCE INTENSITY (MFI) 
IN HEALTHY CONTROLS, SEPTIC CONTROLS AND PATIENTS WITH CIRRHOSIS.  
Differences between healthy controls and patients were calculated using the Kruskal-
Wallis test with Dunn’s test for multiple comparisons.  Patients with cirrhosis but not 
septic controls show increased CD11b expression compared to HC (p=0.023). 
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7.3.2 Neutrophil phagocytic activity (NPA) 
Overall NPA was significantly impaired in patients with cirrhosis compared to HCs 
(p=0.002) [Table 7-3 and Figures 7-3 and 7-5].  SC showed a tendency to reduced NPA 
compared to HC (p=0.119) [Table 7-3 and Figures 7-4 and 7-5]. Although there was a 
tendency for NPA to be reduced in patients with Child-Pugh class A (CPA) cirrhosis, a 
significant reduction was only observed in patients with Child-Pugh class B (CPB) 
(p=0.026) and Child-Pugh class C (CPC) cirrhosis (p=0.023) [Figure 7-6].  
The CPC cohort was further sub-divided based upon the presence or absence of 
diuretic refractory ascites (DRA) [DRA being defined as ascites that cannot be mobilized 
or the early recurrence of which cannot be satisfactorily prevented by medical therapy]. 
(Arroyo and Colmenero, 2003) DRA patients represent an extreme of physiological 
adaptation to splanchnic arterial vasodilatation and portal hypertension and two groups 
are recognised: diuretic resistant ascites where maximal doses of diuretics are ineffective 
(Spironolactone 400mg once daily and furosemide 160mg per day); diuretic intolerant 
ascites whereby patients are unable to take an adequate diuretic dose due to development 
of complications such as AKI or hyponatraemia.  Patients with CPC cirrhosis and DRA 
on non-specific β-blockers had significantly impaired NPA compared to patients not 
taking the drug (p<0.05) [Figure 7-7].  
NPA was not influenced by severity of liver disease as determined by the MELD 
score (p=0.9) or UKELD score (p=0.8).  NPA was not influenced by cirrhosis aetiology 
(p=0.36) [data not shown].  NPA was significantly increased in active drinkers with 




Table 7-3 Neutrophil function indices and cytokines in healthy controls, septic controls and patients with cirrhosis 







Neutrophil phagocytic activity (%) 77.1 (72.2-83.6) 68.9 (59.5-78.5) 
 
63.6 (45.5-75.5)**  
 
0.004 
Neutrophil phagocytic capacity 
(E.coli MFI) 
 
7.99 x104  
(3.74 x104-9.08 x104) 
3.45 x104  
(1.99 x104-4.37 x104) 
3.03 x104  
(1.82 x104-4.36 x104) 
0.019 
Neutrophil spontaneous oxidative  burst 
(%) 
8.7 (5.6-9.3) 7.0 (6.4-10.7) 
 
9.1 (5.6-26.5) 0.284 







7.13 x104  
(6.77 x104-7.55 x104) 
 






85.1 (69.3-92.9)  0.011 
Neutrophil E.coli stimulated rhodamine 
MFI 
 
1.56 x104  
(1.19 x104-2.58 x104) 
3.89x103  
(3.21x103-5.12x103) 
2.72 x104  
(1.62 x104-4.22 x104) 
0.027 
Tumour Necrosis Factor-α pg/mL  9 (3-39) 20 (17-67) 60 (14-384) 0.198 
Interlukin-1β pg/mL 4545 (1429-7346) 872 (69-2652) 8416 (2007-29949) 0.003 
Interleukin -6 pg/mL 21 (16-38) 96 (75-172) 75 (14-435) 0.781 
Interleukin -8 pg/mL 23 (13-34) 65 (34-74) 93 (42-273) 0.380 
Interleukin -10 pg/mL  72 (28-76) 78 (20-289) 145 (57-285) 0.022 
Interleukin -17 pg/mL 66 (46-163) 78 (20-289) 263 (82-948) 0.017 
Data presented as median percentage or mean fluorescence intensity (MFI) and inter-quartile range (IQR) for the variables as appropriate.  p-values 
calculated using the Kruskal-Wallis test with Dunn’s test for multiple comparisons or Mann-Whitney U test as appropriate.  *p<0.05, ** p < 0.01 











FIGURE 7-3 FLOW CYTOMETER PLOTS OF NEUTROPHIL FUNCTION IN A HEALTHY CONTROL (HC) AND A PATIENT WITH STABLE 
CIRRHOSIS. 
Abbreviations: fMLP: Formyl-methionyl-leucyl-phenylalanine; PMA: Phorbol myristate acetate; CD16 PE: Cluster of differentiation 16 – 





FIGURE 7-4 FLOW CYTOMETER PLOTS OF NEUTROPHIL FUNCTION IN A SEPTIC CONTROL. TWO GATED GRANULOCYTE POPULATIONS 
ARE EVIDENT CONSISTENT WITH THE DEVELOPMENT OF TOXIC GRANULATION.   
Abbreviations: fMLP: Formyl-methionyl-leucyl-phenylalanine; PMA: Phorbol myristate acetate; CD16 PE: Cluster of differentiation 16 – 
Phycoerytherin; FITC: Fluorescein isothiocyante
 207 
 
FIGURE 7-5 BASELINE NEUTROPHIL FUNCTION INDICES IN HEALTHY CONTROLS 
COMPARED TO SEPTIC CONTROLS AND PATIENTS WITH CIRRHOSIS.   
Differences between healthy controls (HC) and patients were calculated using the 
Kruskal-Wallis test with post-hoc analysis using Dunn’s multiple comparison test 
(*p<0.05, **p<0.01).  Neutrophil phagocytic activity was reduced in the cirrhosis cohort 
(p=0.002) compared to HC. Neutrophil E. coli stimulated oxidative burst was decreased 









FIGURE 7-6 BASELINE NEUTROPHIL FUNCTION AND SEVERITY OF LIVER 
DISEASE DETERMINED BY CHILD-PUGH SCORE. 
Differences between healthy controls (HC) and patients were calculated using the 
Kruskal-Wallis test with Dunn’s multiple comparison test (*p<0.05). 
This shows that patients with Child Pugh B (CPB) and C (CPC) cirrhosis had impaired 
Neutrophil phagocytic activity compared to HC [HC versus CPB; p=0.026 and HC versus 






FIGURE 7-7 EFFECT OF NON-SELECTIVE Β-BLOCKERS ON NEUTROPHIL 
PHAGOCYTIC ACTIVITY IN PATIENTS WITH CHILD-PUGH C CIRRHOSIS AND 
DIURETIC REFRACTORY ASCITES.  
Patients on β-blockers had significantly worse NPA (p=0.049) than patients with similar 
disease severity not treated with β-blockers. Diuretic refractory (intolerant/resistant) 
ascites was defined as ascites that cannot be mobilized or the early recurrence of which 






FIGURE 7-8 BASELINE NEUTROPHIL FUNCTION INDICES IN ABSTINENT AND 
ACTIVE DRINKERS WITH ALCOHOL-RELATED LIVER CIRRHOSIS  
Differences between active alcohol drinkers and the abstinents were compared using the 
Mann-Whitney U test. Neutrophil phagocytic activity was paradoxically higher in the 
active drinkers compared to the abstinent alcohol drinkers (p=0.029). 
 
Table 7-4 Neutrophil function in abstinent and active drinking patients with cirrhosis due 
to alcohol-related liver disease (ARLD)  † 





























Data presented as median percentage (Interquartile range) of gated neutrophil population 
undergoing phagocytosis of FITC-labelled E.coli. p-values calculated using the Mann-
Whitney U test.  





7.3.3 Neutrophil oxidative burst (OB) 
Neutrophil spontaneous production of ROS (spontaneous oxidative burst [SOB]) was 
unchanged overall in both patients with cirrhosis and SC compared with HC (p=0.014 
and p=0.23 respectively) [Table 7-3 and Figure 7-5].  However, cirrhotic patients 
displayed a highly variable SOB response with 16/49 (33%) showing an elevated SOB 
(>12%), compared to none of the HC and only 1/6 (17%) of the SC.  SOB was not 
influenced by CPS (p=0.56) [data not shown].  SOB was unchanged when comparing 
aetiology, however, intensity of SOB as determined by rhodamine MFI was reduced in 
patients with autoimmune liver disease compared to other aetiologies of liver disease 
(p=0.016) [Figure 7-9].  Overall 60% (6/10) of patients with autoimmune cirrhosis were 
receiving immunomodulatory therapy: 1 patient was receiving azathioprine monotherapy; 
2 patients were on combination azathioprine and low dose prednisolone therapy (less than 
10mg prednisolone/day); 3 patients were receiving low dose prednisolone monotherapy.  
An additional 3 patients with autoimmune liver cirrhosis were receiving ursodeoxycholic 
acid and 1 patient was on no therapy.  The intensity of the SOB positively correlated with 
neutrophil resting and stimulated CD16 expression (p<0.001; r2=0.63) and (p<0.001; 
r2=0.46), respectively and resting CD11b expression (p=0.001; r2=0.55) [data not shown].   
Neutrophil E.coli stimulated burst (ESOB) was reduced in SC compared to HC 
(p=0.034) [Figure 7-5].  The percentage of neutrophils undergoing ESOB in patients with 
cirrhosis was not increased compared to HC (p=0.147) [Table 7-3 and Figure 7-5].  
However, the neutrophils bursting in stable cirrhosis produced significantly more ROS as 
measured by rhodamine MFI compared to HC (p=0.027) [Table 7-3].  Aetiology of liver 
disease (p=0.054), CPS (p=0.48) [Figure 7-6] and active alcohol consumption (p=0.603) 






FIGURE 7-9 BOX AND WHISKER PLOT OF NEUTROPHIL SPONTANEOUS 
RHODAMINE MEAN FLOURESCENCE INTENSITY DEPENDENT ON AETIOLOGY 
OF LIVER DISEASE.   
Differences between aetiology of liver disease were compared using the Mann-Whitney 
U test, *p<0.05. 
Abbreviations: ARLD: Alcohol-related liver disease; Autoimmune: Autoimmune liver 









7.3.4 Neutrophil chemotaxis 
Neutrophil chemotaxis was examined ex vivo in neutrophils from 7 patients with cirrhosis 
(3 stable cirrhosis; 4 HE; 1 AoCLF), one patient post-LT and two healthy control 
samples.  Patient characteristics are shown in Table 7-5.  In a normal neutrophil 
population the number of neutrophils showing reduced CD62L (L-selectin) expression 
would be expected to be less than 10-15%.  Neutrophil activation is associated with loss 
of CD62L through proteolytic cleavage by ADAM-17.  Increased neutrophil activation as 
determined by greater than 10% of the unstimulated neutrophil population showing 
reduced CD62L expression was observed in two patients with cirrhosis at baseline but not 
in a further cirrhotic.  Following fMLP stimulation greater than 90% of neutrophils would 
be expected to demonstrate reduced CD62L expression.   Neutrophil activation of >90% 
was achieved following fMLP stimulation in all patients with cirrhosis.  Neutrophil 
migration across the cell culture insert was unchanged following fMLP stimulation in 2 
patients with cirrhosis and a further sample showed a 7 fold-increase from baseline.  The 
ratio of migrated neutrophils in unstimulated and fMLP stimulated samples ranged from 
0.8-7.2 in the patients with cirrhosis and 15.5-26.4 in HC [Table 7-6].  Following LT 
neutrophil activation (low CD62L expression) at rest returned to <10% but a high level of 
unstimulated neutrophil migration was seen with an appropriate enhanced neutrophil 
migration response following fMLP exposure [Table 7-6].  Neutrophil chemotaxis was 
studied in 4 patients with HE and 1 patient with AoCLF.  Unfortunately, a patient sample 
from one of the HE patients spoiled so baseline CD62L expression could not be 
determined.  However, three patients (2 patients with HE and 1 patient with AoCLF) 
showed a reduced level of baseline neutrophil CD62L expression and higher levels of 
baseline migration across the cell culture insert.  Neutrophil chemotactic response to 
fMLP was impaired in patients with HE and AoCLF with migration decreasing in 4 
patients (3 x HE and 1 x AoCLF) and one patient with HE mounting only a modest 5-fold 
increase.  The ratio of migrated neutrophils in unstimulated and fMLP stimulated samples 
ranged from 0.04-4.7 in HE and AoCLF patients compared to 0.4-7.2 in cirrhosis and 

















Age 29-33 45 (22-65) 42 (29-49) 39 37 
Female 0 2 1 0 0 
Aetiology  HCV/ARLD/AIH ARLD ARLD PSC 
Child-Pugh class 
(A/B/C) 
 0/1/2 0/1/3 0/0/1 - 
Ascites  2 2 1 - 
Albumin (g/L)  38 (25-31) 29 (28-44) 19 23 
Bilirubin 
(µmol/L) 
 148 (55-369)  162 (133-350) 118 19 
WCC (x 109/L)  7.2 (3.8-8.3) 11.0 (2.4-12.2) 18.6 5.5 
CRP (mg/L)  51 (7-64) 29 (27-30) 123 29 
 AST (IU/L)  122 (54-123) 75 (66-94) 71 27 
Antibiotics  2 3 1 0 
Data presented as median (range) as appropriate. 
Abbreviations:   AoCLF: Acute-on-chronic liver failure; AIH: autoimmune hepatitis; AST: Aspartate 
Aminotransferase; ARLD: alcohol-related liver disease; CRP: C-reactive protein; HCV: Hepatitis C virus; 
HE: Hepatic encephalopathy; LT: liver transplantation; PSC: primary sclerosing cholangitis; WCC: white 
















Table 7-6 Neutrophil migration through cell culture inserts with a pore size of 3.0 µm 
























HC1 92 10 1427 93 15.5  
HC2 578 6 15261 95 26.4  
Cirrhosis1 106 21 82 92 0.8 79 
Cirrhosis2 5565 6 5157 99 0.9 94 
Cirrhosis3 239 14 1723 94 7.2 52 
HE1 525 9 57 95 0.13 112 
HE2 5588 24 325 85 0.66 53 
HE3 4716 25 177 97 0.04 186 
HE4 55  263 92 4.78 41 
AoCLF1 3650 6 175 97 0.05 70 
Cirrhosis 
Post-LT 
4507 9 20279 97 4.5 20 
ALF 3576 26 5514 99 1.54 40 
Absolute number of migrated neutrophils acquired by flow-cytometry after acquisition of 
2000 counting bead events.  Shaded cells indicate results not available. 
Abbreviations: ALF: acute liver failure; AoCLF: Acute-on-chronic liver failure; Formyl-
methionyl-leucyl-phenylalanine; HC: Healthy control; HE: Hepatic encephalopathy: LT; 

















7.3.5 Relationship between neutrophil function, plasma ammonia, serum 
sodium and biochemical parameters  
In all patients with cirrhosis, elevated plasma ammonia concentration correlated with 
decreasing NPA (p=0.01; r2=0.13) [Figure 7-10]. Decreasing NPA was also associated 
with declining neutrophil count (p<0.001; r2=0.185) and increasing IgG levels (p=0.041; 
r2=0.185) [Figure 7-15].  NPA was not influenced by serum sodium (p=0.98), serum CRP 
levels (p=0.054 or concomitant antibiotic prescription (p=0.217).  Other laboratory 
markers of inflammation and organ function as stated in Table 7-2 were compared to 
NPA but no association was found.   
Baseline clinical and laboratory parameters did not show any association with 
SOB or ESOB in patients with cirrhosis.     
 
7.3.6 Relationship between neutrophil function and plasma cytokines 
Plasma concentrations of pro- and anti-inflammatory cytokines were increased in patients 
with stable cirrhosis compared to levels seen in HC when comparing the natural 
logarithm (ln) of levels of TNFα, IL-1β, IL-6, IL-8, IL-10 and IL-17, p<0.01 for all 
comparisons) [Table 7-3].  Cytokine levels were also elevated in cirrhotic patients 
compared to SC.  Only levels of IL-6 and IL-8 in SC were significantly elevated above 
levels seen in HC (both p<0.05) suggesting that the intensity of the inflammatory 
response was greatest in the cirrhotic cohort.  Cytokine levels were elevated in a similar 
manner across all 3 Child-Pugh classes (A-C) suggesting the inflammatory response is 
independent of liver disease severity [data not shown].  
 Declining NPA correlated with increasing plasma IL-17 concentration ng/ml 
(p=0.031:r20.122) [Figure 7-11].   
Increased SOB correlated with increasing levels of lnTNFα (p=0.012; r2=0.13), 
lnIL-6 (p=0.006; r2=0.15), lnIL-8 (p=0.004; r2=017) and lnIL-10 (p=0.018; r2=0.115) 
[Figure 7-12]. Increased ESOB correlated with increasing levels of lnIL-1β (p=0.021; 
r2=0.13), InIL-8 (p=0.002; r2=0.2), InIL-10 (p=0.003; r2=0.17) and InIL-17 (p=0.005; 











FIGURE 7-10 ASSOCIATIONS BETWEEN NEUTROPHIL PHAGOCYTIC ACTIVITY AND 
NEUTROPHIL COUNT, GAMMA GLOBULIN AND PLASMA AMMONIA IN 












FIGURE 7-11 LOGISTIC REGRESSION ANALYSIS OF NEUTROPHIL PHAGOCYTIC 
ACTIVITY AND THE NATURAL LOGARITHM OF IL-17 CONCENTRATION NG/ML 









FIGURE 7-12 LOGISTIC REGRESSION ANALYSIS OF NEUTROPHIL SPONTANEOUS 
OXIDATIVE BURST AND PLASMA LEVELS OF PRO- / ANTI-INFLAMMATORY 
CYTOKINES IN PATIENTS WITH STABLE CIRRHOSIS. 
Increasing neutrophil SOB was associated with elevated levels of TNFα, IL-6, IL-8 and 







FIGURE 7-13 LOGISTIC REGRESSION ANALYSIS OF NEUTROPHIL E.COLI 
STIMULATED OXIDATIVE BURST AND PLASMA LEVELS OF PRO- / ANTI-
INFLAMMATORY CYTOKINES IN PATIENTS WITH STABLE CIRRHOSIS. 
Increasing neutrophil ESOB was associated with elevated levels IL-1β, IL-8, IL-10 and 















7.4  Study to determine the contribution of neutrophil dysfunction on the 
increased susceptibility to infection seen in patients with cirrhosis 
The number of patients undergoing LT, and 90-day and 1-year LT-free survival are 
shown in Table 7-3 and Figure 7-1. LT-free survival was significantly higher in the stable 
cirrhosis cohort compared to the AoCLF cohort both at 90-days, and at 1-year (p<0.01). 
Seven deaths (14%) occurred in the 12 months following recruitment in the stable 
cirrhosis cohort (5 deaths occurred within 90-days). Two patients developed MODS 
secondary to infection; 1 polymicrobial infection including candidaemia (endocarditis); 
and 1 bowel perforation. Five died following discharge (4 had been declined LT due to 
co-morbidity and 1 after alcohol recidivism). Median time to death was 77-days (range 
46-196). Sixteen patients in the cirrhosis cohort underwent successful LT after a median 
of 34-days (range 5-316). One patient developed HE during the same admission and 
underwent LT after 22 days. Six further episodes of infection occurred within 90-days [3 
bacteraemias, 1 urinary tract infection and 2 SBP].  
In the AoCLF group eight deaths occurred at a median of 12 days (range 1-81).  
Seven deaths occurred due to MODS secondary to bacterial/fungal bacteraemia.  One 
patient developed peritonitis due to a diverticular perforation and was managed with 
surgical resection and survived to discharge after a 10-day ICU stay. Three of the AoCLF 
cohort underwent successful LT after 1, 3 and 45-days (3 died on the waiting list). 
Overall in all the cirrhotic patients recruited, 26% (n=19) either had infection at 
the time of sampling (AoCLF) or developed an episode in the subsequent 90-days.  
Neutrophil function indices were good predictors of outcome and survival in both 
stable cirrhosis and AoCLF. Neutrophil SOB on recruitment was a predictor of survival at 
90-days and 1-year from baseline on ROC curve analysis AUROC 0.81 (95% CI 0.64-
0.97); p=0.026 and 0.76 (95% CI 0.61-0.91); p=0.03 respectively [Figure 7-14]. Using 
SOB ≥12% as a cut-off predicted 90-day mortality with 80% sensitivity and 71% 
specificity. Furthermore, evaluating 90-day survival using a Kaplan-Meier and log rank 
analysis, SOB ≥12% differentiated survivors from non survivors (p=0.015) [Figure 7-14] 
but just failed to reach significance at 1-year (p=0.053). 
 Neutrophil phagocytic capacity (NPC), as determined by the FITC MFI, 
predicted 90-day survival in the cirrhosis cohort. On ROC curve analysis AUROC 0.83 
(95% CI 0.68-0.97); p=0.021 and using NPC ≥ 19167 as a cut-off predicted 90-day 
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survival with 78% sensitivity and 80% specificity; p=0.01 on Kaplan-Meier log-rank 
analysis and 1-year survival p<0.001 [Figure 7.15].  
NPA predicted a composite end-point of active infection and subsequent 
development of infection within 90-days of sampling on ROC curve analysis AUROC 
0.71 (95% CI 0.56-0.86); p=0.011.  Using NPA<67.2% as a cut-off was predictive of 










FIGURE 7-14 AREA UNDER THE RECEIVER OPERATOR CURVES [AUROC] (A) AND 
KAPLAN-MEIER SURVIVAL ANALYSES (B) AS DEFINED BY ADMISSION 
NEUTROPHIL RESTING OXIDATIVE BURST IN PATIENTS WITH STABLE 
CIRRHOSIS.  
SOB was a predictor of poor outcome with an AUROC of 0.81 (95% CI 0.68-0.97) and using 
neutrophil SOB>12% as a cut-off gives a sensitivity of 80% and specificity of 71% with an 
increased 90-day mortality demonstrated on Kaplan-Meier log-rank analysis (p=0.015).   
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FIGURE 7-15 AREA UNDER THE RECEIVER OPERATOR CURVE [AUROC] (A) AND 
KAPLAN-MEIER SURVIVAL ANALYSIS (B) AS DEFINED BY ADMISSION 
NEUTROPHIL PHAGOCYTIC CAPACITY [NPC] IN PATIENTS WITH STABLE 
CIRRHOSIS. 
NPC was a predictor of poor outcome with AUROC of 0.84 (95% CI 0.68-0.97) and using NPC < 
19,176 as a cut-off gives a sensitivity of 80% and specificity of 86% with a corresponding 
increased 90-day mortality demonstrated on Kaplan-Meier log-rank analysis (p=0.01). 
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7.5 Study to determine the impact of developing hepatic encephalopathy 
on neutrophil function in cirrhosis 
Patients with HE showed a number of differences in their baseline characteristics when 
compared to the stable cirrhosis cohort [Tables 7-1 and 7-2].  In the HE cohort the 
predominant aetiology of liver disease was ARLD (69%), 77% of patients had low grade 
HE (West-Haven I-II) and 23% had high grade (West-Haven III-IV). (Harold and Milton, 
1979) The majority were receiving empirical antibiotics (23% had active infection) and 
90-day transplant free survival was inferior when compared to patients with stable 
cirrhosis (45% v’s 69%, p<0.05).  When comparing the HE cohort to patients with stable 
cirrhosis baseline laboratory parameters of inflammation, renal function and serum 
sodium were similar, however, patients with HE had an increased baseline INR compared 
to patients with stable cirrhosis, p<0.05, and as a consequence liver failure scores were 
increased; CPS (p<0.01); MELD (p<0.05); and UKELD (p<0.05) [Table 7-2].  
Interestingly, no difference in plasma arterial ammonia concentration was observed 
between patients with stable cirrhosis and those with HE (p=0.786).  
 Ongoing impairment of neutrophil phagocytosis was observed following the 
development of HE with impaired NPA compared to HC (p=0.005).  [Figure 7-16 and 7-
17 and Table 7-7].  There was enhanced spontaneous production of ROS (SOB) from 
neutrophils in HE with elevated SOB compared to patients with stable cirrhosis (p=0.032) 
[Figures 7-16 and 7-17].  ESOB was unchanged in HE compared to HC and stable 
cirrhosis.  In the HE cohort an association was observed between increasing levels of 
bilirubin and deteriorating NPA (p=0.017, r2=0.45) [Figure 7-19].  Increased neutrophil 
SOB was associated with increasing neutrophil cell volume assessed by neutrophil 
forward scatter Geometric MFI (p=0.012, r2=0.69) [Figure 7-19].  
7.6 Study to determine the impact of developing acute-on-chronic liver 
failure on neutrophil function in cirrhosis 
In the AoCLF cohort the aetiology of liver disease was predominantly ARLD or 
autoimmune liver diseases.  The majority of AoCLF patients had DRA and were 
receiving antibiotics (92%) with active infection being seen in 58%.  The 90-day 
transplant free survival was significantly inferior to patients with stable cirrhosis (8% 
versus 69%, p<0.001).  Patients with AoCLF exhibited significant increases in 
 226 
inflammatory markers (neutrophil count and CRP both p<0.01); hepatic function (serum 
bilirubin, INR, AST, all p<0.01); and renal function (serum creatinine, p<0.01) compared 
to stable cirrhosis [Table 7-2].  Consequentially patients with AoCLF demonstrated 
higher baseline liver failure (CPS, MELD and UKELD, all P<0.01) and multi-organ 
failure scores (APACHEII and SOFA, both P<0.01) [Table 7-2].  No difference in plasma 
arterial ammonia concentration was observed between patients with stable cirrhosis and 
those with AoCLF (p=0.786). 
Ongoing impairment of neutrophil phagocytosis was seen following the 
development of AoCLF with impaired NPA compared to HC (p=0.017) [Figure 7-16 and 
7-17 and Table 7-7].  There was enhanced spontaneous production of ROS (SOB) from 
neutrophils in AoCLF with elevated SOB compared to patients with stable cirrhosis 
(p=0.037) [Figures 7-16 and 7-17].  Ex-vivo neutrophils retained the capacity to generate 
an oxidative burst after E.coli challenge following the development of AoCLF.  The 
trajectory of neutrophil phagocytic dysfunction in patients with stable cirrhosis following 
the development in infection and subsequent deterioration to AoCLF, was one of a 
progressive decline over time culminating in profound neutrophil malfunction.  This 
predisposed the patient to secondary infection, MODS and invariably a terminal decline 
[Figure 7-18].  
In patients with AoCLF no correlation was observed between NPA, neutrophil 
oxidative burst and plasma ammonia concentration.  However, reduced NPA was 
associated with increasing liver transaminases (AST p=0.01; r2=0.48) and APACHE II 






FIGURE 7-16 NEUTROPHIL FUNCTION IN PATIENTS WITH STABLE CIRRHOSIS 
COMPARED TO PATIENTS WITH CIRRHOSIS FOLLOWING THE DEVELOPMENT 
OF HEPATIC ENCEPHALOPATHY (HE) AND ACUTE-ON-CHRONIC LIVER 
FAILURE (AOCLF).   
Groups were compared using the Kruskal-Wallis test with Dunn’s multiple comparison test, 
*p<0.05.  Patients with HE and AoCLF had an enhanced resting production of reactive oxygen 

















Table 7-7 Neutrophil function in healthy controls and patients with cirrhosis complicated 
by hepatic encephalopathy and acute-on-chronic liver failure.   
Neutrophil function 




















































































Data presented as median percentage (inter quartile range) of gated neutrophil population 
undergoing phagocytosis of FITC-labelled E.coli.  p-values calculated using the Kruskal-





FIGURE 7-17 FLOW CYTOMETER PLOTS OF NEUTROPHIL FUNCTION INDICES IN A PATIENT WITH HEPATIC ENCEPHALOPATHY AND A 
PATIENT WITH ACUTE-ON-CHRONIC LIVER FAILURE 
Abbreviations: fMLP: Formyl-methionyl-leucyl-phenylalanine; PMA: Phorbol myristate acetate; CD16 PE: Cluster of differentiation 16 – 




FIGURE 7-18 DYNAMICS OF NEUTROPHIL PHAGOCYTIC ACTIVITY (%) COMPARED 
TO BASELINE FOLLOWING THE DEVELOPMENT OF INFECTION AND/OR 

















FIGURE 7-19 LOGISTIC REGRESSION ANALYSIS OF NEUTROPHIL PHAGOCYTIC 
ACTIVITY VERSUS SERUM BILIRUBIN CONCENTRATION IN PATIENTS WITH 
HEPATIC ENCEPHALOPATHY. 
Graph shows association between declining NPA versus increasing serum bilirubin 
concentration (p=0.017) in patients with hepatic encephalopathy.   
 
 
FIGURE 7-20 LOGISTIC REGRESSION ANALYSIS OF NEUTROPHIL PHAGOCYTIC 
ACTIVITY VERSUS SERUM ASPARTATE AMINOTRANSFERASE AND APACHE II 
SCORE IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE. 
Graph shows association between declining NPA and increasing serum AST 
concentration (p=0.03) and APACHE II score (p=0.01) in patients with acute-on-chronic 





7.7 Impact of liver transplantation on neutrophil function in cirrhosis  
In the cirrhosis cohort 16 patients underwent LT after a median of 34 days (range 5-315).  
Pre-LT the median plasma ammonia concentration was 70 µmol/L (IQR 52-108) and this 
dropped to a median of 25 µmol/L (IQR 8-10) 72-hours post-LT (p<0.01).  Patients were 
assessed at a median of 9.5 days post LT (IQR 5.8-14.5).  However, at the time of 
assessment serum levels of cytokines TNFα, IL-1β, IL-6, IL-10 and IL-17 were 
unchanged compared to baseline with only levels of IL-8 showing a significant reduction 
[data not shown].  There was a tendency towards improvement in NPA and resting and E. 
coli stimulated ROS production in ex vivo neutrophils 72-hours post-LT [Figures 7-21 
and 7-22].  The response was highly variable with some patients showing a marked 
improvement especially in those with the most severe impairment, whilst the converse 
was true in patients who had normal NPA pre-LT.  Overall NPA change post-LT failed to 
reach significance using the Wilcoxon matched pairs test suggesting ongoing impairment 
in neutrophil phagocytic function possibly driven by the persisting inflammatory response 
probably as a consequence of major surgical insult and hepatic reperfusion injury 
independent of plasma ammonia levels.   
 
 
FIGURE 7-21 CHANGES IN EX VIVO NEUTROPHIL PHAGOCYTIC ACTIVITY 
FOLLOWING LIVER TRANSPLANTATION IN PATIENTS WITH CIRRHOSIS.  




FIGURE 7-22 FLOW CYTOMETER PLOTS OF NEUTROPHIL FUNCTION INDICES OF A PATIENT WITH CIRRHOSIS BEFORE AND FOLLOWING 
SUCESSFUL LIVER TRANSPLANTATION. 
Abbreviations: fMLP: Formyl-methionyl-leucyl-phenylalanine; PMA: Phorbol myristate acetate; CD16 PE: Cluster of differentiation 16 – 
Phycoerytherin; FITC: Fluorescein isothiocyanate. 
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7.8 Impact of organ-targeted therapies on neutrophil function  
A reduction in serum ammonia was not achieved in patients on CVVH in either the CLD 
[Table 7-6] or the ALF cohorts and no significant difference was observed in neutrophil 
phagocytosis or oxidative burst parameters between the 2 cohorts.  Patients on CVVH 
were generally more unwell as assessed by increasing APACHE II and SOFA scores even 
when adjusted for the presence of renal failure (both P<0.001) as well as increasing HE 
grade, vasopressor requirement and mechanical ventilation.   
 A single 51-year old patient with ALF secondary to acetaminophen overdose, 
requiring mechanical ventilation for high grade HE, underwent plasmapheresis.  The 
patient was declined for LT due to psychiatric co-morbidity. Following 72-hours of 
plasmapheresis a reduction in arterial ammonia from 159 mmol/L to 66 mmol/L was 
achieved; with this ex vivo NPA improved from 69.3 to 94.0%.  A reduction in levels of 
TNFα, IL-1β, IL-10, IL-17 were seen but not IL-6.  The patient avoided further septic 
insult and survived to discharge.   Plasmapheresis is therefore likely to be a more 
effective than conventional CVVH in reducing serum ammonia as well as removing other 
circulating humoral factors such as PAMPs, DAMPs and plasma cytokines.
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Table 7-8 Effect of continuous veno-venous haemofiltration (CVVH) on plasma 
ammonia, neutrophil function and plasma cytokine concentrations in patients with 
cirrhosis complicated by acute-on-chronic liver failure. 












64 (52-69) 68 (43-75) 0.75 
Neutrophil spontaneous 
oxidative burst (%) 
 
10 (5-38) 24 (6-55) 0.71 
Neutrophil E.coli 
stimulated burst (%) 
 
85 (81-92) 87 (74-96) 1.00 
Neutrophil resting forward 
scatter geometric MFI 
 





TNFα pg/mL median 
(IQR) 
 
63 (48-225) 99 (44-178) 0.83 
IL-1β pg/mL median (IQR) 
 
7333 (1617-27841) 17241 (1773-73433) 0.81 
IL-6 pg/mL median (IQR) 
 
66 (44-168) 202 (73-2480) 0.21 
IL-8 pg/mL median (IQR) 
 
185 (153-616) 433 (197-618) 0.83 
IL-10 pg/mL median (IQR) 
 
155 (74-296) 766 (233-3268) 0.25 
IL-17 pg/mL median (IQR) 
 










7.9 Discussion  
These data show that circulating neutrophils in patients with cirrhosis display an activated 
phenotype (increased surface expression of CD11b and loss of CD62L) with a reduced 
capacity to phagocytose microbes and impairment of chemotactic migration before and 
after fMLP stimulation.  An elevated spontaneous production of ROS from circulating 
neutrophils is present in a third of cirrhotic patients and this deteriorates further following 
the development of HE and AoCLF suggesting a putative role in the development of 
organ failure.  Furthermore, circulating neutrophil dysfunction in cirrhosis predicts 
infection and 90-day survival in stable cirrhosis.   
An enhanced expression of CD11b, which in combination with CD18 forms the 
dimeric Mac-1, was found on the surface of circulating neutrophils in cirrhosis.  In 
addition circulating neutrophils show a loss of surface CD62L (L-selectin), but 
unchanged levels of CD16, indicating a primed neutrophil phenotype. These findings 
mirror those of Rosenbloom et al who showed an increasing surface density and avidity 
of the complement receptors CD11b and CD35 on circulating neutrophils in cirrhosis 
correlating with increasing serum IL-6 levels.    (Rosenbloom et al., 1995)  CD11b levels 
correlated with the intensity of SOB and engagement of CD11b on neutrophils increased 
ROS production. (Nathan et al., 1989) Determination of an expanded range of neutrophil 
surface receptors would help further characterise neutrophil phenotype and confirm a 
sepsis-like phenotype but in addition might identify patients at increased risk of 
developing infections such as SBP and dynamic changes in neutrophil phenotype might 
serve as biomarkers to prognosticate.  Such work should include CD62L expression in an 
expanded cohort of patients, β-integrins, chemokine receptors e.g. CXC2, CD49d, CD64 
and TLRs.      
The declining NPA observed in patients with cirrhosis was found to be associated 
with increasing severity of liver disease as measured by Child-Pugh class, supporting 
previous findings of other groups. (Rajkovic and Williams, 1986, Tritto et al., 2011) 
Nevertheless, phagocytic dysfunction to some degree appears to be a universal 
phenomenon observed in most patients with cirrhosis.  
 Other groups have reported neutrophil phagocytosis to be normal (Kirsch et al., 
2000, Panasiuk et al., 2005) or even increased in cirrhosis. (Neugebauer et al., 2008) The 
apparent discrepancy in observations between studies may be explained by enhanced 
rates of neutrophil apoptosis due to poor handling, sample contamination with endotoxin 
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or the use of ammonia chloride for red cell lysis. In addition it is important to exclude 
cigarette smokers and those who have undertaken vigorous exercise in the last 24 hours 
from the healthy control cohort as these factors can impair NPA/NPC.   
Overall we report a reduction in the percentage of neutrophils undergoing 
phagocytosis (phagocytic activity) but Tritto et al mirror our findings using the geometric 
median uptake of E.coli by neutrophils (E.coli GMFI [phagocytic capacity]) showing that 
either measure is valid.  
Paradoxically, our data suggests active alcohol consumers have higher levels of 
NPA than abstinent drinkers with comparable severity of liver disease, which may be 
explained by enhanced neutrophil priming through increased bacterial translocation from 
the gut. (Bode et al., 1987).  
The observed association between elevated plasma ammonia concentration and 
impaired NPA replicates Dr Shawcross and colleagues previous observations. (Shawcross 
et al., 2008a) Acute increases in plasma arterial ammonia concentration induced by a 
simulated upper gastrointestinal bleed have been shown to induce neutrophil swelling and 
phagocytic dysfunction in patients with stable cirrhosis. The adverse impact of ammonia 
exposure on neutrophil function can be abrogated ex vivo following incubation of the 
neutrophils with an agonist of the p38-MAPK pathway. (Shawcross et al., 2008a) It has 
been postulated that ammonia-induced neutrophil swelling induces phosphorylation of 
p38-MAPK which serves as an important cell osmoregulator. (vom Dahl et al., 2001) 
p38-MAPK is also upregulated during neutrophil priming and activation, with down-
stream effects including the promotion of apoptosis and the activation of pro-
inflammatory transcription factors. 
Further support of a central-role for activated p38-MAPK in NPA comes from the 
observation that in patients with diuretic intolerant/resistant ascites the concomitant use of 
propranolol was associated with worsening of NPA. This may offer an explanation as to 
why Serste and colleagues recently identified increased mortality in patients with 
refractory ascites treated with propranolol. (Serste et al., 2010) Propranolol increases 
neutrophil motility by promoting increased intracellular cyclic GMP activity (Anderson 
and van Rensburg, 1979) and thus might be postulated to have a beneficial effect in 
cirrhosis.  It can however increase p38-MAPK phosphorylation and therefore potentially 
further suppress neutrophil phagocytic function. (Busse and Sosman, 1984) Reduced 
NPA in concert with increased bacterial DNA translocation from the gut into the portal 
vein in patients with refractory ascites might thereby culminate in hepatic endothelial 
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dysfunction, systemic endotoxemia, and resultant systemic inflammatory response. 
(Bellot et al., 2010) 
The finding however, that elevated serum transaminases and hyperbilirubinaemia 
are associated with higher plasma levels of IL-17 and a lower phagocytic capability in 
AoCLF supports hepatic inflammation as being an important driver of neutrophil 
phagocytic dysfunction. IL-17 is a critical mediator of neutrophil recruitment. IL-17 
secretion from effector CD4+ T-cells is thought to be an important mediator of innate 
immune function and the development of chronic inflammation (Qian et al., 2010) and 
IL-17 secreting hepatic cell infiltrates have been shown to be present in patients with 
acute alcoholic hepatitis. (Lemmers et al., 2009) 
The finding of an enhanced spontaneous production of ROS from circulating 
neutrophils in patients who go on to develop infection and organ dysfunction or HE may 
hold the key to understanding why some patients with cirrhosis are susceptible to 
developing MODS and HE. Indeed, cirrhotic patients who have increased basal 
production of ROS appear to be at the highest risk for developing complications and 
MODS.  This is likely to be driven by systemic pro-inflammatory milieu that bathes these 
neutrophils with elevated levels of TNFα, IL-6, IL-8 and IL-10 generated principally as a 
consequence of bacterial infection, with complicating infection being seen in 23% of 
patients with HE and 58% of patients with AoCLF, enhanced bacterial translocation of 
PAMPs across a leaky gut (Neugebauer et al., 2008) or from ‘sterile’ hepatic 
inflammation (DAMPs such as HMGB-1) may explain other cases.  These findings 
support the hypothesis that bacterial driven (PAMPs) or ‘sterile’ hepatic inflammation 
induce a dysfunctional response in circulating neutrophils and through homing to other 
endothelial beds can induce oxidative stress and organ-injury.  Similar findings have been 
shown in patients with acute alcoholic hepatitis where an increase in SOB is seen which 
correlates with severity of liver disease. (Parlesak et al., 2003, Mookerjee et al., 2007b) 
Interestingly the phenomenon of increased SOB appears to be independent of plasma 
ammonia levels.  There is a suggestion that immunosuppressive therapies may reduce 
neutrophil SOB as patients with autoimmune liver disease, many of whom were 
immunosuppressed, had reduced SOB compared to other aetiologies of liver disease and 
the effect of corticosteroid therapy in patients with acute alcoholic hepatitis deserve 
further study.   
Perhaps the most powerful observation of this study is that baseline circulating 
neutrophil dysfunction is a robust predictor of outcome and 90-day and 1-year survival. 
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Baseline resting neutrophil OB of ≥12% predicted 90-day survival with an AUROC of 
0.81, with survivors at 90-days having a significantly lower resting OB. Impaired NPC is 
also an important determinant of 90-day mortality with an AUROC of 0.83 with survivors 
at 90-days and 1-year having a significantly higher NPC. This implies that neutrophil 
biomarkers can predict medium-term (90-day) and longer-term (1-year) outcome in 
patients with stable cirrhosis. This also supports the findings of Mookerjee and colleagues 
who showed neutrophil dysfunction to be an important outcome predictor in acute 
alcoholic hepatitis. (Mookerjee et al., 2007a)  
Overall the number of samples analysed for chemotaxis was small so it was not 
possible to draw firm statistically significant conclusions.  Intriguingly, a heterogeneous 
response was seen with a number of patients with cirrhosis, either stable or complicated 
by HE or AoCLF, showing either baseline neutrophil activation or increased migration 
with a paradoxical defective migration ability following exposure to the chemokine 
fMLP.  No apparent association with plasma arterial ammonia concentration was seen.  
This supports earlier findings by Fiuza et al who showed an impaired ability of 
neutrophils in patients with cirrhosis to migrate using a skin window technique.  (Fiuza et 
al., 2000) 
It is interesting to note that neutrophil phagocytosis shows ongoing derangement 
72-hours post-LT associated with persisting elevations in levels of pro- and anti-
inflammatory cytokines.  The ongoing neutrophil dysfunction may be multi-factorial 
including persisting neutrophil maladaptation due to cytokines, wound repair, hepatic 
ischaemia-reperfusion injury and immunosuppression.  The persistence of phagocytic 
dysfunction in the early post-transplant phase may explain the ongoing predisposition to 
infection.    
It is surprising that haemodialysis does not appear to have an effect on neutrophil 
phagocytic dysfunction; however, our study was underpowered to detect this change.  It 
has been shown that CVVH can reduce plasma ammonia levels with greater ammonia 
clearance achieved with higher filtration volumes.  (Slack et al., 2014) So it may be too 
early to dismiss this approach which merits further investigation.  Other therapies such as 
albumin dialysis may in addition modulate neutrophil function and mandate investigation.   
The evaluation of therapies that directly or indirectly target neutrophil dysfunction 
in patients with cirrhosis may therefore have a profound impact on reducing the inevitable 

















Chapter 8 - The role of the p38-mitogen activated 
protein kinase pathway in mediating circulating 















Serum ammonia levels are raised in ALF and liver cirrhosis due to a reduced urea 
synthesis capacity and porto-caval shunting.  It has recently been shown by Shawcross et 
al. that ammonia at physiological concentrations commonly seen in acute and chronic 
liver failure causes neutrophil swelling, leading to a reduced phagocytic capacity and high 
spontaneous OB (Shawcross et al., 2008b).  These results were replicated in patients with 
cirrhosis with induced hyperammonemia suggesting a direct toxic effect of ammonia on 
neutrophils; an effect exacerbated by the presence of hyponatraemia.  
 Ammonia has also been shown to depress neutrophil chemotaxis (Coppi and 
Niederman, 1989)  and can impair neutrophil energy metabolism, through inhibition of 
phosphate-dependent glutaminase (Sbarra and Karnovsky, 1959)  
 The susceptibility of neutrophils to ammonia is used to the advantage of some 
microorganisms and has been shown to be a virulence factor in helicobacter pylori 
infection and human periodontal infection. (Mayo et al., 1997, Niederman et al., 1990)    
 The p38-MAPK intracellular signalling pathway appears to be important in 
mediating this ammonia-induced dysfunction.  Phosphorylation of p38-MAPK is a 
critical step in the neutrophil response to stress: it functions as a key osmoregulator, 
regulator of inflammatory gene expression (e.g. TNFα, IL-1 and IL-12), promotes 
phagocytosis and can lead to activation of neutrophil apoptotic pathways. (Zu et al., 1998, 
vom Dahl et al., 2001, Zarubin and Han, 2005) Activation of p38-MAPK signalling 
occurs through a kinase cascade following surface receptor ligation.  Neutrophil p38-
MAPK appears to be specifically activated by TNFα, GM-CSF, fMLP, PMA and 
inomycin. (Doyle et al., 2004, Zu et al., 1998, Hidari et al., 1997)  SB203580 is a specific 
inhibitor of p38-MAPK activation and reduces the production of IL-8 and superoxide 
following neutrophil stimulation by TNFα (Zu et al., 1998) in addition to reducing 
neutrophil chemotaxis in response to fMLP.  
The hypothesis that ammonia impairs neutrophil function by inducing cell-
swelling resulting in elevated levels of phosphorylated p38-MAPK (the activated form) 
leading to activation of homeostatic mechanisms to correct cell swelling and induction of 
transcription of inflammatory genes within neutrophils [Figure 4-1] was tested indirectly 
by correlating blood ammonia concentration with neutrophil swelling assessed through 
flow-cytometry forward scatter, using a method previously reported for hepatocyte cell 
volume regulation, (Carini et al., 1999) and directly by measuring the neutrophil cross-
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sectional area utilising  transmission electron-microscopy (TEM).  The effects of p38-
MAPK modulators on neutrophil function and evaluation of activated and total p38-



















FIGURE 8-1 NEUTROPHIL CROSS-SECTIONAL AREA DETERMINED BY TRANSMISSION ELECTRON MICROSCOPY ON ISOLATED 
NEUTROPHILS FROM PATIENTS WITH CIRRHOSIS (N=3) AND HEALTHY CONTROLS (N=2).  






FIGURE 8-2 TRANSMISSION ELECTRON MICROGRAPH OF A RESTING NEUTROPHIL 
ISOLATED FROM A HEALTHY CONTROL, (A - 4800X AND B - 9300X)  
These healthy neutrophils have a spherical shape, multi-lobed nucleus, dense cytoplasm 






FIGURE 8-3 TRANSMISSION ELECTRON MICROGRAPHS OF A NEUTROPHIL 
PSEUDOPODIUM ENVELOPING OPSONISED E.COLI ISOLATED FROM A 






FIGURE 8-4 TRANSMISSION ELECTRON MICROGRAPH OF RESTING NEUTROPHILS 
ISOLATED FROM A PATIENT WITH ACUTE ALCOHOLIC HEPATITIS (890X) 
This micrograph shows a loss of spherical shape with a highly granular cytoplasm and 







FIGURE 8.5 TRANSMISSION ELECTRON MICROGRAPH OF A NEUTROPHIL 
ISOLATED FROM A PATIENT WITH SUB-ACUTE LIVER FAILURE (4800X)   
This micrograph shows extensive vacuolisation, pale cytoplasm and reduction in 
cytoplasmic granules in a patient with sub-acute liver failure secondary to hydralazine.
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FIGURE 8-6 TRANSMISSION ELECTRON MICROGRAPH OF A NEUTROPHIL 
ISOLATED FROM A PATIENT WITH CHILD-PUGH B ALCOHOL-RELATED 
CIRRHOSIS (ABSTINENT) FOLLOWING PHAGOCYTOSIS OF OPSONISED E.COLI.  
(1900X) 




FIGURE 8-7 TRANSMISSION ELECTRON MICROGRAPH OF A NEUTROPHIL 
ISOLATED FROM A PATIENT WITH CHILD-PUGH B ALCOHOL-RELATED 
CIRRHOSIS (ACTIVE DRINKER) FOLLOWING EXPOSURE TO OPSONISED E.COLI. 
(2900X) 
This micrograph shows neutrophil phagosomes surrounded by granules (toxic 











FIGURE 8-8 GRAPH SHOWING AVERAGE NEUTROPHIL SURFACE AREA COMPARED 
TO PLASMA AMMONIA IN A HEALTHY CONTROL AND 2 PATIENTS WITH 
CIRRHOSIS. 
Measurements of 12 representative neutrophils were obtained for each sample with bars 
showing the mean and standard error of the readings.   
Sample 1 - healthy control (plasma ammonia concentration 13µmol/L); Sample 2 - 
patient with cirrhosis and low ammonia concentration (35µmol/L); Sample 3 - patient 
with cirrhosis and high ammonia concentration (135µmol/L).  Differences between the 
healthy control and patients were calculated using the Kruskal-Wallis test with Dunn’s 
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8.2 Study to determine whether ammonia contributes to neutrophil 
swelling and dysfunction through changes in the p38-MAPK pathway 
Ten ALF patients, with a median SOFA score of 16 (IQR 14-17) and APACHE II score 
of 22 (IQR 19-25), and ten patients with cirrhosis, with a median MELD score 27 (IQR 
16-38) had blood drawn and incubated with neutrophil modulators. The median arterial 
ammonia level in the ALF group was 88 µmol (IQR 44-158; 9/10 on haemofiltration) and 
cirrhosis group was 62 µmol (49-99) µmol/L. Baseline NPA was 67% (IQR 54-75) in the 
ALF group and 72% (39-84) in the CLF group compared to >85% in healthy controls.  
Ex vivo incubation of isolated neutrophils with 200µmol/L ammonium chloride 
for 90-minutes taken from these patients reduced NPA by 7.3 % (IQR 3.3-14.3, p<0.05) 
[Figure 8-8].  The p38-MAPK agonist isoproterenol [Sigma, UK] (2 µmol/L) 
significantly abrogated the ammonia-induced phagocytic impairment and improved 
bactericidal capacity (p<0.007).  The specific p38-MAPK antagonist SB203580 
[Calbiochem, UK] (40 µmol/L) however, exacerbated the ammonia-induced reduction in 
neutrophil phagocytic activity by a median of 5.2% (IQR 1.4-15.6); p=0.003 [Figure 8-8].  
Flow cytometer plots showing the changes in neutrophil characteristics following 
exposure to p38-MAPK modulators are shown in Figure 8-9.  There appears to be a 
robust dose response relationship between the SB203580 induced suppression of NPA 
and the enhancement of NPA seen with isoproterenol [Figure 8-10]. 
 Ammonia was shown to supress both PMA and E.coli stimulated SOB but 
interestingly appeared to be a more potent inhibitor of PMA-induced burst than E. coli 
SOB [Figure 8-11].  PMA is known to activate p38-MAPK following activation of PKC 
and subsequent phosphorylation and ammonia’s effects therefore appears to be specific to 
this pathway whereas E. coli can still generate a burst via alternative pathways.  
Isoproterenol (2 µmol/L) reversed the ammonia-induced increase in neutrophil SOB 
(p<0.001) and at the same time reduced the ability of neutrophils to generate an ESOB 
(p<0.05) [Figure 8-11 and 8-12].   SB203580 (40 µmol/L) did not appear to further 





FIGURE 8-9 THE EFFECT OF A 90-MINUTE PRE-INCUBATION WITH AMMONIA WITH 
AND WITHOUT THE P38-MAPK MODULATORS SB203580 AND ISOPROTORENOL 
ON NEUTROPHIL PHAGOCYTIC ACTIVITY IN 10 PATIENTS WITH CIRRHOSIS 





FIGURE 8-10 FLOW PLOTS OF NEUTROPHIL PHAGOCYTOSIS FOLLOWING 90-
MINUTE INCUBATION WITH P38-MAPK MODULATORS. 
Granulocytes were gated on forward and side scatter characteristics and neutrophils 
identified by labelling with CD16-PE.  Neutrophil phagocytosis was determined by 
uptake of opsonised E.coli labelled with FITC. Prior to neutrophil function testing 
neutrophils were pre-incubated for 90-minute with: A- phosphate buffered saline 
(control); B- Ammonium chloride 200 µmol/L; C- SB203580 40 µmol/L (Calbiochem, 
UK); D-Isoproterenol 2 µmol/L (Sigma, UK). 
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FIGURE 8-11 EFFECT OF INCREASING CONCENTRATIONS OF THE P38-MAPK 





FIGURE 8-12 FLOW-PLOTS OF NEUTROPHIL PHORBOL MYRISTATE ACETATE AND E.COLI STIMULATED OXIDATIVE BURST 
FOLLOWING 90-MINUTE INCUBATION WITH PHOSPHATE BUFFERED SALINE AND INCREASING CONCENTRATIONS OF 
AMMONIUM CHLORIDE. 
These plots show that there is an early defect in PMA-induced oxidative burst at ammonium chloride concentrations of 200 µmol/L but E.coli 
stimulated oxidative burst shows a progressive decline as ammonium chloride concentration increases.  This suggests E. coli activates neutrophil 






FIGURE 8-13 THE EFFECT OF A 90-MINUTE PRE-INCUBATION WITH AMMONIA AND 
THE P38-MAPK MODULATORS SB203580 AND ISOPROTERENOL ON 
NEUTROPHIL RESTING (A) AND E.COLI STIMULATED (B) OXIDATIVE BURST IN 





8.3 Study to investigate activation of the p38-MAPK pathway in 
neutrophils isolated from patients with liver failure and the impact of 
p38-MAPK modulation. 
Cytokine bead array assays of neutrophils were performed after a 90-minute incubation 
with PBS or 200µmol/L ammonium chloride and either PBS or one of the p38-MAPK 
modulators isoproterenol (2 µmol/L) and SB203580 (40 µmol/L).  Samples had been 
stored at -80°C prior to the cytokine bead array assay being performed.  Three healthy 
control samples, 5 patients with cirrhosis, 4 patients with ALF and one patient post-LT 
for ALF due to paracetamol were analysed.  Samples were analysed on 2 separate 
occasions on the first there was a problem with the set-up of data acquisition on the flow 
cytometer as the PMT voltages were not set correctly and so the gates could not be 
correctly set for the plex analysis.  On the second occasion excellent standard curves of 
the housekeeper protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
phosphorylated and total p38-MAPK were achieved [Figure 8-15].  However, when 
analysis of samples was performed the housekeeper protein GAPDH was undetectable 
and the yield of both total and phosphorylated p38 was very low suggesting that the 
samples had deteriorated following storage [Table 8-1].  Unfortunately there was 
insufficient stored sample for further analysis and therefore no meaningful analysis of 











Table 8-1 Cytokine bead array of neutrophils from healthy controls and patients with 



































HC 11.5 2.1 5.7 2.0 4.4 3.4 3.5 2.0 
Cirrhosis 12.8 3.6 14.1 3.2 5.0 3.1 4.6 3.4 
ALF 17.1 3.9 11.8 3.0 4.9 2.9 4.3 3.2 
Post-LT 12.3 3.5 10.4 2.5 3.7 3.3 3.9 1.7 
 
A low yield of total and phosphorylated p38-MAPK (U/mL) was obtained likely 
representing background activity of the antibodies used in the experiment.   
Abbreviations: HC: Healthy control; ALF: Acute liver failure; LT: Liver transplantation; 

























FIGURE 8-14 STANDARD CURVES OBTAINED FOR GADPH, TOTAL AND 
PHOSPHORYLATED P38-MAPK USING CYTOKINE BEAD ARRAY 




These data show compelling evidence that neutrophils in patients with liver disease 
develop a ‘swollen’ phenotype with increased cell volume correlating with plasma 
ammonia levels.  Furthermore, transmission electron microscopy studies have revealed 
profound abnormalities in the neutrophil ultrastructure with loss of rounded shape, 
extensive vacuolisation, pale cytoplasm and paucity of mitochondria.  These findings in 
the setting of liver disease are novel and reveal that the neutrophils exist in a ‘stressed’ 
state probably as a consequence of DNA damage in response to elevated levels of ROS.  
This appearance is likely to represent neutrophil aging or ‘senescence’ whereby 
neutrophils undergo a change in the ‘cell state’ rendering them unable to respond to 
chemoattractants such as fMLP, undertake respiratory burst or to degranulate. (Whyte et 
al., 1993) Neutrophils are terminally differentiated short lived cells and cellular functions 
can be limited the mechanism of cellular senescence associated with up-regulation of 
CXCR4 on the neutrophil surface resulting in bone marrow homing and apoptosis.  
Neutrophil senescence occurs in parallel with spontaneous apoptosis, and indeed 
neutrophil apoptosis is thought to be the major factor in the functional senescence of 
neutrophils.  (Lee et al., 1993)  Neutrophil senescence in the setting of liver disease is 
likely to be secondary to ammonia-induced mitochondrial damage or ROS-associated 
with reduced apoptosis secondary to LPS stimulation, the secretion of GM-CSF secretion 
and pro-inflammatory cytokines.  Neutrophil apoptosis is a critical event in the resolution 
of sepsis and is reduced in severe sepsis due to the presence of LPS, pro-inflammatory 
cytokines, colony stimulating factors and IL-10 possibly regulated by intracellular kinase-
pathways. (Keel et al., 1997) In liver disease there is ongoing hepatic inflammation 
associated with chronic endotoxemia potentially setting up a ‘perfect storm’ to prolonge 
the life span of dysfunctional ‘stressed’ neutrophils.  Interestingly a group that looked 
into a small populations of mainly HCV-related cirrhosis showed enhanced apoptosis in 
ex-vivo neutrophils (Ramirez et al., 2004) from decompensated cirrhotics compared to 
compensated liver disease.  However, neutrophils need careful handling ex-vivo and 
sudden removal from a supportive environment where apoptosis is inhibited to an ex-vivo 
environment lacking support could trigger apoptosis so further studies in this area are 
required.   
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The most pivotal finding of the study is further tantalising evidence that activation 
of the p38 MAPK signal transduction system is an important protective mechanism for 
neutrophils and appears to be downregulated in acute and chronic liver disease.  In 
addition healthy control neutrophils display a profound reduction in both PMA and E coli 
stimulated OB after exposure to increasing concentrations of ammonia; an effect 
abrogated by the p38 MAPK agonist isoproterenol.   Kinase systems such as NF-κB and 
p38-MAPK are known to be critical in cellular immune activation and in the response to 
infection but their widespread distribution within mammalian cells limits their use as 
therapeutic targets. This study provides clear evidence that targeting the cytoprotective 
p38-MAPK pathway is a valuable strategy in cirrhosis with agonists showing the ability 
to reverse the ammonia-induced impairment to neutrophil phagocytosis while supressing 
neutrophils ability to burst.  It is interesting to note that PMA induced burst was more 
specifically affected by ammonia than E. coli SOB.  This give further support for the 
direct perturbation of this pathway by ammonia as PMA is known to activate p38-MAPK 
following activation of PKC and subsequent phosphorylation.  Therefore p38-MAPK 
activation would allow antibacterial properties of the neutrophil to be maintained whilst 
avoiding ROS mediated bystander damage. 
This is very exciting as p38-MAPK agonists potentially offer a targeted therapeutic 
strategy that can reverse the fundamental neutrophil defects in cirrhosis and potentially 
reduce rates of infection.  Unfortunately due to failure of the cytokine bead array assay 
direct confirmatory evidence that ammonia inhibits neutrophils directly through this 
pathway could not be proven.   The low level of proteins for analysis means that either 
there were problems in the protein extraction step or the final concentration of protein in 
the samples.  Another factor that may have led to deterioration is that the denatured 
samples were stored for some months prior to analysis due to difficulty obtaining further 
CBA kits.  In future I would perform the denaturation step, on appropriately exposed 
neutrophils, followed by protein estimation using the Bradford assay to ensure a 
consistent yield of denatured protein on fresh samples.  Only once good standard curves 
had been achieved and flow-cytometer set-up optimised would I proceed with the CBA.  
In addition I would design the CBA plex to include other kinase systems e.g. ERK and 
JNK.  A second confirmatory method such as western blotting could have been 
performed too act as a validation set.     
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Despite this difficulty, Shawcross et al. have previously shown up-regulation in 
phosphorylation of the p38-MAPK using western blotting in the absence of up-regulation 
of other kinase pathways following ammonia exposure.  (Shawcross et al., 2008a)  It 
would however, be important to confirm if this is a direct p38-MAPK effect secondary to 
cell volume changes or direct ammonia-induced toxicity and in particular to exclude the 
involvement of other kinase pathways.  It remains unclear if ammonia causes neutrophil 
swelling through osmotic stress, or through direct effects on aquaporin molecules as seen 
in brain astrocytes.  (Rama Rao and Norenberg, 2007).  It is interesting to note that 
blocking antibodies directed towards aquaporin-9 in neutrophils inhibits pseudopodium 
formation and motility-related shape changes.  (Loitto et al., 2002) Another possible 
mechanism whereby ammonia causes neutrophil dysfunction is through energy depletion 
within the neutrophil as they are reliant on the conversion of glutamine to glutamate a 
process inhibited by ammonia. (Sbarra and Karnovsky, 1959) 
The previous effects of hyponatraemia seen in normal ex vivo neutrophils appears to be 
immaterial for neutrophils from patients with liver disease, failing to show significance 
on univariate analysis. The reasons for this are unclear but indicate a degree of neutrophil 
adaptation increasing resistance to the cell volume increases induced by hyponatraemia.  
It is interesting to note that hypernatraemia appears to modulate neutrophil function and 
increasing TLR expression in a murine model of thermal injury following the use of 
hypertonic saline. (Chen et al., 2006) Active correction of hyponatraemia and mild 
hypothermia is a standard of care in ALF; a strategy that has been associated with a 
decline in mortality from cerebral oedema.  (Bernal et al., 2013) Whilst both strategies are 
neuroprotective they have additional benefits in reducing neutrophil activation in ALF, a 
setting where significant adaptation is unlikely to have had time to develop.    
Ammonia-induced cell volume changes along with failure of p38-MAPK 
activation appear to be critical factors in the dysfunction of neutrophils in patients with 
acute and chronic liver disease.  A more detailed understanding of how ammonia affects 
changes in neutrophil kinase pathways is required.  p38-MAPK agonists offer exciting 
new targets to abrogate neutrophil dysfunction and susceptibility to infection in liver 






























This thesis is the most comprehensive work to date characterising circulating neutrophil 
dysfunction in patients with acute and chronic liver failure.  The data demonstrate the 
presence of neutrophil swelling, impaired phagocytosis and enhanced neutrophil 
spontaneous oxidative burst in patients with acute and chronic liver failure and 
contributes to increased susceptibility to infection.  In patients admitted to ICU with ALF 
and SALF changes to all aspects of neutrophil function persist until spontaneous 
recovery, death or LT.  Furthermore, the morphological studies show that circulating 
neutrophils isolated from patients with both ALF and cirrhosis display striking 
phenotypic changes along with changes in surface receptor expression and reduced 
chemotactic activity.  Ammonia contributes to neutrophil swelling and further impairs 
neutrophil phagocytosis and augments SOB.  Modulators of p38-MAPK can reverse this 
dysfunction suggesting that activation of this pathway can protect against the ammonia-
induced neutrophil swelling and dysfunction.    
 The main criticisms of this body of work are the heterogeneity of the patient 
groups and the failure to achieve recruitment targets in some of the planned patient 
cohorts thus reducing the statistical power of the study.  Continued recruitment of patients 
into some of the cohorts may strengthen the robustness of some of the findings and detect 
more subtle changes.   
 
9.1 Neutrophil dysfunction in ALF 
Circulating neutrophils in patients with ALF and SALF demonstrate a significant 
reduction in neutrophil surface expression of CD16 (FcγRIII) thereby reducing the ability 
of the neutrophil to bind to opsonised microbes akin to patients with sepsis and MODS. 
Pronounced impaired of phagocytic activity of opsonised E. coli was also observed in 
neutrophils isolated from patients with ALF and particularly SALF. These functional 
differences appear to impact on survival form ALF/SALF, particularly phagocytic 
dysfunction with patients who died or required LT showing a lower NPA at presentation 
compared to non-LT survivors.  
Surface receptor data for circulating neutrophils in patients with ALF and SALF 
did not show the expected changes with a significant reduction in neutrophil surface 
expression of CD16 (FcγRIII) being the only difference detected.  This data should be 
interpreted with caution as data for surface receptor expression was not available on all 
samples particularly for CD11b and CD62L thus reducing the power of the study.  The 
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expected sepsis phenotype, of enhanced expression of CD11b, reduced CD62L and stable 
levels of CD16 was not see in the septic controls cohort suggesting either a small sample 
size or activation of neutrophils in the healthy control cohort.  Overall, the study did 
under-recruit in the healthy control (n=11) and septic control (n=6) cohorts as we initially 
planned to recruit 24 to each cohort.  Indeed, the sepsis controls did not demonstrate the 
expected surface receptor changes and were not as unwell as expected particularly when 
the organ failure scores in the sepsis cohort were compared to the ALF cohort suggesting 
that the cohorts are not as well matched in terms of organ failure possible explaining the 
lack of surface receptor changes in the sepsis cohort.  Clearly ALF and sepsis are 
different and the reported variation in CD16 levels could be real so further studies should 
be performed to confirm these findings particularly with an expanded array of surface 
receptors.  Interestingly, in other work we have shown that enhanced neutrophil CD64 
expression is seen in ALF in the absence of infection suggesting sterile inflammation can 
induce CD64 expression; a phenomenon previously only reported in sepsis supporting the 
theory that sterile inflammation and hepatic-derived DAMPs can induce changes in 
circulating neutrophils with the caveat that subclinical infection cannot be excluded. 
(Abeles et al., 2012)   
The observation of a reduction in NPA in ALF/SALF cohorts akin to that 
frequently observed in sepsis, (Brown et al., 2006) may explain why patients with ALF 
exhibit phenotypic features of septic shock with microvascular dysfunction, 
hemodynamic instability, coagulopathy, encephalopathy, MODS and high levels of 
circulating pro-inflammatory cytokines.  Why the severity of NPA is less so in those 
presenting with ALF compared to SALF is less clear and perhaps the answer lies in the 
chronicity of onset of neutrophil impairment.  A significant proportion of the ALF cohort 
were acetaminophen-induced ALF (40%) characterised by a rapid onset of liver failure 
and a significant CARS response may not have developed yet, whereas the more 
insidious time course of SALF (70% seronegative autoimmune disease) may lead to an 
enhanced CARS response and a more severe reduction in phagocytic ability seen 
although interestingly IL-10 levels were comparable. The TEM studies show features of 
neutrophil senescence in patients with ALF and this may be induced through oxidative 
stress, enhanced neutrophil life-span or a failure of stress granulopoiesis to replenish 
these cells.  Senescent neutrophils can show reduced phagocytosis thus offering a further 
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explanation for the changes seen as well as the ammonia-induced changes. I=indeed, this 
may explain the time-dependent nature of the defect.     
It is disappointing that haemodialysis does not appear to have an effect on 
neutrophil phagocytic dysfunction; however, our study was underpowered to detect this 
change.  It has been shown that CVVH can reduce plasma ammonia levels with greater 
ammonia clearance achieved with higher filtration volumes.  (Slack et al., 2014) So it 
may be too early to dismiss this approach particularly as this aspect of the study was 
observational.  However, CVVH is commenced at an early stage in many patients with 
acute and chronic liver failure for management of hyperammonaemia, acid-base 
disturbance and AKI and so whilst it would offer mechanistic support it is unlikely to 
change management.  Other therapies such as albumin dialysis and plasmapheresis may 
modulate neutrophil function to a greater extent than CVVH through removal of 
cytokines, DAMPs and PAMPs and comparative studies are mandated.   
The heterogeneity of the two groups in terms of aetiology of liver disease does 
mean that we may not be comparing like with like particularly in respect to the speed of 
onset of liver failure and the varying severity of disease. This may affect neutrophil 
dysfunction and the severity of the SIRS, subsequent CARS response and the varying 
potential for recovery.  The timing of sampling may make a difference; whilst patients 
were sampled within 48-hours of admission this was dependent on the timing of transfer 
to the ICU which was referring centre dependent and on the dynamics of presentation. In 
AALF this was probably more consistent as all patients presented with hyperacute ALF 
whereas a number of patients with viral liver disease were transferred and de-escalated 
from ICU within 48-hours with rapidly improving encephalopathy and subsequent 
spontaneous recovery.   
One criticism of previous studies of neutrophil dysfunction was that the clinical 
relevance of the documented changes was unclear.  However, one of the critical findings 
form the data is that NPA on admission appears to be a predictor of spontaneous survival 
compared to conventional organ failure scores such as SOFA and MELD which did not 
predict poor outcome in this study.  Trying to understand the relationship between 
neutrophil phagocytic dysfunction and poor prognosis therefore seems critical.  The 
incidence of ‘culture positive’ sepsis was low in this ALF/SALF cohort overall and 
indeed the observed deaths could not be directly attributed to infection, suggesting 
phagocytic dysfunction is either a reflection of general immune activation or a specific 
factor related to the severity of the liver injury.  Peak plasma ammonia levels 
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demonstrated a robust correlation with poor phagocytic function in SALF and high 
circulating levels of IL-10 and IL-17.  Ammonia was previously shown to impair NPA 
and induce spontaneous OB in healthy neutrophils exposed to supraphysiological 
concentrations of ammonia ex vivo and in rats fed an ammonia-rich diet. (Shawcross et 
al., 2008a) The peak arterial ammonia concentration did not however correlate with 
impaired NPA in the ALF cohort but might be attributed to the impact of ammonia 
reduction by CVVH prior to neutrophil sampling.  Interestingly LT, with associated 
normalisation of plasma ammonia levels resulted in rapid improvement of neutrophil 
phagocytic function within 72 hours but not complete reversal, which could be the result 
of ischemia-reperfusion phenomena, ongoing production of pro-inflammatory 
cytokines/SIRS or sepsis.   
Pro- and anti-inflammatory cytokine profiles might be expected to show a closer 
association with neutrophil OB than phagocytic activity although this was not generally 
the case.  Higher plasma IL-10 and IL-17 concentrations correlated with impaired NPA 
and may suggest the development of a CARS in this condition (Antoniades et al., 2008) 
with involvement of T-regulatory cells (T-regs). (Lewis et al., 2012) However, the 
condition with the highest levels of pro-inflammatory cytokines, AALF demonstrated 
only modest neutrophil dysfunction.  CD4+CD25+CD127-FOXP3+ T-regs directly 
inhibit neutrophil function, promoting apoptosis and death when exposed to 
lipopolysaccharide through TLR4 expressed on their surface which inhibits pro-
inflammatory activities. (Lewkowicz et al., 2006) This is an important role in the direct 
control of innate immune responses.  Upon activation, these T-reg can either induce 
themselves or CD4+CD25-FOXP3-T effector cells to differentiate into IL-17A producing 
cells, Th17, in the presence of TGF-beta and/or IL-6. (Xu et al., 2007) In contrast to the 
role of T-regs on neutrophils, one of the functions of Th17 is to recruit neutrophils into 
inflamed tissue further increasing the antimicrobial response in vitro and in vivo. 
(Annunziato et al., 2008, Kolls et al., 2008)  
Possible mechanisms to explain the observed reduction in NPA could include 
direct toxicity to neutrophils through cell swelling, neutrophil senescence mediated 
through oxidative stress, a CARS response or suppression by T-regs.  The mechanisms 
seem complex and may be multiple but understanding the mechanisms seems central to 
unlocking the immune pathology and realising the potential to improve outcome in this 
condition.  Interestingly, NPA did not show any association with SIRS score, organ 
failure scores or pro-inflammatory cytokine levels.  The SIRS score has poor sensitivity 
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and narrow range with many parameters such as tachycardia, tachypnoea, respiratory 
alkalosis, fever and neutropenia being features of ALF and are therefore unlikely to be 
useful in this setting.   Organ failure scores are relatively blunt tools to correlate with 
NPA and indeed, would be expected to correlate better with SOB. In addition the 
heterogeneity of the cohort here probably limits my findings.  In particular I would not 
exclude an effect of pro-inflammatory cytokines on the basis of this study alone.  
Measurement of pro-inflammatory cytokine levels in the serum has limitations with a 
variation in concentrations away from the liver and so the effects of priming with cells 
circulating through the liver bed and local concentrations or gradients may be of greater 
importance. Indeed, cytokine effects can be additive and peripheral levels may be reduced 
by CVVH.  Cytokines mediate indirect effects on neutrophils through the activationof the 
vascular endothelium or other inflammatory cells that modulate function.  Certainly an 
expanded range of cytokines, DAMPs and PAMPs need to be considered in future studies 
and multivariate analysis should be employed to exclude confounding factors.   
There was no evidence of enhanced neutrophil spontaneous production of ROS 
contributing to the development of MODS and poor outcomes in ALF/SALF in this 
study.  Circulating neutrophils may not reflect activation of marginated neutrophils in the 
liver and other vascular beds within organs such as the lung and kidney so it is difficult to 
draw firm conclusions.  In addition, ALF and SALF patients are a heterogeneous patient 
group who are prone to deteriorating rapidly necessitating a number of invasive 
interventions such as haemofiltration, mechanical ventilation and mild hypothermia 
potentially influencing neutrophil function and which are difficult to control for 
constituting the main weakness of this study. Furthermore, the empirical use of potent 
broad-spectrum antibiotics and anti-fungals as standard of care in this study is also likely 
to have abrogated any increased susceptibility to developing sepsis in this cohort.   
 
9.2 Neutrophil dysfunction in cirrhosis 
In patients with stable cirrhosis, my data confirm that primed dysfunctional 
neutrophils circulate with impaired chemotaxis and phagocytic function. The circulating 
neutrophil dysfunction predisposes to infection and predicted the development of 
infection, organ dysfunction and survival at 90-days and 1-year.  Furthermore, patients 
who displayed evidence of increased oxidative stress with spontaneous production of 
ROS from circulating neutrophils were susceptible to the development of HE and 
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AoCLFwith associated poor outcome. This supports a central role for circulating 
dysfunctional neutrophils in the pathogenesis of extra-hepatic organ dysfunction in 
cirrhosis.   
Secondly, TEM studies confirmed that ammonia-induced neutrophil swelling 
correlated with neutrophil phagocytic dysfunction, swelling and activation of p38-MAPK.   
Thirdly, mechanistic studies demonstrated that abrogation of the neutrophil dysfunction 
seen in liver failure can be achieved by pre-incubation of ex vivo neutrophils with specific 
modulators of p38-MAPK. Neutrophils exposed to the p38-MAPK agonist isoprotorenol 
recovered phagocytic capability offering a novel therapeutic target to prevent that may 
reduce the development of HE and AoCLF in cirrhosis.    
Morphological studies using TEM have thrown up some very interesting 
observations by confirming that patients with cirrhosis have an increased neutrophil cross 
sectional area compared to controls, correlating with increasing plasma ammonia levels.  
Furthermore, TEM studies have revealed profound abnormalities in the neutrophil 
ultrastructure with loss of rounded shape, extensive vacuolisation, pale cytoplasm and 
paucity of mitochondria. In the setting of liver disease these findings are novel and may 
signify neutrophil senescence either as a consequence of neutrophil oxidative stress from 
enhanced spontaneous ROS production via NADPH oxidase, or a prolonged neutrophil 
life-span as a consequence of reduced clearance through apoptosis.   
Neutrophil senescence has previously been described and renders neutrophils 
unable to respond to chemoattractants, carry out respiratory burst or degranulate.  (Whyte 
et al., 1993)  Interestingly, the chemotaxis experiment shows a variable response to the 
chemoattractant fMLP, with neutrophils from patients with cirrhosis showing an activated 
phenotype with loss of CD62L.  However, the ability of neutrophils to migrate following 
fMLP stimulation appeared to be impaired although findings were to some extent 
heterogenous.  The findings of the chemotaxis assay would therefore support neutrophil 
senescence.   No apparent association with plasma arterial ammonia concentration was 
seen.  This supports earlier findings by Fiuza et al. who showed an impaired ability of 
neutrophils in patients with cirrhosis to migrate using a skin window technique.  (Fiuza et 
al., 2000) Interestingly ammonia has been reported to inhibit the fMLP receptor but 
although the chemotaxis response is impaired the activation response is not, so ammonia 
may not be the aetiological agent here.    Circulating neutrophils in patients with cirrhosis 
retained the ability to generate an ESOB and degranulation appeared to be increased with 
the increased surface expression of CD11b although the response to other chemo-
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attractants was not specifically investigated.  TNFα levels are increased which along with 
GM-CSF can extend neutrophil life-span as well as LPS priming both of which could be 
potential mechanisms for the altered chemotaxis response.   
Clearly data on apoptosis is needed and it is interesting to note that G-CSF has 
been shown to enhance survival in patients with AoCLF who were treated with 
intermittent dosing over a month. These patients had fewer episodes of sepsis and 
improved outcome at 2-months associated with increased circulating numbers of 
neutrophils and CD34+ cells   (Garg et al., 2012)  suggesting that G-CSF enhances 
mobilisation of new neutrophils from the bone marrow.   
The TEM studies, need to be reproduced particularly with a less intensive method 
perhaps using techniques such as oil immersion light microscopy or confocal microscopy 
to make it more practical to study in greater detail.  Interestingly, using the GMFI of the 
forward scatter as a marker of cell volume did not intimate any difference between 
control and disease neutrophils, which is probably a consequence of sample preparation.  
Whole blood preparation for assessment of neutrophil cell volume involved a density 
graded centrifugation technique with Polymorphoprep™, which involves a prolonged 
exposure to a hyperosmolar solution with subsequent restoration of osmolality, after 
separation, by addition of 0.45% saline solution. Normal cells may be more resistant to 
the effects of the hyperosmolar solution on cell volume than cells from patients with liver 
disease. Ideally a whole blood technique would prevent this issue as well as reducing 
handling and maintaininga constant temperature.    
The data show that circulating neutrophils in cirrhosis exhibit a classical activated 
phenotype of cell surface receptors, with enhanced expression of CD11b, loss of CD62L 
and unchanged levels of CD16.  In addition neutrophils from patients with cirrhosis show 
a reduced capacity to phagocytose microbes with impairment of chemotactic migration 
following fMLP stimulation.  The caveat in interpreting the up-regulation of neutrophil 
surface receptor expression in liver disease, particularly CD62L, is that there is a high 
degree of CD62L in the maturating pool within the BM and these can be released during 
stress granulopoiesis from the BM. L-selectin is lost through neutrophil aging and 
following corticosteroid exposure.  (van Eeden et al., 1999)  Upregulation of the β2-
integrins CD18 and CD11b is considered a sensitive marker of neutrophil activation and a 
whole blood preparation is considered a preferable assay to prevent activation particularly 
following the cell lysis and wash steps and I would look to develop this assay in the 
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future.  There are further markers of activation, particularly the β1-integrin CD49d 
(VLA4), the high affinity Fcγ receptor CD64, the CXCR1 chemokine receptor and the 
PRR TREM-1 and these could be assessed  by using multiple antibodies with different 
fluorochromes on the same assay.  Other concerns result from the heterogeneity of the 
group and exclusion of infection in the recruited cohort. A number of the patients in the 
stable cirrhosis cohort had been clear from infection for only 7-days and questions have 
to be raised as to whether this was long enough and had infection really been excluded at 
recruitment and subsequent sampling.  
The finding of an enhanced spontaneous production of ROS from circulating 
neutrophils in patients who go on to develop infection and organ dysfunction or HE may 
hold the key to understanding why some patients with cirrhosis are susceptible to 
developing MODS and HE. Indeed, patients with cirrhosis who have increased basal 
production of ROS appear to be at the highest risk for developing complications and 
MODS.  This is likely to be driven by the systemic pro-inflammatory milieu that bathes 
these neutrophils with elevated levels of TNFα, IL-6, IL-8 and IL-10 generated 
principally as a consequence of bacterial infection, with complicating infection being seen 
in 23% of patients with HE and 58% of patients with AoCLF. Enhanced bacterial 
translocation of PAMPs across a leaky gut (Neugebauer et al., 2008) or from ‘sterile’ 
hepatic inflammation (DAMPs such as HMGB-1) may explain other cases.  These 
findings support the hypothesis that bacterial driven (PAMPs) or ‘sterile’ hepatic 
inflammation induces a dysfunctional response in circulating neutrophils and through 
homing to other endothelial beds can induce oxidative stress, organ-injury and the 
development of the clinical syndromes of AoCLF and HE.  Similar findings have been 
shown in patients with acute alcoholic hepatitis where an increase in SOB is observed 
which correlates with severity of liver disease. (Parlesak et al., 2003, Mookerjee et al., 
2007b) Interestingly, the phenomenon of increased SOB appears to be independent of 
plasma ammonia levels and indeed the mechanisms which lead to neutrophil NPA being 
reduced seems to be separate from that of enhanced resting OB.   
The finding however, that elevated serum transaminases and hyperbilirubinaemia 
are associated with higher plasma levels of IL-17 and a lower phagocytic capability in 
AoCLF supports hepatic inflammation as being an important driver of neutrophil 
phagocytic dysfunction. IL-17 is a critical mediator of neutrophil recruitment. IL-17 
secretion from effector CD4+ T-cells is thought to be an important mediator of innate 
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immune function and the development of chronic inflammation, (Qian et al., 2010) and 
IL-17 secreting hepatic cell infiltrates have been shown to be present in patients with 
acute alcoholic hepatitis. (Lemmers et al., 2009) 
Ammonia-induced neutrophil swelling correlates with neutrophil phagocytic 
dysfunction and activation of the p38-MAPK pathway. Neutrophil swelling correlated 
with peak arterial concentration and could be abrogated ex-vivo following incubation with 
the p38-MAPK agonist isoproterenol.  Further support of a central-role for activated p38-
MAPK in NPA comes from the observation that in patients with diuretic 
intolerant/resistant ascites the concomitant use of propranolol was associated with 
worsening of NPA. This may offer an explanation as to why Serste and colleagues 
recently identified increased mortality in patients with refractory ascites treated with 
propranolol. (Serste et al., 2010) Propranolol increases neutrophil motility by promoting 
increased intracellular cyclic GMP activity (Anderson and van Rensburg, 1979) and thus 
might be postulated to have a beneficial effect in cirrhosis.  Propranolol inhibits p38-
MAPK phosphorylation and can therefore suppress neutrophil phagocytic function. 
(Busse and Sosman, 1984) Reduced NPA in concert with increased bacterial DNA 
translocation from the gut into the portal vein in patients with refractory ascites might 
thereby culminate in hepatic endothelial dysfunction, systemic endotoxemia, and resultant 
systemic inflammatory response. (Bellot et al., 2010) 
The observed association between elevated plasma ammonia concentration and 
impaired NPA replicates Dr Shawcross and colleagues previous observations. (Shawcross 
et al., 2008a) Acute increases in plasma arterial ammonia concentration induced by a 
simulated upper gastrointestinal bleed have been shown to induce neutrophil swelling and 
phagocytic dysfunction in patients with stable cirrhosis. The adverse impact of ammonia 
exposure on neutrophil function can be abrogated ex vivo following incubation of the 
neutrophils with an agonist of the p38-MAPK pathway. (Shawcross et al., 2008a) It has 
been postulated that ammonia-induced neutrophil swelling induces phosphorylation of 
p38-MAPK which serves as an important cell osmoregulator. (vom Dahl et al., 2001) 
p38-MAPK is also upregulated during neutrophil priming and activation, with down-
stream effects including the promotion of apoptosis and the activation of pro-
inflammatory transcription factors.  However, the association between ammonia and 
neutrophil phagocytosis remains circumstantial and p38-MAPK activation may occur 
through other mechanisms.  Indeed the correlation between NPA in patients with cirrhosis 
and serum ammonia is modest at best and although it has been reproduced other factors 
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such as neutrophil count and gammaglobulin levels show a similar magnitude of effect. 
Multivariate analysis of potential serological factors is required in an expanded cohort or 
within a single aetiology cohort in order to reduce confounders.  The correlation with 
neutrophil count is interesting and a possible explanation may be that patients with 
cirrhosis who can mount a neutrophilia may be able to release younger more vigorous 
neutrophils from the bone marrow that can improve NPA.  Clearly loss of opsonins such 
as IgG will reduce NPA as has previously been shown with low complement levels in 
ascites.  (Such et al., 1988)  The finding of ammonia levels correlating with NPA is a 
consistent finding, however, the exact mechanism through which ammonia causes 
neutrophil swelling is yet to be elucidated.  Interestingly, ex-vivo neutrophils incubated 
with ammonia appeared to inhibit PMA-activated oxidative burst more profoundly that 
ESOB.  PMA is known to activate p38-MAPK following activation of PKC and 
subsequent phosphorylation and ammonia’s effects therefore appears to be specific to this 
pathway whereas E. coli can still generate a burst via alternative pathways.  This then 
begs the question that if cell swelling is implicated in neutrophil malfunction, is this 
achieved through similar mechanisms to astrocytes by the intracellular conversion of 
glutamate to glutamine or other toxic effects on mitochondria?    
The role of p38-MAPK appears to be fascinating and it seems this multifunctional 
kinase is able to protect against the cell swelling effects of ammonia.  The more important 
question is perhaps what causes inactivation of phosphorylated p38-MAPK? Is it reduced 
phosphorylation perhaps due to oxidative stress or enhanced breakdown?  What is clear is 
that there is reversibility in the process and recovery can be seen with isoproterenol which 
promotes phosphorylation of p38-MAPK.  Isoproterenol activation of p38-MAPK 
appears to be acting through an alternative mechanism via cAMP activation.  
Interestingly, β2-adrenoceptor agonists such as adrenaline and noradrenaline lead to 
reduction in the bacteriocidal activity of the neutrophil against S. aureus, E. cloacae and 
Proteus ruttgeri without decreasing phagocytosis of bacteria.  (Qualliotine et al., 1972)  
Although both are less potent than isoproterenol and are often present in elevated levels 
in patients with cirrhosis and ALF/SALF, the relevance of these effects in vitro is unclear.   
It is a shame that the CBA assay did not yield any useful results as this would have shed 
some light on the level of  background phosphorylated p38-MAPK activation.   
Perhaps the most powerful observation of this study is that baseline circulating 
neutrophil dysfunction is a robust predictor of outcome and 90-day and 1-year survival. 
 274 
Baseline resting neutrophil OB of ≥12% predicted 90-day survival with an AUROC of 
0.81, with survivors at 90-days having a significantly lower resting OB. Impaired NPC is 
also an important determinant of 90-day mortality with an AUROC of 0.83 with survivors 
at 90-days and 1-year having a significantly higher NPC. This implies that neutrophil 
biomarkers can predict medium-term (90-day) and longer-term (1-year) outcome in 
patients with stable cirrhosis. This also supports the findings of Mookerjee and colleagues 
who showed neutrophil dysfunction to be an important outcome predictor in acute 
alcoholic hepatitis. (Mookerjee et al., 2007a)  
Overall the results allow us to speculate that circulating neutrophil dysfunction in 
liver disease appears to be a maladaptive response to chronic inflammation with 
neutrophils ‘dressed for a party but with nowhere to go’ being maintained in a constantly 
primed state within the circulation which eventually culminates in cell exhaustion leading 
to senescence.  There are associations with markers of hepatic inflammation, pro- and 
anti-inflammatory cytokines as well as plasma ammonia levels.  The implication seems to 
be that in chronic liver disease despite raised levels of anti-inflammatory cytokines such 
as IL-10 there is incomplete resolution of the inflammatory response and perpetuation of 
low grade SIRS through LPS priming via TLRs. Reduced CD62L expression may 
indicate a reduced ability to marginate to the vascular endothelium but as yet the 
activation state of other adhesion molecules in unknown.  We can speculate that the 
persisting primed state combined with ammonia-induced cellular swelling and reduced 
clearance through apoptosis leads to neutrophil senescence and reduction in functions 
such as phagocytosis and chemotaxis. One difficulty with this theory is the reversibility 
observed with p38-MAPK modulators and indeed the data still leaves many questions 
unanswered. Further work needs to be carried out to acquire supporting evidence for 




Overall we can see that the neutrophil dysfunction both in ALF and cirrhosis is 
myriad and complex.  These findings support the hypothesis that a combination of 
bacterial translocation, ‘sterile’ hepatic inflammation and ammonia induce a 
dysfunctional response in circulating neutrophils. Through homing to other endothelial 
beds these cells induce oxidative stress and organ-injury.  In addition, other mechanisms 
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of neutrophil dysfunction including senescence resulting from the ravages of oxidative 
stress and defective apoptosis have been suggested.  Agonists of p38-MAPK can improve 
phagocytic ability and suppress resting neutrophil ROS production offering a novel 



































































My studies have raised more questions than answers and in particular to achieve 
the aims of improved mechanistic understanding and the eventual development of 
neutrophil modulating therapies to improve outcomes in liver failure, further work needs 
to be done.  Indeed, I feel I have only just scratched the surface and a much larger body of 
work needs to be done to understand the neutrophil changes which will not only have 
implications for liver failure but also for other conditions such as severe sepsis.   
A comment needs to be made on the rigor of the study and patient selection for 
future studies.  As discussed above, one of the key problems which makes interpretation 
difficult in this observational study is the open inclusion and exclusion criteria meaning 
that there are many factors not controlled for such as age, varying immune activation, 
medication and co-existent conditions.  Tighter inclusion and exclusion criteria are 
required to avoid heterogeneity between groups and patients need to be screened 
rigorously for sepsis prior to inclusion.  In particular concentrating on a single aetiology 
of liver disease such as ARLD may avoid subtle differences in the immunopathology that 
may be present in other aetiologies of chronic liver disease.  Sub-groups should include 
patients on and off prophylactic antibiotics and non-selective β-blockers.  I would also 
point out that it is important that the control group should exclude smokers and 
particularly those who have done vigorous exercise in the last 24-hours as I have found 
that these factors can affect neutrophil function markedly.  
The neutrophil phagocytic dysfunction observed in cirrhosis and ALF/SALF is 
profoundly interesting as it appears central to the immunodeficiency observed and 
triggers a cycle of infection, enhanced neutrophil burst and SIRS, ROS induced organ-
failure and if the patient survives a prolonged CARS phase predisposing to further cycles 
of infection and ultimately in many patients death.  Better understanding of the pathways 
through which this is mediated must include studies into the cytoskeletal rearrangements 
that take place within the dysfunctional neutrophil particularly changes to the Ca2+-
dependent mobilisation and F-actin assembly.  These studies should be complemented by 
observations of neutrophil granule numbers, membrane association and release resulting 
in receptor clustering around the pseudopodium and phagosome cup through imaging and 
flow cytometry studies.    
Neutrophil phagocytic dysfunction is a consistent finding across patients with 
both ALF and cirrhosis but severity is variable and is incompletely explained by liver 
disease severity. Moreover, the SALF work suggests it worsens in the presence of 
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persisting hepatic inflammation.  If the neutrophil defects are akin to sepsis then focusing 
on mechanisms such as priming, senescence, inflammatory cytokines, neutrophil band-
forms and suppression from T-regs should be the next step.  In liver disease this would be 
best explained by low-grade bacterial translocation.  A question remains as to the role of 
sterile inflammation with systemic release of DAMPs and whether a similar sepsis 
phenotype can be generated in the absence of infection.  The aspect of liver disease that 
set it aside from sepsis includes hyperammonaemia and there is much evidence to support 
its pathogenic role.   Defining the neutrophil phenotype seems critical to show the 
similarities and subtle nuances between sepsis and acute and chronic liver failure in order 
to guide and focus mechanistic studies.  Interestingly, phagocytic dysfunction does not 
appear to be worse in cirrhosis with superadded infection such as AoCLF.  Indeed our 
findings show that neutrophils in patients with sepsis show a less severe phagocytic 
dysfunction, going against the perceived wisdom but due to the small numbers of septic 
controls and low organ failure score this should be viewed with some scepticism.  Given 
the redundancy in neutrophil signalling it seems plausible however that more than one 
mechanism may be involved in suppression of neutrophil phagocytosis so there may still 
be a role for pro- and anti-inflammatory cytokines and priming agents and so they should 
not be discounted at this point.  If we assume that the p38-MAPK pathway is critical, one 
possible unifying mechanism may be that DAMPs and PAMPs through pathways such as 
TLR activation, supress p38-MAPK activation thus reducing the neutrophils ability to 
withstand the toxic effects of ammonia leading to swelling and phagocytic dysfunction.  
Microbial infection tips the balance in these primed circulating neutrophils probably 
through changes in the SIRS/CARS axis, likely independent of ammonia, to produce 
toxic neutrophils with enhanced SOB and possibly through granule release or NET 
formation can lead to damage of the vascular endothelium and organ dysfunction. 
Portal hypertension and porto-systemic shunting is clearly important as a source 
of endotoxin which leads to neutrophil priming through TLR-4 and ammonia. The role of 
DAMP’s such as HMGB-1 and other agents which are known to affect the p38-MAPK 
pathway need to be investigated.  Initially I would suggest an expanded cohort of patients 
should be recruited with a single aetiology and multivariate analysis should be performed 
on possible aetiological agents. This may be difficult knowing what to test for as well as 
methodological difficulties such as the notorious difficulty in measuring endotoxin levels.  
Mass spectrometry methods such as matrix assisted laser desorption/ionisation-time of 
flight (MALDI-TOF) could be used to identify molecular signatures which correlate with 
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phagocytic dysfunction.    If samples were collected in an identical fashion they could be 
combined with this data.  Particular attention should be paid to studying an appropriate 
number of healthy controls and septic controls who are more closely matched in terms of 
organ failure.   
Pharmacological experiments using plasma from patients with liver failure on 
healthy neutrophils with the addition of inhibitors such as anti-TNF drugs (e.g. 
infliximab), TLR-2 and TLR-4 receptor blockers and β-adrenoceptor agonists and 
antagonists (e.g. isoproterenol, noradrenaline and propanolol) will subsequently be 
helpful.  
Ammonia is clearly important but again associations are variable and there are 
clearly other factors involved which may increase or reduce the susceptibility to 
ammonia.  It may be that factors such as neutrophil senescence or uncharacterised serum 
humoral factors that inhibit the phosphorylation of p38 MAPK may increase the 
susceptibility of neutrophils to the effects of ammonia.  In particular the effects of β-
blockade on neutrophil dysfunction merits further study to understand if the observed 
effect of these drugs on neutrophils is robust and to confirm if this is affected through the 
p38-MAPK pathway. This would have important implications regarding the use of these 
drugs in the prophylaxis of variceal haemorrhage in advanced cirrhosis. Pre-incubation of 
normal neutrophils with serum from patients with liver disease followed by ammonia 
exposure should be done.  Specifically, looking for protective factors against ammonia 
exposure such as sera from healthy controls, albumin, gamma globulin or G-CSF.   If G-
CSF were beneficial then clinical studies looking at the effect of G-CSF in patients with 
sepsis or AoCLF would be the next logical step with examination of neutrophil functional 
indices as well as episodes of infection and survival as measurable outcomes.    
One of the important and controversial hypotheses is that neutrophils are involved 
in the development of tissue damage and organ dysfunction in patients with liver disease 
and more evidence needs to be developed in this regard.  There are 3 areas to focus on, 
firstly looking at an expanded set of surface expression of adhesion molecules such as 
selectins and integrins, secondly examining margination within the vasculature of these 
organs using flow-cell experiments looking at adhesion in-vitro, and thirdly histological 
evaluation of tissue such as liver explants from patients who undergo transplantation. 
Tissue samples from other organs are difficult to obtain as few patients undergo renal or 
brain biopsies and it would be unethical to do so unless at post-mortem.  Animal models 
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such as the bile-duct ligated rat could be used but there are important immunological 
differences which need to be born is mind with fewer circulating neutrophils being 
present. More powerful experiments would be looking at before and after following 
modulation of neutrophil function either following treatment with isoproterenol or 
techniques such as neutrophil removal utilising columns.  The role of other neutrophil 
functions such as protease release and NET formation should be included, as a modest 
increase in ROS production may not be enough on its own to cause organ dysfunction.  
Another question is to define the phenotype and functionality of neutrophils which 
have migrated across the vascular endothelium as these cells are at the coal face dealing 
with invading organisms and they may not show the functional defects that are 
characteristic of the circulating neutrophil population.  Experiments on neutrophils that 
have trans-migrated across the vascular epithelium in humans have traditionally used a 
skin window technique which artificially creates an often painful blister and the 
applicability of neutrophil changes observed by this technique is controversial.  Ascitic 
fluid is another potential source of neutrophils that have crossed the vascular endothelium 
particularly in patients with decompensated cirrhosis.  Ascitic fluid is often removed as a 
diagnostic procedure to confirm SBP and also large volumes are removed as a palliative 
procedure in patients with tense ascites.  This would potentially provide a source of 
migrated neutrophils to compare although methods to optimise yield would need to be 
developed.  Experiments to isolate and look at the phenotype and functionality of 
migrated neutrophils from patients with SBP needs to be done.  Some authorities now 
recognise that reverse migration can occur back into the circulating pool and defining 
neutrophil sub-sets may allow a better understanding.   
Examination of circulating neutrophils within portal blood would be valuable if 
enhanced priming due to increased bacterial translocation of products such as endotoxin 
and LTA occurs.  Portal blood from patients with cirrhosis or ALF/SALF can be obtained 
either directly at time of LT or during TIPS procedures either for variceal bleeding or 
intractable ascites.  The assumption is that neutrophil priming occurs in this circulation 
from factors released in the liver or from porto-systemic shunting and study of the 
inflammatory milieu in this circulation is more likely to identify causative agents.  Again 
a number of bacterial molecular signals have been defined by MALDI-TOF and 
examination of the plasma by this technique is likely to yield information about the 
degree of bacterial translocation and PAMP’s present.  Comparing peripheral circulating 
neutrophils at the same time as similarities and differences could be sought.   
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TEM should be reserved for looking at the ultrastuctural changes present in 
neutrophils from patients with liver failure in an expanded cohort to ensure that these 
changes are reproducible and how they compare to patients with sepsis.  The hypothesis 
that neutrophil senescence may in part explain neutrophil dysfunction needs to be further 
explored.   In addition looking for mitochondrial changes that are typical of oxidative 
damage should be sought and careful assessment of phagosome structure in response to 
E. coli exposure can be looked at following immunogold labelling of F-actin to define 
defects.  Dynamic confocal microscopic studies of neutrophil behaviour would 
complement these studies. (Allen, 2007)  Granule structure and contents can be studied 
using immunogold labelling of MPO or the cytosolic NADPH subunits (gp91phox or 
p22phox) to try to better understand the state of NADPH activation and efficiency of 
neutrophil killing as well as depletion.   
As already explained above, neutrophils display an activated phenotype of surface 
receptor expression with upregulation of CD11b, reduced CD62L and unchanged CD16 
levels as typified in sepsis.  Other receptors which could be looked at include the 
integrins: CD11b/CD18; and CD49d (VLA4), PRRs: TLR-2; TLR-4; and Trem-1, Fcγ 
receptors: CD32, CD64 and chemokine receptors CXCR2 and CXCR4 as per Table 2-2.   
This would allow determination of the level of neutrophil activation and comparison to 
the sepsis phenotype. Upregulation of the β2-integrins CD18 and CD11b is considered a 
sensitive marker of neutrophil activation and a whole blood preparation is considered a 
preferable assay to prevent activation particularly following the cell lysis and wash steps 
and I would look to develop this assay in the future.  CD18 upregulation originates from 
specific granules with CD11b being present in secretory granules along with the 
complement receptor CD35. CD18/CD11b as well as representing neutrophil activation 
serves as a marker of neutrophil degranulation.  Neutrophil subsets have recently been 
defined with the observation that reverse trans-endothelial migration can occur from the 
adluminal-to-luminal space.  (Beyrau et al., 2012) In addition CD32 can be used as a 
marker to exclude eosinophils although the numbers present in patients with liver disease 
will be small.   
Further studies of neutrophil chemotaxis should be performed on neutrophils 
isolated from more selective cohorts of single aetiology liver disease at different stages of 
presentation and following infection to ensure that the findings are reproducible. Looking 
at neutrophil migration responses to other chemokines particularly liver chemokines, such 
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as osteopontin, may be more relevant to the pathology encountered to ensure that the 
defects remain.   
Neutrophils do not operate in isolation and the immunopathology affects other 
innate and adaptive immune cells with PBMC’s and IL-17 T-cells being of particular 
interest and co-culture studies should be performed.  Relevant to this is the role of 
neutrophils in orchestrating the inflammatory response through the production of 
cytokines and initial intracellular cytokine studies on T-cells co-cultured with neutrophils 
show promise.  These experiments are important as it is increasingly recognised that 
neutrophils contribute themselves to the inflammatory milieu recruiting monocytes, 
dendritic cells, NK cells and T-cells as well as promoting survival and differentiation of 
B-cells,  
A broader understanding of the neutrophil dysfunction should be sought looking 
at chemotaxis, NADPH oxidase dysfunction, cytoskeletal re-arrangements and neutrophil 
granules as this may help elucidate a common pathway for the development of 
dysfunction. Further mechanistic studies are critical particularly as blanket therapies such 
as corticosteroids are a double-edged sword.  Looking at intracellular signalling right 
form the level of TLR and FcγR receptors down to p38-MAPK and other intracellular 
kinase cascades through to the generation intracellular cytokines is warranted.  The 
availability of small molecule inhibitors or murine knockout models may ultimately offer 
translational targets and therapies.  Currently available therapies such as plasmapheresis 
in ALF and G-CSF in AoCLF could offer hope in the meantime 
There is clearly a greater needfor therapeutic trials to look at potential in vivo 
modulators of neutrophils. G-CSF holds promise, being able to promote release of 
neutrophils from the bone marrow and reduce apoptosis, and has shown some promise in 
patients with ALF and AoCLF in terms of reducing mortality and septic episodes 
respectively.  The effect on neutrophil function was not studied and this would provide a 
useful insight.  There is controversy as to what the effect of a higher proportion of 
immature band-forms would have and delaying apoptosis in older cells may be 
undesirable.  Studies with ex-vivo neutrophils could be up-scaled to human clinicial trials 
if shown to be beneficial as studying ex vivo neutrophils in isolation will only give us a 
limited insight. The effect of immunosuppressant drugs on neutrophils needs to be better 
understood in particular to look at the effects in patients treated with corticosteroids 
especially using sequential samples with patients as their own controls and controlling 
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tightly for sepsis.  The effect of intravenous immunoglobulin, plasmapheresis and CVVH 
should be studied either ex vivo or in vivo.   Other potential targets include IL-33 a 
member of the IL-1 superfamily and TLR4-activated platelets.  IL-33 appears to be a key 
regulator of neutrophil function during SIRS.  In mouse models administration of IL-33 
prevented the down-regulation of CXCR2 on circulating neutrophils and thus increased 
migration to inflamed tissues and promoted bacterial clearance.  (Alves-Filho et al., 2010) 
In addition, TLR4-activated platelets have been shown to bind adherent neutrophils 
during sepsis and promote NET formation, which may lead to bacterial trapping but also 
to endothelial and tissue damage in vivo and in vitro. (Clark et al., 2007) 
 Overall, neutrophil dysfunction underpins much of the immune dysfunction 
present in acute and chronic liver failure.  The causes appear complex but ammonia plays 
a central role. Specific targets and therapeutic manipulation holds promise for the future 
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